<SEC-DOCUMENT>0001628280-25-011735.txt : 20250310
<SEC-HEADER>0001628280-25-011735.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20250310170036
ACCESSION NUMBER:		0001628280-25-011735
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250310
DATE AS OF CHANGE:		20250310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		25724638

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>cpix-20250310.htm
<DESCRIPTION>DEF 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b5516545-3d7c-4e11-85cf-2d47d7746d5a,g:3cc3fa37-86c9-402e-a504-d48283fc97bb,d:fa04aa8a69de418e832ab1f08fb0d35a-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:cpix="http://www.cumberlandpharma.com/20250310" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20250310</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-2">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-3">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-4">DEF 14A</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20250310.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="ecd:MeasureAxis"><ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="ecd:MeasureAxis"><ecd:MeasureAxis.domain>2</ecd:MeasureAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="ecd:MeasureAxis"><ecd:MeasureAxis.domain>3</ecd:MeasureAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="ecd:MeasureAxis"><ecd:MeasureAxis.domain>4</ecd:MeasureAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON,&#160;DC 20549</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SCHEDULE&#160;14A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proxy Statement Pursuant to Section&#160;14(a) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> the Securities Exchange Act of 1934</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed by the Registrant&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed by a Party other than the Registrant&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box:</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Preliminary Proxy Statement</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Confidential, for Use of the Commission Only (as permitted by Rule&#160;14a-6(e)(2))</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Definitive Proxy Statement</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Definitive Additional Materials</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Soliciting Material Pursuant to &#167;240.14a-12</span></div><div style="margin-top:7pt;padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-1">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of Filing Fee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Check the appropriate box):</span></div><div style="margin-bottom:1pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No fee required.</span></div><div style="margin-bottom:1pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Fee paid previously with preliminary materials</span></div><div style="margin-bottom:1pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_4"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.185%"><tr><td style="width:1.0%"/><td style="width:80.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.030%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page Number</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_7">NOTICE OF ANNUAL MEETING OF SHAREHOLDERS</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_7">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_10">PROXY STATEMENT FOR ANNUAL MEETING OF SHAREHOLDERS TO BE HELD APRIL 22, 2025</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_10">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_13">PROPOSAL I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_13">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_16">PROPOSAL II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_16">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_19">AUDIT COMMITTEE REPORT</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_468">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_22">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_22">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_25">DELINQUENT SECTION 16(a) REPORTS</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_25">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">COMPENSATION DISCUSSION AND ANALYSIS</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_489">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_31">EXECUTIVE COMPENSATION AND RELATED INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_31">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_34">GRANTS OF PLAN-BASED AWARDS</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_34">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">CORPORATE GOVERNANCE</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_479">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_43">SHAREHOLDER PROPOSALS</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_43">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifa04aa8a69de418e832ab1f08fb0d35a_46">OTHER MATTERS</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ifa04aa8a69de418e832ab1f08fb0d35a_46">43</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="cpix-20250310_g1.jpg" alt="cumberlandpharmalogoa01.jpg" style="height:74px;margin-bottom:5pt;vertical-align:text-bottom;width:333px"/></div><div style="margin-top:13pt;padding-left:3.37pt;padding-right:3.37pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March 13, 2025</span></div><div style="margin-top:8pt"><span style="color:#003e7e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEAR FELLOW SHAREHOLDERS:</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are invited to join us for the 2025 Annual Meeting of Shareholders of Cumberland Pharmaceuticals Inc. The meeting will be held on April 22, 2025 at 9:30 a.m. Central Time, at Cumberland&#8217;s Corporate Offices located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The enclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Notice of Annual Meeting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Proxy Statement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> describe the formal business to be transacted at this year's Annual Meeting.  The Board's recommendations on these items are included with the proposals, and your support is important.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shareholders of record can vote their shares by marking the enclosed proxy, signing and dating the proxy card and mailing it in the enclosed envelope.  Shareholders can also vote using the Internet or mobile device.  Instructions for using these alternative voting methods are included in the enclosed proxy card.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely,</span></div><div style="margin-top:8pt"><img src="cpix-20250310_g2.jpg" alt="ajbackgroundpicture.jpg" style="height:61px;margin-bottom:5pt;vertical-align:text-bottom;width:89px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A. J. Kazimi</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Chairman and Chief Executive Officer</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">NOTICE OF ANNUAL MEETING OF SHAREHOLDERS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">TO BE HELD APRIL 22, 2025</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2025 Annual Meeting of Shareholders of Cumberland Pharmaceuticals Inc., will be held on April 22, 2025, at 9:30 a.m. Central Time, at the Cumberland Pharmaceuticals Inc., Music City Boardroom, 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203. The items of business are: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;To consider and act upon a proposal to elect to the Company's Board of Directors, Dr. Gordon R. Bernard, Mr. Joseph C. Galante and Mr. A.J. Kazimi;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2) &#160;&#160;&#160;&#160;To ratify a proposal to consider the appointment of Carr, Riggs &amp; Ingram, L.L.C., as the Company's independent registered public accounting firm for the 2025 fiscal year;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)  Any other business that may properly come before our annual meeting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shareholders of record at the close of business on February 28, 2025 are entitled to receive notification and vote at the Annual Meeting and any adjournments or postponements of the meeting.  If you were a shareholder at the close of business on February 28, 2025, you are entitled to vote at the Annual Meeting.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We are furnishing our proxy materials to you under Securities and Exchange Commission rules that allow companies to deliver proxy materials to their shareholders on the Internet. We believe this approach allows us to provide shareholders with a timely and convenient way to receive proxy materials and vote, while lowering the costs of delivery and reducing the environmental impact of our Annual Meeting. On or about March 13, 2025, we will begin mailing a Notice of Internet Availability of Proxy Materials (&#8220;Notice&#8221;) to our shareholders.  We have provided access to our proxy materials on the Internet. The proxy materials include our 2024 Annual Report to Shareholders, our Annual Report on Form 10-K for 2024 and the Proxy Statement and proxy card.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Whether or not you plan to attend the Annual Meeting, we ask that you carefully read through the proxy statement and the voting instructions to ensure that your shares are represented. If you attend the meeting you may withdraw any previously given proxy and vote your shares in person.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By order of the Board of Directors,</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A. J. Kazimi</span></div><div style="margin-top:8pt"><img src="cpix-20250310_g2.jpg" alt="Image3.jpg" style="height:61px;margin-bottom:5pt;vertical-align:text-bottom;width:89px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chairman and Chief Executive Officer</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> THE SHAREHOLDERS MEETING TO BE HELD ON APRIL 22, 2025</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">This Proxy Statement, our 2024 Annual Report to Shareholders and our Annual Report on Form&#160;10-K for 2024 are available at:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> http://www.cstproxy.com/cumberlandpharma/2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.  Directions to attend the Annual Meeting and vote in person are available on our website,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"> www.cumberlandpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. From the homepage, link through the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> &#8220;Investor Relations&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> page to the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> &#8220;Events Calendar&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> page. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Voting Your Shares</span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You may vote if you owned shares of our common stock at the close of business on February 28, 2025.  You may vote in person, or submit a proxy by the Internet, mobile device or mail as follows:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internet:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">www.cstproxyvote.com</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mail:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complete, sign, date and return your proxy card in the postage-paid envelope provided.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In Person:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attend our annual meeting and vote by ballot</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If you submit your proxy via Internet, you do not need to return your proxy card.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1600&#160;West End Avenue, Suite&#160;1300</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nashville, Tennessee 37203</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(615)&#160;255-0068</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROXY STATEMENT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FOR ANNUAL MEETING OF SHAREHOLDERS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TO BE HELD APRIL 22, 2025 </span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL INFORMATION ABOUT THE ANNUAL MEETING AND VOTING</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Proxy Statement accompanies the Notice of Annual Meeting of Shareholders of Cumberland Pharmaceuticals Inc., a Tennessee corporation (&#8220;we,&#8221; &#8220;our,&#8221; "Cumberland," or &#8220;the Company&#8221;), in connection with the solicitation of proxies by and on behalf of our Board of Directors for use at our Annual Meeting to be held on April 22, 2025, at 9:30 a.m. Central Time, at the offices of Cumberland Pharmaceuticals Inc., 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203, and at any postponement or adjournment of the meeting.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are furnishing proxy materials to our shareholders primarily via the Internet under rules adopted by the Securities and Exchange Commission (the "SEC"), instead of mailing printed copies of those materials to each shareholder.  These materials are available to shareholders via the Internet at the following website: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">http://www.cstproxy.com/cumberlandpharma/2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  On March 13, 2025, we will begin mailing to our shareholders a Notice of Internet Availability of Proxy Materials containing instructions on how to access our 2024 Annual Report to Shareholders, our Annual Report on Form 10-K for 2024 and the Proxy Statement and proxy card. The Notice of Internet Availability of Proxy Materials also instructs you on how to access your proxy card or to vote via the Internet or mobile device. We pay&#160;the entire cost of soliciting your proxy, including the cost of preparing, assembling, printing, mailing or otherwise distributing the Notice of Internet Availability of Proxy Materials and these proxy materials.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This process is designed to expedite the shareholders receipt of proxy materials, lower the cost of the Annual Meeting and help conserve natural resources. If you receive a Notice of Internet Availability of Proxy Materials by mail, you will not receive a printed copy of the proxy materials in the mail unless you request a copy. Shareholders who would prefer to continue to receive printed proxy materials should follow the instructions included in the Notice of Internet Availability of Proxy Materials.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What is the Purpose of the 2025 Annual Meeting?</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the 2025 Annual Meeting, shareholders will act upon the matters outlined in the attached Notice of Annual Meeting and described in detail in this Proxy Statement, which are: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;consider and act upon a proposal to elect to the Company's Board of Directors, Dr. Gordon R. Bernard, Mr. Joseph C. Galante and Mr. A.J. Kazimi;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) ratify the appointment of Carr, Riggs &amp; Ingram, L.L.C. as our independent registered public accounting firm for 2025; </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) &#160;to transact such other business as may properly come before our annual meeting or any postponement or adjournment of the meeting. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our management will report on our performance during the fiscal year ended December&#160;31, 2024 and respond to questions from shareholders. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Board does not anticipate that any other matters will come before the 2025 Annual Meeting, your executed proxy gives the official proxies the right to vote your shares at their discretion on any other matter properly brought before the Annual Meeting.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Who Is Entitled to Vote at the 2025 Annual Meeting?</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only shareholders of record at the close of business on February 28, 2025, or the &#8220;record date,&#8221; will be entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the meeting.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What Are the Voting Rights of the Holders of Our Common Stock?</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our common stock are entitled to one vote per share with respect to each of the matters to be presented at the Annual Meeting. With regard to the election of directors, holders of common stock are entitled to vote for as many individuals as there are director seats to be elected, which for the 2025 Annual Meeting includes three (3) Class III</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">director seats. The election of directors is by plurality voting, meaning that the three nominees receiving the greatest number of votes cast will be elected; provided that a quorum is present. On each other matter to be presented, a matter will be approved if the votes cast in favor of the action exceed the votes cast opposing the action.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abstentions will not be counted towards the tabulation of votes cast on matters properly presented to the shareholders (except the election of directors). In the election of directors, if more votes are withheld than votes for the election of a director, that director must tender his or her resignation to the Board of Directors; the Board of Directors will have 90&#160;days to consider the matter and act. Any director who tenders his or her resignation due to this process cannot participate in any decision, unless the election resulted in less than two directors serving on the Board of Directors.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What Constitutes A Quorum?</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bylaws provide that the presence, in person or by proxy, of the holders of a majority of shares entitled to vote at our Annual Meeting shall constitute a quorum. On the record date there were 13,936,854 shares of our common stock (excluding restricted shares) issued and outstanding and such shares are the only shares entitled to vote at the Annual Meeting.  Therefore, we anticipate that the quorum for our Annual Meeting will be 6,968,428 shares.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Your Proxy may be sent directly to the broker that holds your shares. A broker may vote your shares on your behalf without instructions for routine matters, such as Proposal II.  However, a broker must have instructions from you to vote your shares with respect to non-routine matters, such as Proposal I.  A vote that is not cast because the broker lacks instructions from you is called a &#8220;broker non-vote.&#8221; Broker non-votes will be treated as shares present for the purpose of determining whether a general quorum is present at the Annual Meeting, but they will not be counted as a vote FOR or AGAINST a non-routine matter or as an abstention on any non-routine matter. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">What Are the Board&#8217;s Recommendations?</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless you provide other instructions on your proxy card, the persons named as proxy holders on the proxy card will vote in accordance with the recommendations of the Board of Directors. The Board&#8217;s recommendations are set forth together with the description of the Proposal in this Proxy Statement. In summary, the Board recommends a vote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> FOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> election to the Board of Directors of the nominees for the three (3) Class III directorships named in this Proxy Statement (see Proposal I), and a vote </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the ratification of the appointment of Carr, Riggs &amp; Ingram, L.L.C. as our independent registered public accounting firm for the year ending December&#160;31, 2025 (see Proposal II).</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proxy holders will vote in their discretion with respect to any other matter that may properly come before the Annual Meeting.</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proxies</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the enclosed proxy card is executed, returned in time and not revoked, the shares represented thereby will be voted at the Annual Meeting and at any postponement or adjournment of the meeting in accordance with the instructions indicated on such proxy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  IF NO INSTRUCTIONS&#160;ARE INDICATED ON THE PROXY CARD, THE OFFICIAL PROXIES WILL VOTE (1)&#160;&#8220;FOR&#8221; PROPOSAL&#160;I DESCRIBED IN THIS PROXY STATEMENT: (2) "FOR" THE RATIFICATION OF THE APPOINTMENT OF CARR, RIGGS &amp; INGRAM, L.L.C. AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025; AND (3) AS TO ANY OTHER MATTERS PROPERLY BROUGHT BEFORE THE ANNUAL MEETING OR ANY POSTPONEMENT OR ADJOURNMENT THEREOF, IN THE SOLE DISCRETION OF THE PROXY HOLDERS.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shareholder who has returned a proxy card may revoke it at any time prior to its exercise at the Annual Meeting by (i)&#160;giving written notice of revocation to our Corporate Secretary, (ii)&#160;properly submitting to Cumberland Pharmaceuticals Inc. a duly executed proxy bearing a later date or (iii)&#160;appearing at the Annual Meeting and voting in person. All written notices of revocation of proxies should be addressed as follows: Cumberland Pharmaceuticals Inc., 1600&#160;West End Avenue, Suite&#160;1300, Nashville, Tennessee 37203, Attention: Corporate Secretary.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL&#160;I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ELECTION OF DIRECTORS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Board of Directors</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 22, 2025, our Board of Directors will consist of seven directors, divided into three classes, serving staggered three-year terms. One of three classes is elected each year to succeed the directors whose terms are expiring. At this 2025 Annual Meeting, the term of the three (3) Class III directors expire. The individuals nominated for election as director in Class III at this 2025 Annual Meeting would, if elected, hold office for a three-year term expiring in 2027.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Nominees</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Bernard, Mr. Galante and Mr. Kazimi are currently serving as directors of the Company.  There are currently five independent directors serving on our Board.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nomination to serve as Class&#160;III Directors, for term expiring in 2028</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gordon R. Bernard.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dr.&#160;Bernard, 73, Dr. Gordon Bernard served as our Medical Director from 1999 until 2010 and currently serves as Chair of our Medical Advisory Board. He has served on our Board of Directors since 2010. Dr. Bernard is currently the Melinda Owen Bass Professor of Medicine and former Chief of the Division for Allergy, Pulmonary &amp; Critical Care Medicine for Vanderbilt University Medical Center (VUMC). In addition, he was formerly the Executive Vice President for Research at VUMC and former Chairman of VUMC&#8217;s Pharmacy, Therapeutics and Diagnostics Committee, which is responsible for approving their formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980 and has been the Steering Committee Chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994 through its conclusion in 2014. This Network is one of the few federally supported ongoing systems for the conduct of research in the hospital Intensive Care Unit. He holds a B.S. from the University of Southwestern Louisiana and an M.D. from Louisiana State University. As an intensivist, and former Medical Director for the Medical ICU, Dr. Bernard is in a strategic position to observe the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs. The board believes Dr. Bernard&#8217;s medical background is extremely valuable as the Company seeks to continue expanding its pipeline with promising products that offer advancement to patient care and are well-positioned competitively.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joseph C. Galante.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mr.&#160;Galante, 75, became a member of our Board of Directors in 2018. He is a music industry executive with extensive experience that scans a celebrated career. He is accredited with developing the careers of Alabama, Dave Mathews Band, Dolly Parton, Kenny Chesney, Brad Paisley, Martina McBride, Carrie Underwood, Clint Black, Miranda Lambert, and the Judds, among others. Mr. Galante began at RCA Records in New York, followed by a transfer to RCA Nashville where he served as a director at the label, followed by the role of Vice President of Promotion and Marketing. At the age of 32 he became the youngest person ever named to run a major country record label. In 1990 he was appointed President of RCA Records US based in New York. He returned to Nashville as Chairman to run the RCA and BNA labels in Nashville. Under his leadership, RCA Records was the number one country label for eleven consecutive years. He then served as Chairman of Sony Music Nashville for six years. He was presented with the Bob Kingsley Living Legend Award by the Opry Trust to honor his work for country music. In 2022, Mr. Galante was given the esteemed honor of being inducted into the Country Music Hall of Fame. Mr. Galante is currently a member of the Board of Directors of Pinnacle Financial Partners whose shares are listed on the Nasdaq stock exchange, Fishbowl Spirits, LLC and serves as the Chair of the Country Music Association Foundation. He holds a B.S. in finance and marketing from Fordam University. The Board believes his successful business track record, entrepreneurial and public company experience make him a valuable member of our board.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A.J. Kazimi.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mr.&#160;Kazimi, 67, is the Chairman of our Board of Directors and Chief Executive Officer who founded Cumberland in 1999. His career includes over 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of key Company brands, while also leading the acquisition of the Company&#8217;s other commercial products. He was responsible for Cumberland&#8217;s initial public offering and listing on the Nasdaq stock exchange. Mr. Kazimi also serves as Chairman and Chief Executive of Cumberland Emerging Technologies, a joint initiative with Vanderbilt University and the state of Tennessee, designed to support the development of early-stage life sciences programs and companies. Prior to joining Cumberland, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company&#8217;s growth from its start-up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions. He is Chairman of the Board for the Gettysburg Foundation which partners with the National Park Service to preserve that historic military park. He is also a member of the Board of the Tennessee Historical Society. He previously served on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. and the Board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors. Mr. Kazimi holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt University Owen Graduate School of Management. The Board believes that Mr. Kazimi brings strategic insight, leadership and a history of successful execution to the Board along with a wealth of experience in both the biopharmaceutical industry and the development of emerging companies.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class&#160;I Directors Expected to Stand For Re-Election in 2026</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kenneth J. Krogulski</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Mr. Krogulski, 67, joined Cumberland&#8217;s Board of Directors in 2017. He has 45 years of experience in security analysis and portfolio management and is currently the Managing Partner and Chief Investment Officer of Berkshire Asset Management, LLC, an independent SEC registered investment advisory firm.  Prior to Berkshire, Mr. Krogulski began his career in financial services at First Eastern Bank, N.A., now PNC Financial, where he advanced to Chief Investment Officer of their Trust Department. Mr. Krogulski is currently on the Board of Allied Services Integrated Health System. He previously served as a Director of Landmark Community Bank (LDKB: Nasdaq) and numerous nonprofit organizations. Mr. Krogulski holds a B.S. in finance from Indiana University of Pennsylvania and earned his M.B.A. from Wilkes University. In addition, he holds the Chartered Financial Analyst designation. The Board believes Mr. Krogulski&#8217;s extensive financial experience plays a significant role in guiding the Company&#8217;s strategy and offers valuable services in directing Cumberland&#8217;s growth.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caroline R. Young. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Young, 50, joined our Board of Directors in 2016. She brings two decades of health care and life sciences to the role. Currently, she serves as Vice President of Partnership Development at Frist Cressey Ventures, where she focuses on accelerating value for their partnerships and enhancing relationships with industry-wide stakeholders. Previously Ms. Young partnered with Former U.S. Senate Majority Leader Bill Frist to launch NashvilleHealth, a first-of-a-kind initiative to reduce disparities and drive community-level health improvement. Prior to that role, Caroline led one of the nation&#8217;s premier health care industry associations, the Nashville Health Care Council, where she cultivated a national network of executives in support of industry leadership and innovation. She also held prior positions as the founding Executive Director of Life Sciences and Director of Communications and Advertising at the State of Tennessee's Department of Economic and Community Development. Ms. Young holds an M.S. from the University of Tennessee and a B.A. from the University of Mississippi. The Board believes Ms. Young&#8217;s national healthcare industry experience and strategic innovation initiatives are valuable as the Company continues to build a strong portfolio of products that serve the medical community.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class&#160;II Directors Expected to Stand For Re-Election in 2027</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Martin S. Brown, Jr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Mr. Brown, 61, has served on our Board of Directors since 2022.  He previously served for ten years on the Board of Directors of Brown-Forman, which is a New York Stock Exchange listed company. For more than thirty years, Mr. Brown has also been a practicing attorney in Nashville with Adams and Reese, LLP, and its predecessor firm. Adams and Reese is a multi-state law firm with nearly 250 attorneys located in 20 offices. His clients primarily are privately held businesses and their owners. He has been listed in Best Lawyers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> national peer review guide in the corporate law category since 2009. Since 2018 he has served on the Board of Directors of the parent company of Aegis Sciences Corporation, a widely accredited forensic toxicology laboratory. Mr. Brown also has served as a board member or officer for many community organizations, including the Land Trust for Tennessee, Nashville Public Radio, Montgomery Bell Academy, Nashville Public Television, Centerstone Mental Health Center, Cheekwood Estate and Gardens, and the Tennessee chapter of the Nature Conservancy. He is a member of the Economic Club of Nashville and the Nashville Capital Network.  Mr. Brown earned his law degree from Vanderbilt University after receiving his undergraduate degree from Yale University. The Board believes Mr. Brown&#8217;s significant legal knowledge and experience with a public listed company are critical as the Company continues to navigate the responsibilities associated with being a public company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">James R. Jones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Mr. Jones, 77, has served as a member of our Board of Directors since 2010. Mr. Jones&#8217; 36-year career in professional accounting at KPMG LLP included the role of Managing Partner at their Nashville, Tennessee office from 1999 to 2006. He served in various capacities during his career at KPMG which also included positions at their offices in Jackson, Mississippi, Washington, D.C. and Greenville, South Carolina. During his tenure with KPMG, Mr. Jones led a team of more than 100 individuals providing accounting services for an extensive client base. Following retirement in 2006, he has served as an advisor as well as provided various consulting services to several companies, including acting as liaison between management and the board of directors of a long-term care facility and serving as interim CEO of a charitable organization. He is currently a board director and member of the audit committees of Argent Trust Company of Tennessee and Belmont University. Mr. Jones also serves as a member of our Audit Committee and is our Audit Committee financial expert. Mr. Jones holds a B.S. from Mississippi College and an M.B.A from Mississippi State University. The board believes Mr. Jones&#8217; significant accounting background will strengthen Cumberland&#8217;s existing financial capabilities and play a key role as the company is subject to increasingly stringent accounting and auditing regulations as a public entity.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to the section labeled &#8220;CORPORATE GOVERNANCE&#8221; for a discussion of the various committees of our Board of Directors and the composition and duties of these committees, as well as the nomination process for directors, and a discussion of other corporate governance and ethical considerations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on their qualifications and experience, we believe the aforementioned nominees for directorship are suitable nominees to serve on the Board and we believe the nominees will be available and able to serve as directors. In the event that a nominee is unable to serve, our Board may designate a substitute nominee, and the proxy holders will vote the proxies for the substitute nominee as they may determine.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE BOARD OF DIRECTORS STRONGLY RECOMMENDS THAT THE SHAREHOLDERS VOTE &#8220;FOR&#8221; THE ELECTION OF EACH OF THE DIRECTOR NOMINEES LISTED ABOVE.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL&#160;II</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPOSAL TO RATIFY APPOINTMENT OF </span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARR, RIGGS &amp; INGRAM,  L.L.C. AS OUR INDEPENDENT REGISTERED </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee of our Board of Directors has appointed the firm of Carr, Riggs &amp; Ingram, L.L.C. (&#8220;CRI&#8221;) as our independent registered public accounting firm to audit our consolidated financial statements for the fiscal year ending December&#160;31, 2025. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not required to seek shareholder approval for the appointment of our independent registered public accounting firm; however, the Audit Committee and the full Board of Directors believe it to be a sound corporate governance practice to seek such approval. If the appointment is not ratified, the Audit Committee will investigate the reasons for shareholder rejection and will re-consider the appointment. Even if the selection is ratified, the Audit Committee in its discretion, may direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of our Company and our shareholders. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Representatives of CRI will be present at the Annual Meeting and will have an opportunity to make a statement, if they so desire, and will be available to respond to appropriate questions.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE BOARD OF DIRECTORS STRONGLY RECOMMENDS A VOTE &#8220;FOR&#8221; THE RATIFICATION OF THE APPOINTMENT OF CARR, RIGGS &amp; INGRAM, L.L.C. AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2025.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_468"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AUDIT COMMITTEE REPORT</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors appointed the undersigned directors as members of the Audit Committee and adopted a written charter setting forth the procedures and responsibilities of the Audit Committee. Each year, the Audit Committee Chairman reviews the charter and its adequacy in light of applicable Nasdaq Global Select Market rules.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee is comprised of three directors, all of whom are independent in accordance with the listing standards of the Nasdaq Global Select Market and within the meaning of Rule 10A-3 of the Securities Exchange Act of 1934, as amended.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee is responsible for providing oversight of the Company&#8217;s accounting and financial reporting process as well as the audit of the Company&#8217;s financial statements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the last year, and earlier this year in preparation for the filing with the SEC of our Annual Report on Form 10-K for the year ended December 31, 2024, or the 10-K, the Audit Committee:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewed and discussed the audited financial statements with management and the Company&#8217;s independent registered public accounting firm;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewed the overall scope and plans for the audit and the results of the independent registered public accounting firm&#8217;s examinations;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">met with management periodically during the year to consider the adequacy of the Company&#8217;s internal controls and the quality of its financial reporting and discussed these matters with the Company&#8217;s independent registered public accounting firm and with appropriate Company financial personnel;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discussed with the Company&#8217;s senior management, independent registered public accounting firm and appropriate Company financial personnel the process used for the Company&#8217;s chief executive officer and chief financial officer to make the certifications required by the SEC and the Sarbanes-Oxley Act of 2002 in connection with the 10-K and other periodic filings with the SEC;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstrated independence from management and exhibited through directives, actions and behavior, the importance of integrity and ethical values in supporting the functioning of the system of internal control and financial reporting; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewed and discussed with the independent registered public accounting firm (1) their judgments as to the quality (and not just the acceptability) of the Company&#8217;s accounting policies, (2) the written communication required by the Public Company Accounting Oversight Board (PCAOB) Ethics and Independence Rule 3526, "Communication with Audit Committees Concerning Independence" and the independence of the independent registered public accounting firm and (3) the matters required to be discussed with the Audit Committee under auditing standards generally accepted in the United States, including PCAOB Auditing Standard No. 16, &#8220;Communication with Audit Committees.&#8221; </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In reliance on these reviews and discussions referred to above, as well as private discussions with the independent registered public accounting firm and appropriate Company financial personnel, the Audit Committee recommended to the Board of Directors the inclusion of the audited financial statements of the Company and its subsidiaries in the Annual Report on Form 10-K.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing actions and the responsibilities set forth in the Audit Committee charter, it clarifies that it is not the duty of the Audit Committee to plan or conduct audits or to determine that the Company&#8217;s financial statements are complete and accurate and in accordance with generally accepted accounting principles. Management is responsible for the Company&#8217;s financial reporting process including its system of internal controls, and for the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States. </span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent registered public accounting firm is responsible for expressing an opinion on those financial statements. Audit Committee members are not necessarily accountants or auditors by profession or experts in the fields of accounting or auditing. Therefore, the Audit Committee has relied, without independent verification, on (i) management&#8217;s representation that the consolidated financial statements have been prepared with integrity and objectivity and in conformity with accounting principles generally accepted in the United States and (ii) the representations of the independent registered public accounting firm included in their report on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee met regularly with management and the independent registered public accounting firm, including private discussions with the independent registered public accounting firm, and received the communications described above. The Audit Committee has also established procedures for (i) the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and (ii) the confidential, anonymous submission by the Company&#8217;s employees of concerns regarding questionable accounting or auditing matters. However, this oversight does not provide us with an independent basis to determine that management has maintained appropriate accounting and financial reporting principles or policies, or appropriate internal controls and procedures designed to assure compliance with accounting standards and applicable laws and regulations. Furthermore, our considerations and discussions with management and the independent registered public accounting firm do not assure that the Company&#8217;s consolidated financial statements are presented in accordance with generally accepted accounting principles or that the audit of the Company&#8217;s financial statements has been carried out in accordance with generally accepted auditing standards.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee is responsible for recommending the independent registered public accounting firm to serve as the Company&#8217;s auditors each year and for monitoring the auditor&#8217;s qualifications, performance and independence. The Audit Committee maintains written procedures that require it to pre-approve the scope of all auditing services to be performed by the Company&#8217;s independent registered public accounting firm. The Audit Committee&#8217;s procedures prohibit the independent registered public accounting firm from providing any non-audit services unless the service is permitted under applicable law and is pre-approved by the Audit Committee or its Chair.  Although applicable regulations waive these pre-approval requirements in certain limited circumstances, the Audit Committee reviews and pre-approves all non-audit services provided by the Company's independent registered public accounting firm. The Audit Committee has determined that the provision of non-audit services by the Company's independent registered accounting firm is compatible with maintaining such firm's independence.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you would like additional information on the responsibilities of the Audit Committee, please refer to its charter, a copy of which is posted on the Company&#8217;s website at</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.cumberlandpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and is also available in print to any shareholder who requests it. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Submitted by the Audit Committee</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.923%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Mr. James R. Jones</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Mr. Kenneth J. Krogulski</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Mr. Joseph C. Galante</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Chair)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Registered Public Accounting Firm</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Audit Committee of the Board of the Company engaged Carr, Riggs &amp; Ingram, L.L.C. (&#8220;CRI&#8221;) to serve as the Company's independent registered public accounting firm for the Company for the years ended December 31, 2024 and 2023. The Audit Committee previously engaged FORVIS LLP (&#8220;FORVIS&#8221;) to serve as the Company&#8217;s independent registered public accounting firm for the years ended December 31, 2022, 2021 and 2020, and the interim period ended March 31, 2023. On May 18, 2023, the Company informed FORVIS of its decision to not retain FORVIS as the Company&#8217;s independent registered public accounting firm.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate fees billed to us for professional services by CRI for the fiscal year ended December 31, 2024 and 2023 were as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:54.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Audit Fees</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">405,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">353,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Audit-Related Fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tax Fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All Other Fees</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">405,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">353,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the above table, in accordance with the definitions and rules of the SEC, &#8220;Audit Fees&#8221; includes fees related to professional services for the audit of our consolidated financial statements included in our Form 10-K, the review of financial statements included in our Form 10-Q&#8217;s and for services that are normally provided by auditors in connection with statutory and regulatory filings or engagements.  Audit fees also include those in connection with the Company&#8217;s equity offerings.  Those fees were $34,500 and $18,800 for the years ended December 31, 2024, and 2023, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee also has adopted a formal policy concerning approval of audit and non-audit services to be provided by the independent auditor to the Company. The policy requires that the Audit Committee pre-approve all services performed by the Company's independent registered public accounting firm for the Company, including audit services and permitted audit-related and non-audit services. The Audit Committee approved all audit and non-audit services provided during fiscal years 2024 and 2023, respectively, prior to performing such services.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure of changes in the Company's independent registered public accounting firm</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Item 9(d) of Schedule 14A, the Company must provide the disclosure required by Item 304(a) of Regulation S-K, similar to the disclosures previously provided by the Company in its Form 8-K dated May 24, 2023 (the "Auditors Current Report"). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decision to change the independent registered public accounting firm of the Company was recommended and approved by the Audit Committee of the Board of Directors. The Audit Committee completed a review of the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.  As a result of this review, on May 18, 2023, the Audit Committee informed FORVIS of its decision to dismiss FORVIS as the Company's independent registered public accounting firm, effective as of that date. In addition, on May 18, 2023, the Audit Committee informed CRI that they were selected as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.  CRI had obtained provisional approval, with their appointment to become effective upon the execution of an engagement letter and related completion of CRI's final client acceptance procedures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company's fiscal years ended December 31, 2022, 2021 and 2020, and the subsequent interim period through May 18, 2023, there were (i) no &#8220;disagreements&#8221; (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and FORVIS on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to FORVIS&#8217;s satisfaction, would have caused FORVIS to make reference to the subject matter of the disagreement in its report on the Company's consolidated financial statements for the relevant year, and (ii) no "reportable events" as that term is defined in Item 304(a)(1)(v) of Regulation S-K. The audit reports of FORVIS on the consolidated financial statements of the Company as of December 31, 2022, and 2021, contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2023, the Company provided FORVIS with a copy of the disclosures of the Auditors Current Report and requested FORVIS to, as promptly as possible, furnish the Company with a letter (the "FORVIS Letter") addressed to the Securities and Exchange Commission (&#8220;SEC&#8221;) stating whether FORVIS agrees with the statements made by the Company in response to Item 304(a) of Regulation S-K and, if not, stating the respects in which it does not agree.  FORVIS furnished to the Company the FORVIS Letter addressed to the SEC dated May 24, 2023, which stated that FORVIS agrees with the statements made in response to Item 304(a) insofar as they relate to their Firm.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 30, 2023, CRI completed its final client acceptance approval process and the Audit Committee formally engaged CRI as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.  During the Company's fiscal years ended December 31, 2022, 2021 and 2020, and the subsequent interim period through May 30, 2023, neither the Company, nor anyone on its behalf, consulted with CRI regarding (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company's consolidated financial statements, and neither a written report nor oral advice was provided to the Company that CRI concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a &#8220;disagreement&#8221; (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a &#8220;reportable event&#8221; (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_22"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based solely upon information made available to us, the following table sets forth information with respect to the beneficial ownership of our common stock as of February 28, 2025 (except as otherwise indicated) by (1)&#160;each person who is known by us to beneficially own more than five percent of our common stock (based solely on our review of SEC filings); (2)&#160;each of our directors and nominees; (3)&#160;our Chief Executive Officer, Chief Financial Officer and our three most highly compensated executive officers (other than our CEO and CFO), or collectively, our Named Executive Officers; and (4)&#160;all executive officers and directors as a group. Unless otherwise indicated, each of the persons below has sole voting and investment power with respect to the shares beneficially owned by such person and the address of each beneficial owner listed on the table is c/o&#160;Cumberland Pharmaceuticals Inc., 1600&#160;West End Avenue, Suite&#160;1300, Nashville, Tennessee 37203. To the knowledge of the Company, no other person or entity holds more than 5% of the outstanding shares of common stock, except as set forth in the following table.  No common stock beneficially owned by any director or named executive officer has been pledged as security for a loan.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:48.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.140%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of Beneficial Owner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares of Common Stock Beneficially Owned</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent of Outstanding Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,790,296</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth J. Krogulski</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,843</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Galante </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,856</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James R. Jones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,646</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James L. Herman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,255</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caroline R. Young </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,318</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,003</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Todd M. Anthony</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,328</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christopher T. Bitterman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,683</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin S. Brown, Jr.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gordon R. Bernard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors and executive officers as a group (11 persons)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,305,728</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.85&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Over 5% Shareholders</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Millennium Management LLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.369%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The SEC has defined "beneficial ownership" of a security to mean the possession, directly or indirectly, of voting power and/or investment power over such security. A stockholder is also deemed to be, as of any date, the beneficial owner of all securities that such stockholder has the right to acquire within 60 days after that date through (1) the exercise of any option, warrant or right, (2) the conversion of a security, (3) the power to revoke a trust, discretionary account or similar arrangement or (4) the automatic termination of a trust, discretionary account or similar arrangement. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, our common stock subject to options or other rights (as set forth above) held by that person that are currently exercisable or will become exercisable within 60 days thereafter, are deemed outstanding, while such shares are not deemed outstanding for purposes of computing percentage ownership of any other person.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on 13,936,854 shares of common stock outstanding on February 28, 2025.</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes 32,000&#160;shares that Mr.&#160;Kazimi has the right to acquire upon the vesting of restricted stock and 88,000 of incentive stock options.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes 6,500 shares Mr.&#160;Krogulski has the right to acquire upon the vesting of restricted stock.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes 2,500 shares Mr. Galante has the right to acquire upon the vesting of restricted stock.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes 2,500 shares Mr.&#160;Jones has the right to acquire upon the vesting of restricted stock.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes 3,000 shares Mr.&#160;Herman has the right to acquire upon the vesting of incentive stock options.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes 2,500 shares Ms. Young has the right to acquire upon the vesting of restricted stock.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes 20,000 shares Mr.&#160;Hamm has the right to acquire upon the vesting of restricted stock and 3,000 of incentive stock options.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes 3,000 shares Mr. Anthony has the right to acquire upon the vesting of incentive stock options.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes 2,000 shares Mr. Bitterman has the right to acquire upon the vesting of incentive stock options.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Includes 2,500 shares Mr. Brown has the right to acquire upon the vesting of restricted stock.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Bernard, as required by a policy change by his employer, is prohibited from owning shares in a pharmaceutical company.  The policy change resulted in Dr. Bernard selling 118,729 shares during 2019, but it did not impact his ability to serve on the Company's Board of Directors. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based solely on a Schedule 13G filed on February 11, 2025 by Integrated Core Strategies (US) LLC, Millenium Management LLC, Millenium Group Management LLC and Israel A. Englander.  As reported in the Schedule 13G, (i) Integrated Core Strategies (US) LLC has shared voting power and shared dispositive power over 1,229,557 shares and (ii) Millenium Management LLC, Millenium Group Management LLC and Israel A. Englander have shared voting power and shared dispositive power over 1,229,633 shares. The address of Integrated Core Strategies (US), Millenium Management LLC, Millenium Group Management LLC and Israel A. Englander LLC is 399 Park Avenue, New York, NY 10022.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedging Policy</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently does not have any policies prohibiting the hedging of Company securities by its executive officers or directors.</span></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_25"></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DELINQUENT SECTION 16(a) REPORTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 16(a) of the Securities Exchange Act of 1934, our directors and executive officers and persons holding more than 10% of any class of our equity securities, are required to file with the SEC initial reports of their ownership of our common stock and reports of changes in such ownership. The Company is required to identify in its proxy statement whether it has knowledge that any person required to file such a report may have failed to do so in a timely manner. Based solely upon a review by the Company of copies of these reports filed with the SEC and written representations furnished to the Company by its officers and directors, all of the persons subject to the Section 16(a) reporting requirements filed the required reports on a timely basis with respect to fiscal 2024, , other than each of Martin S. Brown, Jr., Joseph C. Galante, James R. Jones, Kenneth J. Krogulski, and Caroline R. Young filed an amendment to a Form 4 on January 30, 2025 to correct the number of shares granted to such director, as reported in a prior timely filed Form 4 on March 26, 2024.  The Form 4 amendments were the result of an administrative error. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_489"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">COMPENSATION DISCUSSION AND ANALYSIS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Compensation Discussion and Analysis provides a detailed description of our executive compensation philosophy and programs, the decisions the Compensation Committee has made under those programs and the factors considered in making those decisions. The information in this Compensation Discussion and Analysis should be read in conjunction with the Summary Compensation Table and the related tables and narratives that follow this Compensation Discussion and Analysis. For purposes of this Compensation Discussion and Analysis, the following individuals were our &#8220;Named Executive Officers&#8221; for fiscal year 2024:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A.J. Kazimi, Chief Executive Officer</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">James L. Herman, Executive Vice President National Accounts and Corporate Compliance Officer</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Todd M. Anthony, Vice President Organizational Development</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Christopher T. Bitterman, Vice President Sales &amp; Marketing</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">John M. Hamm, Vice President Accounting &amp; Finance and Chief Financial Officer</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, Cumberland continued to advance its long-term strategy, building its brands, progressing its clinical programs, and supporting the Company&#8217;s domestic and international commercial partners.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights for the year include the following: </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtained FDA Orphan Drug Designation for the ifetroban Duchenne Muscular Dystrophy program.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Also obtained FDA Rare Disease Designation for the ifetroban Duchenne Muscular Dystrophy program.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Received FDA approval for the Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sNDA with the new, two bag dosing regimen.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supported the submission for the approval of Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Mexico.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Helped advance the submissions for the approval of Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Packaged and supplied Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the launch of the product in Saudi Arabia.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Published results from a real world patient data analysis comparing Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to key competitor.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Progressed the patient enrollment in the Phase II ifetroban clinical studies.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Entered into a corporate partnership for the development of a new gastroenterological imaging agent.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced top line results from a Phase II clinical trial for a treatment for delirium in hospitalized patients.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completed the reorganization and expansion of the oncology sales division supporting Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Launched Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Cumberland packaging, supplied by new manufacturer.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created new patient benefit verification and sampling programs for Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successfully implemented co-promotion initiatives to support Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtained Medicaid coverage for Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in additional states.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Launched new packaging and distribution arrangement for Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reorganized and expanded national accounts capabilities.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implemented new initiatives and procedures to enhance corporate cyber-security.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our executives' compensation is tied to and rewards both Company and individual performance:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We review our compensation programs periodically to ensure that they are appropriate and competitive.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have annual agreements for each of our employees that do not have a change-of-control feature.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We generally do not provide perquisites.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide what we believe is a competitive total compensation package to our executive management team through a combination of base salary, annual bonuses, grants under our long-term equity incentive compensation plan, retirement plan and broad-based benefits programs. We place significant emphasis on performance-based incentive compensation programs. This Compensation Discussion and Analysis explains our compensation philosophy, policies and practices.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">        Role of Advisory Vote on Compensation of our Named Executive Officers</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board recognizes the fundamental interest our shareholders have in the compensation of our executive officers. At the 2023 Annual Meeting, our shareholders approved, on an advisory basis, the compensation of our Named Executive Officers. Based upon the results of such advisory vote and our review of our compensation policies and decisions, the Board and Compensation Committee believe that these policies and decisions are consistent with our compensation philosophy and objectives discussed below and align the interests of our Named Executive Officers with the long-term goals of the Company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the advisory vote of our shareholders at the 2020 Annual Meeting, the Board determined that the Company would hold shareholder advisory votes on executive compensation once every three years. The next shareholder advisory vote on executive compensation is scheduled to occur at the Annual Meeting of Shareholders of the Company to be held in 2026. While the say on pay vote is not binding on the Board or the Company, we will continue to review our executive compensation program in the future and will consider the views of our shareholders as well as other developments during such review.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Philosophy and Objectives</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      Our compensation programs are designed to achieve the following objectives:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain talented and experienced executives;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">motivate and reward executives whose knowledge, skills and performance are critical to our success;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">align the interests of our executive officers and shareholders by motivating executive officers to increase shareholder value and rewarding them when shareholder value increases;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide a competitive compensation package in which total compensation is primarily determined by company and individual results along with the creation of long term shareholder value;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensure fairness among the executive management team by recognizing the contributions each executive makes to our success; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compensate our executives so they will manage our business to meet our long-range objectives.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When making decisions on setting compensation for our Named Executive Officers, the Compensation Committee considers, among other factors, their importance to us and the business, the individual's past salary history, market compensation for similar positions and the contributions to be made by the individual to the company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following principles to guide our decisions regarding executive compensation:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide compensation packages considering market levels;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require performance goals to be achieved that will increase long term value to our shareholders;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">offer a comprehensive benefits package to all full-time employees; and </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide fair and equitable compensation consistent with experience and performance.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">            </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Compensation Process</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee and management each play a role in designing our executive compensation programs and determining performance levels and associated payouts. The roles of the Compensation Committee and management are carefully determined to reflect best practices.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Role of the Compensation Committee</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee, which is composed entirely of independent directors, oversees our executive compensation programs.  Each year, the Compensation Committee reviews and approves the elements of compensation for all Named Executive Officers. Our Compensation Committee independently considers appropriate compensation for our Chief Executive Officer ("CEO") during an executive session without the CEO present. Our Compensation Committee meets with the CEO outside the presence of all other Named Executive Officers to consider their compensation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">     Role of Management</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CEO annually reviews each of the other Named Executive Officer&#8217;s performance with the Compensation Committee and makes recommendations to the Compensation Committee with respect to the appropriate base salary, annual bonuses and grants of long-term equity incentive awards. In developing these recommendations, information from the Radford Global Life Sciences Survey (the &#8220;Radford Survey&#8221;) is considered. Based in part on these recommendations from our CEO, the Compensation Committee approves the annual compensation package for our Named Executive Officers other than our CEO and also approves compensation guidelines for the rest of the Company.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    Competitive Marketplace Assessment</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In making compensation determinations, our Compensation Committee periodically considers published survey data to guide compensation decisions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee reviews data in the Radford Survey of 800 biopharmaceutical companies to determine whether base salary, annual bonuses and long-term equity incentive awards for each of our Named Executive Officers are generally in the range of reported compensation for positions similar to those held by each Named Executive Officer.</span></div><div style="margin-top:8pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Determining the Individual Compensation of our Named Executive Officers</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation programs do not encourage excessive risk taking but reward achievement of short-term and long-term financial and strategic objectives through a balanced mix of compensation components not overly weighted towards the short term and through the use of multiple performance factors related to both Company-wide metrics and individual performance goals. The Compensation Committee determines adjustments in each element of compensation paid to our Chief Executive Officer and other Named Executive Officers based on a review of annually established corporate and individual objectives. These annual objectives help identify achievements made by our executive officers. Increases or decreases in compensation in relation to the midpoint of the range identified in the Radford Survey are based on our Compensation Committee&#8217;s review of each Named Executive Officer&#8217;s performance, as well as other factors including the Compensation Committee&#8217;s assessment of the individual&#8217;s past experience, knowledge, future potential and the scope of their responsibilities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate objectives against which our executive officers are evaluated include the performance of our marketed products, progress in our product development activities, progress in expanding our product portfolio through development or acquisition activities, enhancement of our corporate infrastructure and improvement in overall progress in building the Company. Individual objectives for our executive officers involve more specific progress in areas of personal responsibility and vary by individual. The achievement of particular corporate and individual objectives does not determine compensation levels in a formulaic manner.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elements of Compensation</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      Overall, our compensation programs are designed to be consistent with the objectives and principles set forth above. We believe the objectives of our compensation programs are collectively best achieved through a compensation package comprised of the following basic elements:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">base salary; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">annual bonuses;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">long-term equity incentive compensation; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other compensation and benefits including retirement, health and welfare benefits.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      A description of the primary role of each compensation element is provided below, followed by a discussion of the individual elements of compensation for the Named Executive Officers, including the CEO, during 2024. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base Salary</span></div><div style="margin-top:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We review salary ranges and individual salaries for our executive officers on an annual basis. We establish the base salary for each Named Executive Officer based on consideration of median pay levels in the market and internal factors, such as the individual's performance and experience, the level of responsibility held, as well as pay of others on our executive team.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, our Compensation Committee reviews recommendations and determines base salaries for each Named Executive Officer based on information in a published survey data, which provides us with a general understanding of the reasonableness and competitiveness of our compensation. We believe the base salaries paid to our executives during 2024 achieved our compensation objectives, compared favorably to market pay levels and were consistent with our goal of providing base salaries that are within the market ranges for similar sized companies in our industry.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Bonuses</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The awards of discretionary annual bonuses are determined after consideration of our corporate and individual objectives and are intended to recognize and reward our Named Executive Officers with cash payments above base salary as determined by our success in a given year. Our Compensation Committee uses a published survey data as a benchmarking guide for bonuses as a percentage of base salary, and then considers each Named Executive Officer's individual performance to determine bonuses paid in a given year. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, adjustments to our Named Executive Officers&#8217; total compensation were made based on an analysis of current market pay levels in the aforementioned Radford Survey. In addition to our analysis of market pay levels, factors taken into account in determining 2024 bonuses included each Named Executive Officer's contributions, performance, role and responsibilities and the relationship of the individual&#8217;s base pay to that of other Named Executive Officers.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-term Equity Incentive Compensation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We award long-term equity incentive grants to our Named Executive Officers as part of our total compensation package. These awards are consistent with our pay for performance principles and align the interests of the executive with the interests of our shareholders. The Compensation Committee reviews and approves the amount of each award to be granted to the individual.  The Compensation Committee's goal is to provide awards that are competitive with the external market.  Long-term equity incentive awards granted to executives are determined after consideration of data included in the Radford Survey. The awards generally vest over a period of four years and are intended to focus our executives on achievement of our long-term strategic goals. Long-term equity incentive awards were made pursuant to our 1999 Stock Option Plan, (the &#8220;1999 Plan&#8221;), until April 2007, and thereafter pursuant to our 2007 Long-Term Incentive Compensation Plan.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2007 Long-Term Incentive Compensation Plan</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purposes of the 2007 Long-Term Incentive Compensation Plan, as amended, (&#8220;2007 Plan&#8221;), are to encourage our employees and consultants to acquire stock and other equity-based interests and to replace the 1999 Plan without impairing the vesting or exercise of any option granted thereunder. In 2020, the 2007 Plan was amended to extend the 2007 Plan, and our ability to make grants thereunder, until April 21, 2026.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2007 Plan authorizes the issuance of each of the following incentives:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incentive stock options (options that meet Internal Revenue Service requirements for special tax treatment);</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nonqualified stock options (all stock options other than incentive stock options);</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock appreciation rights (right to receive any excess in fair market value of shares over a specified price);</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricted stock (shares subject to vesting, transfer and forfeiture limitations); and</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance shares (contingent awards comprised of stock and/or cash and paid only if specified performance goals are met).</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee administers the 2007 Plan. The Compensation Committee is authorized to select participants, determine the type and number of awards to be granted, determine, and  amend (subject to certain limitations) the terms of any award, interpret and specify the rules and regulations relating to the 2007 Plan and make all other necessary determinations. Employees and consultants other than non-employee directors are eligible to participate. We may cancel unvested or unpaid incentives for terminated employees and consultants to the extent permitted by law. Upon the occurrence of a change-of-control event, as defined in the 2007 Plan, all outstanding options will automatically become exercisable in full, and restrictions and conditions for other issued incentives will generally be deemed terminated or satisfied. In addition, our Board of Directors may amend or terminate the 2007 Plan, subject to shareholder approval, to comply with tax or regulatory requirements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2007 Plan, all executive officers were granted shares of incentive stock options in 2024. These options will all vest on the fourth anniversary of their grant date. As of December 31, 2024, there were 641,600 outstanding options to purchase shares of common stock pursuant to the 2007 Plan.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, there were 123,325 shares of unvested restricted stock issued pursuant to the 2007 Plan, which have defined vesting schedules. There were also 1,426,204 shares of common stock outstanding as of December 31, 2024, that were issued pursuant to the 2007 Plan.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Savings Opportunity</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2006, we established a 401(k) plan covering all employees meeting certain minimum service and age requirements. The plan allows all qualifying employees to contribute the maximum tax-deferred contribution allowed by the Internal Revenue Code.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-Highly Compensated Employees, or non-HCEs, do not have a minimum or maximum percentage limit that they can defer. The Highly Compensated Employees, however, are limited to what they can defer based on prior year's testing. Hardship distributions are permitted under well-defined circumstances. Beginning January 2008, our Board approved matching employee contributions. We intend to match a portion of the employee contributions on an annual basis.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health and Welfare Benefits</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      All full-time employees, including our Named Executive Officers, may participate in our health and welfare benefits programs, which consist of medical, dental and vision care coverage, disability insurance and life insurance.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Perquisites</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally do not provide perquisites to our employees.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2025 and 2024, we entered into new, annual employment agreements with all of our employees. The employment agreements provide that individuals may be eligible for any bonus program which has been approved by our Board of Directors. Any such bonus is discretionary and will be subject to the terms of the bonus program, the terms of which may be modified from year-to-year in the sole discretion of our Board of Directors. During the period of employment under these agreements, each of our employees will be entitled to additional benefits, including eligibility to participate in any company-wide employee benefits programs approved by our Board of Directors as well as reimbursement for reasonable expenses.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employment is at-will and may be terminated by us at any time, with or without notice and with or without cause. Similarly, each employee may terminate his or her employment with us at any time, with or without notice. Our employment agreements do not provide for any severance payments in the event employment is terminated for cause nor any severance benefits in the event employment is terminated as a result of death or permanent disability. The employment agreements include noncompetition, non-solicitation and nondisclosure covenants on the part of employees. These agreements also require that, during the term of employment with us and for one year after an individual ceases to be employed by us, each employee may not compete with our business in any manner, unless he or she discloses all the relevant facts and receives a release allowing him or her to engage in a specific activity. Pursuant to the employment agreements, our employees also agree that for a period of one year after the individual ceases to be employed by us, he or she will not solicit business related to the development or sales of pharmaceutical products from any entity, organization or person which is contracted with us, which has been doing business with us, or which the employee knew we were going to solicit business from at the time he or she ceased to be employed. The agreements also prohibit a departing employee from soliciting our employees. The employment agreements impose obligations regarding confidential information and state that any discoveries or improvements conceived, developed or otherwise made by the employees, or with others, are deemed our sole property. The employment agreements do not contain any retirement, resignation or other termination or change in control provisions.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Plan</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we put in place a new retirement benefit plan, the Summit Program, for a select group of senior management and key employees.  These individuals were selected based on tenure, performance and achievement. We may add more individuals to this plan each year.  The decision to add individuals to this plan is discretionary and will be subject to the terms of the Summit Program.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This benefit program is provided through a defined contribution Supplemental Executive Retirement Plan. As a defined contribution plan, the amount to be contributed is quantifiable and predictable in its impact on our cash and earnings. The Board approved our initial contribution to the plan and approves annual contributions thereafter, at its discretion and based on both employee and Company performance. The employees may also be given the option to defer some of their other compensation into this program.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will use Corporate Owned Life Insurance to offset future liabilities under the plan. Utilizing such insurance allows the assets to grow on the gross contributions and thus offset the gross growth against the defined contribution liability.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pension Benefits</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as described above in the Retirement Plan section, we do not have any plan that provides for payments or other benefits at, following, or in connection with retirement.</span></div><ix:nonNumeric contextRef="c-1" name="cpix:TimingOfStockOptionAndOtherEquityAwardGrants" id="f-5" continuedAt="f-5-1" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Timing of Stock Option and other Equity Award Grants</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-5-1">Although the Company does not have a formal policy regarding the timing of awards of stock options, stock appreciation rights (&#8220;SARs&#8221;) and/or similar option-like instruments grants to the Company&#8217;s named executive officers, the Company does not make these awards or any other form of equity compensation in anticipation of the release of material, non-public information. Similarly, the Company does not time the release of material, non-public information based on stock option, SARs or other equity award grant dates for the purpose of affecting the value of any award to the Company's named executive officers.</ix:continuation>  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024 Executive Compensation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee believes that our Named Executive Officers made favorable progress in meeting corporate and individual objectives in 2024 and that the progress justified the resulting increases in base salary as well as annual bonuses and equity awards.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, Cumberland continued to advance its long term strategy, building its brands, progressing its clinical programs, and supporting the Company&#8217;s domestic and international commercial partners.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors considered by our Compensation Committee in assessing officers&#8217; performance in 2024 are set forth below:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">A.J. Kazimi. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception Mr. Kazimi has led the Company's significant corporate initiatives, including our initial public offering and listing on the Nasdaq Global Select Market Exchange. He has raised over $100 million to support the formation, development and growth of the Company. He has developed and guided our strategy to build our commercial portfolio of FDA-approved brands. Mr. Kazimi has also led the acquisitions associated with our portfolio of marketed products, as well as the establishment of our co-promotion arrangements. He has overseen the management and growth of our organization including key executive appointments, guided our favorable Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent defense, and managed the expansion of our patent portfolio. Mr. Kazimi also led efforts with the Company&#8217;s co-promotion and international partners to develop new markets for our brands. During 2024, he oversaw the Company&#8217;s operations which included a growing number of manufacturing partners, several key appointments and overall development of the organization.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">James L. Herman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Mr. Herman managed the Company's key national and regional distribution relationships in 2024, resulting in the continued availability of our marketed brands during the year. He also oversaw our arrangements with managed care and group purchasing organizations, improving the contracts in support of Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to these commercial responsibilities, he continued to lead our corporate compliance efforts which included implementing product serialization requirements as well as the training, communication and oversight of the Company's compliance policies.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Todd M. Anthony.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Anthony is responsible for managing our human resources, office administration, and employee development. He also oversees our national group of medical sales liaisons that support our brands. Mr. Anthony continues to manage all appointments for our organization including the identification, hiring and onboarding of new employees. In his administration role he is also responsible for the Company&#8217;s information technology including hardware, systems and cybersecurity efforts. During 2024, Mr. Anthony continued to oversee and maintain the Company&#8217;s new headquarter facility. He also refined the process for hiring, training and developing the members of our sales organization. He oversaw efforts to enhance cybersecurity policies and procedures. In 2024, Mr. Anthony was the inaugural recipient of the Cumberland Culture Award, for his efforts in defining and disseminating key elements of the Company&#8217;s culture.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Christopher T. Bitterman.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Bitterman coordinated all the sales and marketing activities for the Company in 2024. He oversaw the sales organization comprised of the hospital sales division, field sales division and oncology sales division, introducing new incentive programs to motivate and reward our sales professionals. During 2024, Mr. Bitterman completed the reorganization and expansion of the oncology sales division.  He also assumed responsibility for national account sales and expanded that capability. He led the national and district sales meetings held during the year designed to motivate all sales personnel and coordinate their activities. Mr. Bitterman also oversaw the Company&#8217;s marketing activities and implementation of  the advertising and promotional campaigns, initiatives in support of the Company&#8217;s brands. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">John Hamm. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Hamm served as the Company&#8217;s principal financial officer in 2024 and was responsible for the Company&#8217;s accounting systems and activities. He managed our SEC reporting including the timely filing of our annual, quarterly and other periodic reports during the year. Mr. Hamm also continued to oversee improvements to the Company&#8217;s accounting systems and procedures. During 2024, Mr. Hamm was responsible for our commercial banking relationships, managing our line of credit and optimizing the investment of the Company&#8217;s cash reserves. He managed all tax filings and insurance arrangements for the Company during the year. He also continued to oversee the Company&#8217;s business development, including key co-promotion partnerships as well as the corporate legal activities. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of our non-tenured, non-executive director annual compensation in 2024 included $50,000 plus 2,500 shares of restricted stock issued pursuant to our 2007 Directors' Incentive Compensation Plan, as amended, (the &#8220;2007 Directors&#8217; Plan&#8221;). Annual compensation for each of our tenured (having completed their first three-year term) non-executive directors for service on the Board of Directors for 2024 was $60,000 plus 2,500 shares of restricted stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on their responsibilities and activities, for 2024, the Chairman of our Medical Advisory Board received additional compensation of $40,000, and our Lead Independent Director received an additional 4,000 shares of restricted stock. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual compensation for our tenured, non-executive directors for 2025 will be $60,000 plus 2,500 shares of restricted stock issued pursuant to the 2007 Directors' Plan. The Chairman of our Medical Advisory Board will receive additional compensation of $40,000 in 2025 and our Lead Independent Director will receive an additional 4,000 shares of restricted stock. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All such director fees are paid in a combination of cash and/or equity, as we and each director shall agree. Cash fees will be accrued and paid on either a monthly or quarterly basis. Directors will not receive separate compensation for attendance at board meetings, board committee meetings or other Company board-related activities. Outside directors will be reimbursed for all reasonable and necessary business expenses incurred in the performance of their board responsibilities. The Compensation Committee reviews and approves director compensation. </span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2007 Directors' Incentive Compensation Plan</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purposes of the 2007 Directors&#8217; Plan are to strengthen our ability to attract, motivate, and retain qualified independent directors and to replace the 1999 Plan without impairing the vesting or exercise of any option granted to a director thereunder.  In 2020, the 2007 Directors&#8217; Plan was amended to extend our ability to make grants thereunder, until April 21, 2026.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2007 Directors' Plan authorizes the issuance to non-employee directors of each of the following types of awards:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nonqualified options;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricted stock grants (shares subject to various restrictions and conditions as determined by our Compensation Committee); and</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock grants (awards of shares of our common stock with full and unrestricted ownership rights).</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee administers the 2007 Directors' Plan. In the event of a change in control of the Company (as defined in the 2007 Directors' Plan), all outstanding options would automatically become exercisable in full, and restrictions and conditions for other issued awards shall generally be deemed terminated or satisfied. Our Board of Directors may amend or terminate the 2007 Directors' Plan, subject to shareholder approval, if necessary, to comply with tax or regulatory requirements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, there were no options to purchase shares of common stock issued and 16,500 shares of unvested restricted stock issued which have defined vesting schedules, pursuant to the 2007 Directors' Plan.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Report</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has reviewed and discussed this Compensation Discussion and Analysis with management. Based on its review of this Compensation Discussion and Analysis and discussions with management, the Committee has recommended to the Board that this Compensation Discussion and Analysis be included in this Proxy Statement.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you would like additional information on the responsibilities of the Compensation Committee, please refer to its charter, a copy of which is posted on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.cumberlandpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and is also available in print to any shareholder who requests it.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Submitted by the Compensation Committee</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.923%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Mr. Joseph C. Galante</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Ms. Caroline R. Young</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Dr. Gordon R. Bernard </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Chair)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXECUTIVE COMPENSATION AND RELATED INFORMATION</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the compensation for services in all capacities to our company for our fiscal years ended December&#160;31, 2024, 2023 and 2022 for the Named Executive Officers:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:4.5pt;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"><tr><td style="width:1.0%"/><td style="width:16.056%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Principal Position</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Awards </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonqualified Deferred Compensation Earnings (2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other Compensation (3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A.J. Kazimi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">702,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,167,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt 0 7pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,197,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">James L. Herman</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt 0 10pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,880&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,540&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388,188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Todd M. Anthony</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/><td colspan="3" style="background-color:#bfbfbf;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chris T. Bitterman</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305,965&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt 0 13pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316,287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">John M. Hamm</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/><td colspan="3" style="background-color:#acacac;padding:0 1pt"/></tr></table></div><div style="padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The fair value of restricted stock awards granted March 16, 2022, equaled $2.85 for CEO and $2.59 for other NEOs, the closing price of our common stock on the grant date.  The CEO's fair value was equal to the closing price of our common stock at the date of grant plus 10% for being an over 5% shareholder.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Represents the additions for the Named Executive Officers to the non-contributory, non-qualified defined contribution plan that provides for the payment of benefits from the general funds of the Company.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Represents premiums paid for by the Company with respect to life insurance for the benefit of the Named&#160;Executive Officers.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CEO Pay Ratio</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(u) of Regulation S-K, we are providing the following information about the relationship of the annual total compensation of our employees and the annual total compensation of Mr. A.J. Kazimi, President and Chief Executive Officer (the &#8220;CEO&#8221;):</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2024, our last completed fiscal year, the annual total compensation, including salary, bonus, equity awards, and any deferred compensation of:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our median employee identified at our company (other than our CEO) had total annual compensation of $99,665; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our CEO, as reported in the Summary Compensation Table, for purposes of determining the CEO Pay Ratio had total annual compensation of $1,167,269.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this information, for 2024, the ratio of the annual total compensation of Mr. Kazimi, our CEO, to the annual total compensation of our median employee was estimated to be 12:1.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">This pay ratio is a reasonable estimate calculated in a manner consistent with SEC rules based on our payroll and employment records and the methodology described below. The SEC rules for identifying the median compensated employee and calculating the pay ratio based on that employee&#8217;s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their compensation practices. As such, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies may have different employment and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To identify the median employee, and their annual total compensation, the Company examined its payroll records, for 2024, for all individuals other than the CEO that were employed at December 31, 2024. We determined that our employee population consisted of 91 individuals. Using that employee population, we collected and compared actual base salary, bonus, equity awards and any deferred compensation earned by all employees during 2024.  Compensation for employees that began employment during the year was annualized based on rate of pay applied to a full year. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers of the Company</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is information regarding our Executive Officers including their ages, positions with our company and principal occupations and employers for at least the last five years. For information concerning such executive officers&#8217; ownership of our common stock, see &#8220;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.&#8221;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A.J. Kazimi, Chief Executive Officer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mr.&#160;Kazimi, 67, is the Chairman of our Board of Directors and Chief Executive Officer who founded Cumberland in 1999. His career includes over 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of key Company brands, while also leading the acquisition of the Company&#8217;s other commercial products. He was responsible for Cumberland&#8217;s initial public offering and listing on the Nasdaq stock exchange. Mr. Kazimi also serves as Chairman and Chief Executive of Cumberland Emerging Technologies, a joint initiative with Vanderbilt University and the state of Tennessee, designed to support the development of early-stage life sciences programs and companies. Prior to joining Cumberland, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company&#8217;s growth from its start-up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions. He is Chairman of the Board for the Gettysburg Foundation which partners with the National Park Service to preserve that historic military park. He is also a member of the Board of the Tennessee Historical Society. He previously served on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. and the Board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors. Mr. Kazimi holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt University Owen Graduate School of Management. The Board believes that Mr. Kazimi brings strategic insight, leadership and a history of successful execution to the Board along with a wealth of experience in both the biopharmaceutical industry and the development of emerging companies.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">James L. Herman, Vice President Trade and Distribution.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mr.&#160;Herman, 70, handles all our national accounts sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He is also charged with overseeing our corporate compliance efforts. He has been with us since 2003 and has over 30 years of pharmaceutical industry experience. He previously served as Director of Managed Care and Director of Trade Affairs and Customer Service at Solvay Pharmaceuticals. Prior to that Mr. Herman was with Schwarz Pharma, where he held national sales leadership positions in National Accounts and Managed Care. He holds a B.S. from Indiana University and an M.B.A. from Cardinal Stritch University.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Todd M. Anthony, Vice President Organizational Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Anthony, 64, manages our human resources, information technology and cybersecurity, organizational development and office administration activities. Mr. Anthony has been with Cumberland since 2010. During his tenure, he has made many contributions to training and development initiatives as well as human resources activities. These include the preparation and implementation of sales training materials for each branded product. Under his leadership, the Cumberland Academy was established with a core curriculum and advanced courses designed to provide industry expertise and continued learning opportunities for the office employees. He has over 30 years of pharmaceutical training, development and human resource management experience. Prior to joining Cumberland, he held various positions of increasing responsibilities at Berlex Laboratories Inc. and spent 19 years at that company which is now Bayer HealthCare Pharmaceuticals following the 2006 acquisition of Schering AG. Mr. Anthony holds a B.S. in Nursing from D&#8217;Youville College in Buffalo, NY.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chris T. Bitterman, Vice President Sales and Marketing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Bitterman, 59, joined Cumberland following a distinguished career in Acute Care and pharmaceutical sales management spanning over 25 years. Highlights include his roles as National Sales Director for Lupin Pharmaceuticals, Daiichi Sankyo and Regional Sales Director for Sanofi Aventis, all of which are pharmaceutical manufacturing companies. At Cumberland, Mr. Bitterman first served as the Hospital Sales Director, leading the Hospital Sales division. Mr. Bitterman&#8217;s role then expanded to include the Oncology Business, and he was promoted to Senior Director of Hospital and Oncology Sales. Currently, Mr. Bitterman is the Vice President of Sales &amp; Marketing, where he is responsible for leading the sales and marketing efforts for Cumberland&#8217;s commercial portfolio and delivering annual financial objectives. Mr. Bitterman earned his B.S and M.B.A. degrees from Central Michigan University.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">John M. Hamm, Vice President and Chief Financial Officer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mr. Hamm, 69, is responsible for Cumberland&#8217;s financial systems, and reporting. He also oversees the Company&#8217;s business development and legal activities. Mr. Hamm has over 25 years of finance, accounting and operations experience in several industries, with a majority in health care. He previously held the positions of Chief Operating Officer and Chief Financial Officer, Pharmacy at HealthSpring, Inc., a managed care organization currently operating as Cigna-HealthSpring. Prior to that he was Vice President Finance at Emdeon Business Services. Emdeon Inc., a healthcare technology firm that now operates as Change Healthcare Inc., is a Nasdaq listed company with over $3 billion in annual revenue. Mr. Hamm has a B.S. in Business Administration with a minor in Accounting from Wheeling University. He earned his M.B.A. with an emphasis in Accounting from West Virginia University. He is a Certified Management Accountant (CMA) and Certified Financial Manager (CFM).</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRANTS OF PLAN-BASED AWARDS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding grants of plan-based awards we granted to our Named Executive Officers during the fiscal year ended December&#160;31, 2024:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.236%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.211%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.654%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All Other Stock Awards: Numbers of Shares of Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All Other Stock Awards: Numbers of Incentive Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise or Base Price of Option Awards<br/>($/Sh)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date Fair Value of Stock and Option Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/25/2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.88</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;James L. Herman</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/25/2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,840</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd M. Anthony</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/25/2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,130</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chris T. Bitterman</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/25/2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/25/2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/25/2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive compensation policies and practices, pursuant to which the compensation set forth in the Summary Compensation Table and the Grants of Plan-Based Awards Table was paid or awarded, are described above under &#8220;COMPENSATION DISCUSSION AND ANALYSIS.&#8221; A summary of certain material terms of our compensation plans and arrangements is set forth above under &#8220;COMPENSATION DISCUSSION AND ANALYSIS&#160;&#8212; Base Salary and Annual Bonuses&#8221; and &#8220;COMPENSATION DISCUSSION AND ANALYSIS&#160;&#8212; Long-Term Equity Incentive Compensation.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding unvested stock and unexercised option awards held by our Named Executive Officers as of December&#160;31, 2024:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.847%"><tr><td style="width:1.0%"/><td style="width:18.348%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Securities Underlying Unexercised Options (#) Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Exercise Price ($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Expiration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares or Units of Stock That Have Not Vested (#)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Market Value of Shares or Units of Stock That Have Not Vested ($)</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/17/2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,520&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/24/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James L. Herman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/17/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/24/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd M. Anthony</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/17/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/24/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chris T. Bitterman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/17/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,475&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/24/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/24/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/><td colspan="3" style="background-color:#b6b6b6;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/17/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/24/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A. J. Kazimi:</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">12,000 shares of restricted stock granted on March 17, 2021; 100% vested on March 17. 2025.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">88,000 shares of ISOs granted on March 17, 2021; 100% vested on March 17, 2025.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">20,000 shares of restricted stock granted on March 16, 2022; 100% vested on March 16. 2026.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">80,000 shares of ISOs granted on March 16, 2022; 100% vested on March 16, 2026.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">100,000 shares of ISOs granted on March 24, 2023; 100% vested on March 24, 2027.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">100,000 shares of ISOs granted on March 25, 2024; 100% vested on March 25, 2028.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;James L. Herman:</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3,000 shares of ISOs granted on March 17, 2021: 100% vested on March 17, 2025.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3,000 shares of ISOs granted on March 16, 2022: 100% vested on March 16, 2026.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3,000 shares of ISOs granted on March 16, 2022: 100% vested on March 16, 2026.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3,000 shares of ISOs granted on March 24, 2023: 100% vested on March 24, 2027.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">4,000 shares of ISOs granted on March 25, 2024: 100% vested on March 25, 2029.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Todd M. Anthony:</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3,000 shares of ISOs granted on March 17, 2021: 100% vested on March 17, 2025.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3,000 shares of ISOs granted on March 16, 2022: 100% vested on March 16, 2026.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3,000 shares of ISOs granted on March 16, 2022: 100% vested on March 16, 2026.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3,000 shares of ISOs granted on March 24, 2023: 100% vested on March 24, 2027.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3,000 shares of ISOs granted on March 25, 2024: 100% vested on March 25, 2028.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Chris T. Bitterman:</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,000 shares of ISOs granted on March 17, 2021: 100% vested on March 17, 2025.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,500 shares of ISOs granted on March 16, 2022: 100% vested on March 16, 2026.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,500 shares of ISOs granted on March 16, 2022: 100% vested on March 16, 2026.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,750 shares of ISOs granted on March 24, 2023; 100% vested on March 24, 2027.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,750 shares of ISOs granted on March 24, 2023; 100% vested on March 24, 2027.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,750 shares of ISOs granted on March 25, 2024; 100% vested on March 25, 2028.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;John M. Hamm:</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">3,000 shares of ISOs granted on March 17, 2021: 100% vested on March 17, 2025.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">20,000 shares of restricted stock granted on March 16, 2022; 100% vested on March 16. 2025.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,000 shares of ISOs granted on March 16, 2022: 100% vested on March 16, 2026.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,000 shares of ISOs granted on March 24, 2023: 100% vested on March 24, 2027.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,750 shares of ISOs granted on March 25, 2024: 100% vested on March 25, 2028.</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2,750 shares of ISOs granted on March 25, 2024: 100% vested on March 25, 2028.</span></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option Exercises and Stock Vested</span></div><div style="margin-bottom:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding the exercise of stock option awards and vesting of stock awards held by our Named Executive Officers during the fiscal year ended December&#160;31, 2024:</span></div><div style="margin-bottom:4pt;margin-top:5pt;padding-left:18pt;padding-right:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.330%"><tr><td style="width:1.0%"/><td style="width:36.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares Acquired on Exercise (#)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value Realized on Exercise ($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares Acquired on Vesting (#)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value Realized on Vesting ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James L. Herman</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,814&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd M. Anthony</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chris T. Bitterman</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Qualified Deferred Compensation Table</span></div><div style="margin-bottom:4pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the contributions, earnings and account balances for the Named Executive Officers in the Non-Qualified Deferred Compensation plan.  This plan is a non-contributory non-qualified defined contribution plan that provides for the payment of benefits from the general funds of the Company.  Participation in this plan is limited to a selected group of management or highly compensated employees of the Company.  Vesting in the Company contributions occurs at the earlier of 60 months of plan participation and reaching the age of 65 or 120 months of participation into the plan.  The participants may direct which investment fund the investment amounts are placed within the plan.  If no fund is selected by the participant, the Company contributions will be deemed to be invested in a money market account for the participant. The plan allows participants to defer a portion of their compensation.  The activity was as follows during the fiscal year ended December&#160;31, 2024:</span></div><div style="margin-bottom:4pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.136%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Executive Contributions </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Registrant Contributions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Earnings (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Withdrawals / Distributions /Forfeitures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James L. Herman</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,937&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd M. Anthony</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chris T. Bitterman</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:490.50pt"><tr><td style="width:1.0pt"/><td style="width:18.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:463.00pt"/><td style="width:1.0pt"/></tr><tr style="height:30pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The registrant contributions are included as a component of the summary compensation table while the aggregate earnings are excluded from the summary compensation table. The registrant contributions, in previous years, were included in total compensation for the Named Executive Officers in the Summary Compensation table. </span></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides aggregate information as of December&#160;31, 2024, with respect to shares of our common stock that may be issued under our existing equity compensation plans:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.706%"><tr><td style="width:1.0%"/><td style="width:33.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.557%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.713%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.895%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(c)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares to Be Issued Upon Exercise of Outstanding Options, Warrants and Rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,604</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">none</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">none</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">none</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,604</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation Table</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding the aggregate compensation we paid to the members of our Board of Directors during the fiscal year ended December&#160;31, 2024:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.553%"><tr><td style="width:1.0%"/><td style="width:20.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.505%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.897%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fees Earned or Paid in Cash </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Awards ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Awards ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Gordon R. Bernard</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caroline R. Young</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,810</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth J. Krogulski</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,050</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,050</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;James R. Jones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,810</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Joseph C. Galante</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,810</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Martin S. Brown, Jr.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,500</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,310</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.461%"><tr><td style="width:1.0%"/><td style="width:3.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.306%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On March 23, 2024, restricted shares were awarded with a grant-date fair value of $1.81 per share. As of December 31, 2024, Mrs. Young had 2,500 shares of restricted stock outstanding.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On March 23, 2024, restricted shares were awarded with a grant-date fair value of $1.81 per share. As of December 31, 2024, Mr. Krogulski had 6,500 shares of restricted stock outstanding.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On March 23, 2024, restricted shares were awarded with a grant-date fair value of $1.81 per share. As of December 31, 2024, Mr. Jones had 2,500 shares of restricted stock outstanding.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On March 23, 2024, restricted shares were awarded with a grant-date fair value of $1.81 per share. As of December 31, 2024, Mr. Galante had 2,500 shares of restricted stock outstanding.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On March 23, 2024, restricted shares were awarded width a grant-date fair value of $1.81 per share. As of December 31, 2024, Mr. Brown had 2,500 shares of restricted stock outstanding.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees for fourth quarter 2024 were paid in first quarter 2025.</span></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Pay-Versus-Performance</span></div><div style="margin-top:8pt;text-align:justify;text-indent:21.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents certain information regarding compensation paid to Cumberland&#8217;s CEO and other Names Executive Officers ("NEOs"),  and  certain measures of financial performance, for the four years ended December&#160;31, 2024. The amounts shown below are calculated in accordance with Item 402(v) of Regulation S-K.</span></div><ix:nonNumeric contextRef="c-1" name="ecd:PvpTableTextBlock" id="f-6" escape="true"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.912%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Summary Comp Table Total for CEO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comp Actually Paid to CEO (1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Summary Comp Table Total for non-CEO Named Executive Officers (2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Comp Actually Paid to non-CEO Named Executive Officers</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumberland Total Shareholder Return</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peer Group Total Shareholder Return (3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income (Loss) (4) (in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company Selected Measure - Adjusted Diluted EBIDTA Per Share (5) $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" id="f-7">1,112,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" id="f-8">979,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" id="f-9">315,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" id="f-10">310,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="ecd:TotalShareholderRtnAmt" id="f-11">46.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="ecd:PeerGroupTotalShareholderRtnAmt" id="f-12">61.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-13">6,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="cpix:AdjustedDilutedEBIDTAPerShare" id="f-14">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="INF" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" id="f-15">979,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="INF" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" id="f-16">952,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="INF" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" id="f-17">326,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="INF" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" id="f-18">307,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="INF" name="ecd:TotalShareholderRtnAmt" id="f-19">34.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="INF" name="ecd:PeerGroupTotalShareholderRtnAmt" id="f-20">43.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-21">6,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="INF" name="cpix:AdjustedDilutedEBIDTAPerShare" id="f-22">0.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" id="f-23">583,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" id="f-24">897,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" id="f-25">305,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" id="f-26">281,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="ecd:TotalShareholderRtnAmt" id="f-27">43.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="ecd:PeerGroupTotalShareholderRtnAmt" id="f-28">49.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-29">5,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="cpix:AdjustedDilutedEBIDTAPerShare" id="f-30">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="ecd:PeoTotalCompAmt" format="ixt:num-dot-decimal" id="f-31">1,533,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="ecd:PeoActuallyPaidCompAmt" format="ixt:num-dot-decimal" id="f-32">872,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="ecd:NonPeoNeoAvgTotalCompAmt" format="ixt:num-dot-decimal" id="f-33">411,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" format="ixt:num-dot-decimal" id="f-34">354,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="ecd:TotalShareholderRtnAmt" id="f-35">90.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="ecd:PeerGroupTotalShareholderRtnAmt" id="f-36">72.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-37">3,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="cpix:AdjustedDilutedEBIDTAPerShare" id="f-38">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) <ix:nonNumeric contextRef="c-1" name="cpix:CEO" id="f-39" escape="true">Mr. Kazimi serves as CEO since 2000.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) <ix:nonNumeric contextRef="c-1" name="ecd:NamedExecutiveOfficersFnTextBlock" id="f-40" escape="true">In the years of 2024 and 2023, the other NEOs were Messrs. Herman, Anthony, Bitterman and Hamm. In 2022, the other NEOs were Messrs. Pavliv, Herman, Anthony, Bitterman and Hamm. In 2021, the other NEOs were Messrs. Cearnal, Pavliv, Herman and Hamm. In 2020 the other NEOs were Messrs. Cearnal, Pavliv, Herman and Bonner.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Market index used for this column is S&amp;P 500 - Peer Group Companies. The Peer Group includes: Avadel Pharmaceuticals plc, Harrow Health, Inc., Eagle Pharmaceuticals, Inc., Assertio Holdings, Inc., HLS Therapeutics Inc., EyePoint Pharmaceuticals, Inc., Eton Pharmaceuticals, Inc., Theratechnologies Inc., and Talphera, Inc., formerly AcelRx Pharmaceuticals.  Acorda Therapeutics declared bankruptcy in 2024 and was delisted from the Nasdaq.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) <ix:nonNumeric contextRef="c-1" name="cpix:NetIncomeExplain" id="f-41" escape="true">Net income (loss) for 2024 includes $0.2 million for a payout earned on company owned insurance policies. Net income (loss) for 2023 includes a $2.8 million refund of FDA fees for the periods of 2023 and 2022, a gain of $0.5 million to settle a manufacturing dispute and a gain of $0.3 million for a payout earned on a company owned insurance policy. Net income (loss) for 2022 includes a gain from an insurance settlement in the amount of $0.6 million. Net income (loss) for 2021 includes income from discontinued operations in the amounts of $1.994 million.</ix:nonNumeric>  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) <ix:nonNumeric contextRef="c-1" name="cpix:AdjustedEBITDAExplain" id="f-42" escape="true">Adjusted Diluted EBITDA Per Share is calculated using adjusted EBITDA divided by diluted weighted average common shares outstanding. Adjusted EBITDA excludes the impact of (i) income tax expense (benefit), depreciation and amortization, share based compensation, the cost of non-cash cost of goods sold, write-down of expired inventory and interest income and expense.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) <ix:nonNumeric contextRef="c-1" name="ecd:AdjToPeoCompFnTextBlock" id="f-43" escape="true">To calculate the compensation "actually paid" to the CEO for 2024 in the Summary Compensation Table ("SCT"), an amount equal to $133,465 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) <ix:nonNumeric contextRef="c-2" name="ecd:AdjToPeoCompFnTextBlock" id="f-44" escape="true">To calculate the compensation "actually paid" to the CEO for 2023 in the SCT, deferred compensation of $20,000 was deducted  and an amount equal to $7,150 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) <ix:nonNumeric contextRef="c-3" name="ecd:AdjToPeoCompFnTextBlock" id="f-45" escape="true">To calculate the compensation "actually paid" to the CEO for 2022, the stock awards value of $51,800 in the SCT was deducted, deferred compensation of $20,000 was deducted and an amount equal to $385,862 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) To calculate the compensation "actually paid" to the CEO for 2021, the stock awards value of $38,640 in the SCT was deducted, deferred compensation of $12,500 was deducted  and an amount equal to $609,944 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10) To calculate the compensation "actually paid" to the CEO for 2020, the stock awards value of $356,000 in the SCT was deducted, deferred compensation of $12,500 was deducted and an amount equal to $123,000 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11) <ix:nonNumeric contextRef="c-1" name="ecd:AdjToNonPeoNeoCompFnTextBlock" id="f-46" escape="true">To calculate the compensation "actually paid" to the other NEOs for 2024, the average adjustment amounts included an amount equal to $5,487 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12) <ix:nonNumeric contextRef="c-2" name="ecd:AdjToNonPeoNeoCompFnTextBlock" id="f-47" escape="true">To calculate the compensation "actually paid" to the other NEOs for 2023, the average adjustment amounts included deferred compensation of $20,000 was deducted and an amount equal to $133 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13) <ix:nonNumeric contextRef="c-3" name="ecd:AdjToNonPeoNeoCompFnTextBlock" id="f-48" escape="true">To calculate the compensation "actually paid" to other the NEOs for 2022, the average adjustment amounts included the stock awards value of $12,950 in the SCT was deducted, deferred compensation of $20,000 was deducted and an amount equal to $8,418 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14) To calculate the compensation "actually paid" to the other NEOs for 2021, the average adjustment amounts included deferred compensation of $15,000 was deducted and an amount equal to $42,397 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (15) To calculate the compensation "actually paid" to the other NEOs for 2020, the average adjustment amounts included the stock awards value of $33,227 in the SCT was deducted, deferred compensation of $8,750 was deducted and an amount equal to $136,565 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Relationship Between Pay vs. Performance </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actually Paid vs Company Performance: The relationship between compensation actually paid and Cumberland&#8217;s financial performance over the five year period shown in the table above is described below:</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEO</span></div><ix:nonNumeric contextRef="c-1" name="cpix:PEOYearToYearPaymentAnalysis" id="f-49" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2023 to 2024, compensation actually paid to the CEO increased by $26,739  or 2.8%. Over the same period, the Company&#8217;s Total Shareholder Return ("TSR") increased by 32.3%, while adjusted EBITDA per diluted share decreased by 98.0%. Net income (loss) for 2024, includes $0.2 million for a payout earned on company owned insurance policies. Comparing the operating loss from 2023 to 2024, operating results improved by 32.7%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-2" name="cpix:PEOYearToYearPaymentAnalysis" id="f-50" escape="true">From 2022 to 2023, compensation actually paid to the CEO increased by $55,033  or 6.1%. Over the same period, the Company&#8217;s TSR decreased by 20.4%, while adjusted EBITDA per diluted share increased by 100%. Net income (loss) for 2023, includes a $2.8 million refund of FDA fees for the periods of 2023 and 2022, a gain of $0.5 million to settle a manufacturing dispute and a gain of $0.3 million for a payout earned on a company owned insurance policy. Comparing the operating loss from 2022 to 2023, operating results decreased by 67.5%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-3" name="cpix:PEOYearToYearPaymentAnalysis" id="f-51" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2021 to 2022, compensation actually paid to the CEO increased by $24,868  or 2.8%. Over the same period, the company&#8217;s TSR decreased by 52%, while adjusted EBITDA per diluted share decreased by 47%. Net income (loss) for 2021 includes several one time gains/income including an increase for discontinued operations of $2 million and a gain from the forgiveness of the PPP loan in the amount of $2.2 million. Operating income (loss) excludes the impact of other gains and losses. Comparing the operating loss from 2021 to 2022, operating results improved by 26%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary and deferred compensation. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2020 to 2021, compensation actually paid to the CEO increased by $85,632 or 10.9%. Over the same period, the company&#8217;s TSR increased by 58%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary and bonus compensation.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other NEOs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cpix:NonCEOYearToYearCompensationAnalysis" id="f-52" escape="true">From 2023 to 2024, compensation actually paid to the other NEOs increased by $3,098 or 1.0%. Over the same period, the company&#8217;s TSR increased by 32.3%, while adjusted EBITDA per diluted share decreased by 98.0%. Net income (loss) for 2024, includes $0.2 million for a payout earned on company owned insurance policies.  Comparing the operating loss from 2023 to 2024, operating results improved by 32.7%. Some key factors that drove the changes in compensation actually paid to the NEO were an increase in salary.</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-2" name="cpix:NonCEOYearToYearCompensationAnalysis" id="f-53" escape="true">From 2022 to 2023, compensation actually paid to the other NEOs decreased by $25,985 or 9.0%. Over the same period, the company&#8217;s TSR decreased by 20.4%, while adjusted EBITDA per diluted share increased by 100%. Net income (loss) for 2023, includes a $2.8 million refund of FDA fees for the periods of 2023 and 2022, a gain of $0.5 million to settle a manufacturing dispute and a gain of $0.3 million for a payout earned on a company owned insurance policy. Comparing the operating loss from 2022 to 2023, operating results decreased by 67.5%. Some key factors that drove the changes in compensation actually paid to the NEO were an increase in salary.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-3" name="cpix:NonCEOYearToYearCompensationAnalysis" id="f-54" continuedAt="f-54-1" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2021 to 2022, compensation paid to the other NEOs declined by $73,341 or 21%. Over the same period, the company&#8217;s TSR decreased by 52%, while adjusted EBITDA per diluted share decreased by 47%. Net income (loss) for 2021 includes several one-time gains/income including an increase for discontinued operations of $2 million and a gain from the forgiveness of the PPP loan in the amount of $2.2 million. Operating income (loss) excludes the impact of other gains and losses. Comparing the operating loss from 2021 to 2022, operating results improved by 26%. Some key factors that drove the decrease in pay during this period were leadership transitions within the NEO group, including a partial year of service by the Executive VP of Sales and Marketing. </span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-54-1">From 2020 to 2021, compensation actually paid to the other NEOs increased by $3,542 or 1.1%. Over the same period, the company&#8217;s TSR increased by 58%. Some key factors that drove the changes in compensation actually paid to the other NEO Group were declines in salary and bonus.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company TSR versus Peer Group TSR.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The relationship between the Company&#8217;s TSR and the TSR of the Peer Group Companies is shown below:  </span></div><ix:nonNumeric contextRef="c-1" name="cpix:ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100" id="f-55" escape="true"><div style="margin-top:8pt;text-align:center;text-indent:18pt"><img src="cpix-20250310_g3.jpg" alt="8550" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Tabular List of Financial Performance Measures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Cumberland considers the following to be the most important financial performance measures it uses to link compensation actually paid to its NEOs for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> , to company performance.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.15pt"><ix:nonNumeric contextRef="c-5" name="ecd:MeasureName" id="f-56">Net Revenue</ix:nonNumeric></span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.15pt"><ix:nonNumeric contextRef="c-6" name="ecd:MeasureName" id="f-57">Cash Flow from Operations</ix:nonNumeric></span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.15pt"><ix:nonNumeric contextRef="c-7" name="ecd:MeasureName" id="f-58">EPS before EBITDA</ix:nonNumeric></span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.15pt"><ix:nonNumeric contextRef="c-8" name="ecd:MeasureName" id="f-59">Adjusted Earnings</ix:nonNumeric> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_479"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE GOVERNANCE</span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Meetings of the Board of Directors and Committees</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board of Directors</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The property, affairs and business of our Company are under the general management of our Board of Directors as provided by the laws of the State of Tennessee and our Bylaws. We have standing Audit, Compensation and Governance &amp; Nominating Committees of the Board of Directors. The separately designated standing Audit Committee has been operating, as defined, in accordance with the Securities Exchange Act of 1934, as amended, (the "Exchange Act"). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has adopted a written charter for each of our standing committees that establishes the responsibilities of the respective committee.  The charter of the Audit Committee, the charter of the Compensation Committee, and the charter of the Governance &amp; Nominating Committee are available on our website at www.cumberlandpharma.com under the tab &#8220;Investor Relations - Corporate Governance.&#8221;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors held three meetings during fiscal year 2024, each with full attendance by every director.  Each director also attended all meetings held by all the standing committees of the Board on which such director served during 2024. While the Company currently has no formal policy with respect to the attendance of members of the Board of Directors at annual meetings, all directors did attend our 2024 Annual Meeting.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director Independence</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has affirmatively determined whether each director is independent in accordance with the Nasdaq Global Select Market rules and listing standards. The Board has affirmatively determined that each of Messrs. Jones, Krogulski, and Galante, Dr. Bernard and Ms. Young qualifies as an independent, non-employee director with no relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company Leadership Structure</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business of the Company is managed under the direction of the Board of Directors, which is elected by the Company&#8217;s shareholders. The basic responsibility of the Board of Directors is to oversee the Company by exercising its business judgment to act in what each director reasonably believes to be the best interests of the Company and its shareholders. Such oversight is important and the Board of Directors must act effectively as a working group, so that the Company and its performance may benefit. The role of the Chairman includes providing direction and feedback on the strategy and performance of the Company, serving as chair of meetings of the Board of Directors, setting the Board of Director&#8217;s agenda with the Company, and leading the Board of Directors in anticipating and responding to business challenges. The Board of Directors believes that the advisability of having a separate or combined chairman and chief executive officer is dependent upon the strengths of the individuals that hold those positions and the most effective means of leveraging their strengths. At this time, given the composition of the Company&#8217;s Board, the effective leadership of Mr. Kazimi as both Chairman of the Board of Directors and Chief Executive Officer, and the current challenges faced by the Company, the Board of Directors believes that combining the positions of Chairman of the Board of Directors and Chief Executive Officer provides the Company with the right foundation to pursue the Company&#8217;s strategy and operational objectives, while maintaining effective oversight and objective evaluation of the performance of the Company.  The Board of Directors also has a Lead Independent Director, who chairs meetings and discussions of the independent members of the Board of Directors during the year.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Board Oversight of Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assessing and managing risk is the responsibility of the Company&#8217;s management, while the Board of Directors, as a whole and through its committees, has responsibility for the oversight of risk management. The Audit Committee reviews financial risks that may be material to the Company, as well as major legislative and other developments which could materially impact the Company. In addition, the Board of Directors has delegated to the Compensation Committee the responsibility of assessing the risks associated with the Company&#8217;s compensation practices and policies for employees, including consideration of the counterbalance of risk-taking incentives and risk-mitigating factors in Company practices and policies. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full Board reviews the identified risks that may be material to the Company, including those detailed in the Audit Committee&#8217;s reports and those disclosed in the Company&#8217;s quarterly and annual reports filed with the SEC. The goal of these processes is to achieve serious and thoughtful board-level attention to the Company&#8217;s risk management process and system, the nature of the material risks faced by the Company, and the adequacy of the Company&#8217;s risk management process and system designed to respond to and mitigate these risks.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has instructed the Audit Committee to meet periodically with our management and an independent registered public accounting firm to, among other things, review the results of the annual audit and quarterly reviews and discuss our financial statements, recommend to our Board of Directors the independent registered public accounting firm to be retained, and receive and consider the auditors&#8217; comments as to controls, adequacy of staff and management personnel and procedures in connection with audit and financial controls. The Audit Committee is also authorized to review related party transactions for potential conflicts of interest. The Audit Committee&#8217;s functions are further described under the heading &#8220;Audit Committee Report.&#8221;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee is currently comprised of Mr. James R. Jones (Chairman), Mr. Kenneth J. Krogulski and Mr. Joseph C. Galante. The members of the Audit Committee are &#8220;independent,&#8221; as determined in accordance with the listing standards for companies listed on the Nasdaq Global Select Market. The members also satisfy the Securities and Exchange Commission&#8217;s additional independence requirements for members of audit committees and Rule 10A-3 of the Exchange Act. The Board of Directors has affirmatively determined that James Jones is an &#8220;audit committee financial expert&#8221; as defined under Item 407(d)(5) of Regulation S-K of the Securities Act of 1933 and that each member of the Audit Committee has sufficient financial sophistication to qualify as an audit committee member under Nasdaq Global Select Market listing standards. The Audit Committee met five times during fiscal year 2024.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee is authorized to establish compensation policies for our Company, review annual salaries and bonuses of our executive officers and has the authority to determine the aggregate granting of equity awards, the times at which such equity awards shall be granted, the number of shares issued, the vesting term and any exercise price associated with such equity awards under our equity compensation plans. In addition, the Compensation Committee recommends to the full Board of Directors the compensation of our Chief Executive Officer. In fulfilling its responsibilities, the Compensation Committee has the authority to engage independent compensation consultants or legal advisers when the Compensation Committee determines it to be necessary and appropriate.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee currently consists of Mr. Joseph C. Galante (Chairman), Ms. Caroline R. Young, and Dr. Gordon R. Bernard. The Board of Directors has affirmatively determined that each member of the Compensation Committee is &#8220;independent,&#8221; as such term is defined in the listing standards for companies listed on the Nasdaq Global Select Market, including, without limitation, the specific requirements of Nasdaq Rule 5605(d)(2) for compensation committee members. The Compensation Committee met once during fiscal year 2024.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee reviews the risks and rewards associated with the Company&#8217;s compensation programs. The Compensation Committee designs compensation programs with features that mitigate risk without diminishing the incentive nature of the compensation. We believe our programs encourage and reward prudent business judgment and appropriate risk-taking over the long term.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of the Compensation Committee are set forth above. The Compensation Committee is made up entirely of independent directors and no member of the Compensation Committee was an officer or employee of the Company during 2024, a former officer of the Company or had any relationship during 2024 requiring disclosure under Item 404 of Regulation S-K. In addition, none of the Company&#8217;s executive officers serve as a member of the Board of Directors or Compensation Committee of any entity that has one or more of its executive officers serving as a member of our Board of Directors or Compensation Committee.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nomination of Directors</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Governance &amp; Nominating Committee (the "Governance Committee"), the members of which are currently, Ms. Caroline R. Young (Chairman), Dr. Gordon R. Bernard and Mr. Joseph C. Galante, is responsible for identifying, screening and recommending qualified candidates to serve on our Board of Directors. The Governance Committee is directed, among other things, to develop and recommend to the Board of Directors specific guidelines and criteria for selecting nominees to the Board of Directors, formulate a process to identify and evaluate candidates to be recommended, and evaluate the performance of incumbent members of the Board of Directors to determine whether to recommend such persons for re-election. The Board of Directors has affirmatively determined that all members of the Governance Committee are &#8220;independent&#8221; as defined in the listing standards for companies listed on the Nasdaq Global Select Market. The Governance Committee met one time during fiscal year 2024. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our policy that the Governance Committee consider recommendations for the nomination of directors submitted by our significant, long-term shareholders (generally, shareholders that have beneficially owned more than 5% of our outstanding shares for at least two years). The Governance Committee will give consideration to such recommendations that have been submitted in accordance with procedural requirements adopted by the Governance Committee. All such shareholder nominating recommendations must be in writing, addressed to the Governance Committee, care of the Corporate Secretary at Cumberland Pharmaceuticals Inc., 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203. Submissions must be made by mail, courier or personal delivery. E-mailed submissions will not be considered. Shareholders wishing to recommend nominees for election as directors at an annual meeting should submit such recommendation, together with any relevant information that they wish the Governance Committee to consider, to the Corporate Secretary no later than 120 days prior to the date of the notice of annual meeting and proxy statement released to shareholders in connection with the prior year&#8217;s annual meeting.  The Governance Committee did not receive any such recommendations for our 2024 Annual Meeting.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Governance Committee has determined that, at the minimum, nominees for directorship should possess the highest personal and professional ethics, integrity and values, and be committed to representing the long-term interests of the Company&#8217;s shareholders. They must also have an inquisitive and objective perspective, practical wisdom and mature judgment. The Company endeavors to have a Board representing diverse experience in areas that are relevant to the Company&#8217;s business activities. Directors must be willing to devote sufficient time to carrying out their duties and responsibilities efficiently and should be committed to serve on the Board of Directors for an extended period of time.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to nominating a candidate for election to the Board of Directors, the Governance Committee will review the qualifications of each candidate. Final candidates may be interviewed by the Company&#8217;s Chairman of the Board of Directors and one or more other members of the Board of Directors. The Governance Committee will then make a recommendation to the Board of Directors based on its review, the results of interviews with the candidate and other available relevant information.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether to nominate an incumbent director for reelection, the Governance Committee will evaluate each incumbent&#8217;s continued service, in light of the Board of Director&#8217;s collective requirements, at the time such Director comes up for reelection.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether to include a shareholder recommendation in the Board of Directors slate of nominees, the Governance Committee will consider all information relevant in their business judgment to the decision of whether to nominate the particular candidate for a Board of Directors seat, taking into account the current composition of the Company&#8217;s Board of Directors.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing, shareholders may nominate directors for election without consideration by the Governance Committee so long as we are provided with proper notice of such nomination, which notice includes all the information required pursuant to Regulation 14A under the Exchange Act including a consent to serve as a director.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Governance Committee recommended, and the Board of Directors approved the inclusion of Mr. A.J. Kazimi, Dr. Gordon R. Bernard and Mr. Joesph C. Galante on the Company&#8217;s proxy card for election to the Board of Directors at the 2025 Annual Meeting based on the aforementioned review process. In doing so, the Governance Committee has affirmatively determined that Dr. Bernard and Mr. Galante are &#8220;independent&#8221; under Nasdaq listing standards and SEC rules and regulations.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sustainability Report</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, we released our annual Sustainability Report (the "Sustainability Report"), which details Cumberland&#8217;s activities pertaining to our environmental, social and governance matters. We remain committed to sustainability and to maintaining transparency of our corporate operations. We also hold ourselves to high standards of ethical practices and understand the importance of recognizing and addressing our impact on our constituents, the community and the environment.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sustainability Report notes that during 2023 we provided nearly 3 million patient doses of our products, safely disposed of over 5,891 pounds of expired and damaged products and had no product recalls. We also had no Company brands listed on the FDA&#8217;s MedWatch Safety Alerts for Human Medical Products, and no clinical trials terminated due to failure to practice good clinical standards during 2023.  The Sustainability Report also highlights our investment in our employees through our continuing education programs and employee development initiatives. We reported that during 2023 women represented 44% of Cumberland&#8217;s workforce, and 15% of our employees were minorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Code of Business Conduct and Ethics</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted a Code of Business Conduct and Ethics that applies to all of our employees, officers and directors, including the principal executive officer, principal financial officer and principal accounting officer. It covers all areas of professional conduct, including but not limited to, conflicts of interest, disclosure obligations, insider trading, confidential information, as well as compliance with all laws, rules and regulations applicable to the Company&#8217;s business. You can access the latest copy of our Code of Business Conduct and Ethics on our website, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.cumberlandpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Or, to obtain a copy the Code of Business Conduct and Ethics, without charge, any person may submit a written request to Cumberland Pharmaceuticals Inc., 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203 Attention: Corporate Secretary.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insider Trading Policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an insider trading policy (the &#8220;Insider Trading Policy&#8221;) governing the purchase, sale and other dispositions of our securities by our directors, officers and employees. We believe our Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations. Our Insider Trading Policy prohibits trading while in possession of material nonpublic information. A copy of our Insider Trading Policy is filed as Exhibit 19.1 to our Annual Report on Form 10-K for the year ended December 31, 2024.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transactions with Related Persons</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee&#8217;s charter charges it with the responsibility to review and approve any proposed transaction between the Company and any related person, as defined in Item 404 of Regulation S-K.  Since January 1, 2023, there have been no transactions involving the Company and a related person, and currently, no related person, to our knowledge, is a party to any material transactions with the Company other than the compensation discussed in the section labeled &#8220;Executive Compensation and Related Information.&#8221;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, no director or executive officer, to our knowledge, is a party to any material legal proceeding adverse to the interests of the Company. Additionally, no director or executive officer has a material interest in a material proceeding adverse to the Company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Communications with the Board</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any shareholder can communicate with all directors or with specified directors by sending correspondence to our Corporate Secretary at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203. All such letters will be forwarded to the entire Board or to the director(s) specified by the shareholder.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you would like additional information on the responsibilities of the Governance &amp; Nominating Committee, please refer to its charter, a copy of which is posted on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.cumberlandpharma.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and is also available in print to any shareholder who requests it.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Submitted by the Governance &amp; Nominating Committee</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">           </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.923%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Ms. Caroline R. Young</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dr. Gordon R. Bernard</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mr. Joseph C. Galante</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Chair)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_43"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHAREHOLDER PROPOSALS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting each year, the Board of Directors submits to shareholders its nominees for election as directors. The Board of Directors may also submit other matters to the shareholders for action at the Annual Meeting. Any proposal which a shareholder intends to present in accordance with Rule&#160;14a-8 of the Exchange Act at our next annual meeting of shareholders to be held in 2026 must be received by Cumberland Pharmaceuticals Inc., no later than 5:00 p.m. Central Time on November 13, 2025. Only proposals conforming to the requirements of Rule&#160;14a-8 of the Exchange Act that are timely received by the Company will be included in the Proxy Statement and Proxy in 2026. Any such proposal should be directed to our Corporate Secretary at our principal executive offices located at 1600&#160;West End Avenue, Suite&#160;1300, Nashville, Tennessee 37203.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To comply with the universal proxy rules, shareholders who intend to solicit proxies in support of director nominees, other than the Company's nominees, at our next annual meeting of shareholders to be held in 2026 must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than February 21, 2026.</span></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER MATTERS</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Miscellaneous</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management does not intend to present any other items of business and is not aware of any matters other than those set forth in this Proxy Statement that will be presented for action at the Annual Meeting. However, if any other matters properly come before the Annual Meeting, the persons named in the enclosed proxy intend to vote the shares of our common stock that they represent in accordance with their best judgment.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Report</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Report has been made available to shareholders and is posted on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">http://www.cstproxy.com/cumberlandpharma/2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The Company will provide, without charge, a copy of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024, upon the written request of any shareholder. Requests can be made by writing to: Cumberland Pharmaceuticals Inc., 1600&#160;West End Avenue, Suite&#160;1300, Nashville, Tennessee 37203, Attention: Corporate Secretary.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By order of the Board of Directors,</span></div><div style="margin-bottom:9pt;text-align:justify"><img src="cpix-20250310_g2.jpg" alt="Image4.jpg" style="height:61px;margin-bottom:5pt;vertical-align:text-bottom;width:89px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.J. Kazimi</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chairman and Chief Executive Officer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 13, 2025</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_49"></div><hr style="page-break-after:always"/><div style="min-height:9pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><img src="cpix-20250310_g4.jpg" alt="cumberlandlogoa02a01.jpg" style="height:72px;margin-bottom:5pt;vertical-align:text-bottom;width:316px"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a shareholder of Cumberland Pharmaceuticals Inc. you have the option of voting your shares electronically through the Internet, eliminating the need to return the proxy card.  Your electronic vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated and returned the proxy card.  Votes submitted electronically over the Internet or by mobile device must be received by 11:59 p.m., Eastern Time, on April 21, 2025.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.308%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Vote Your Proxy on the Internet:</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Vote Your Proxy on your Mobile:</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Vote Your Proxy via the mail:</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">OR</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">OR</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Go to www.cstproxyvote.com</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Have your proxy card available when you access the above website.  Follow the prompts to vote your shares.</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On your Smartphone/Tablet, open the QR Reader and scan the below image. Once the voting site is displayed, enter your Control Number from the proxy card and vote your shares.</span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark, sign, and date your proxy card, then detach it, and return it in the postage-paid envelope provided.</span></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:372.00pt"><tr><td style="width:1.0pt"/><td style="width:370.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;VOTING ELECTRONICALLY OR BY PHONE</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#218;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FOLD AND DETACH HERE AND READ THE REVERSE SIDE </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#218;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROXY</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.676%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.554%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">This Proxy, when properly executed, will be voted in the manner directed herein by the undersigned shareholder. If no direction is made, this Proxy will be voted FOR Proposals 1 AND 2.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"><div style="text-align:center"><img src="cpix-20250310_g5.jpg" alt="xa01.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:82px"/></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Abstain</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1. For the election as directors of the nominees listed below, except to the extent that authority is specifically withheld.</span></div><div><span><br/></span></div><div style="padding-left:63pt"><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> all Nominees listed to the left</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">WITHHOLD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AUTHORITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> to vote (except as marked to the contrary for all nominees listed to the left</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2. To ratify the appointment of Carr, Riggs &amp; Ingram, L.L.C. as independent registered accounting firm of the Company for fiscal year ending December 31, 2025.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:20pt;font-weight:700;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:20pt;font-weight:700;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:20pt;font-weight:700;line-height:100%">o</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOMINEES:                                                          (1)   Dr. Gordon R. Bernard                                        (2)   Mr. Joseph C. Galante  <br/>(3)   Mr. A. J. Kazimi                                 </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:20pt;font-weight:700;line-height:100%">o</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:20pt;font-weight:700;line-height:100%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:20pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(INSTRUCTION: To withhold authority to vote for any individual nominee, write that nominee's name on the space provided below.)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" rowspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:0 1pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting.</span></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">I understand that I may revoke this Proxy only by: (i) written instructions to that effect, signed and dated by me, which must be actually received by the Corporate Secretary prior to the commencement of the Annual Meeting; (ii) properly submitting to the Company a duly executed proxy bearing a later date; OR (iii) appearing at the Annual Meeting and voting in person.</span></td></tr></table></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:24.479%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COMPANY ID:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PROXY NUMBER:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ACCOUNT NUMBER:</span></td></tr></table></div><div style="padding-left:4.5pt;padding-right:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Signature  _________________________________ Signature if Held Jointly____________________________________ Date____________ , 2025. </span></div><div style="padding-left:4.5pt;padding-right:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Please sign exactly as your name appears on your stock certificate. When shares are held by joint tenants, both should sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such. If the </span></div><div style="padding-left:4.5pt;padding-right:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">shares are owned by a corporation, sign in the full corporate name by the President or other authorized officer. If the shares are owned by a Partnership, sign in the name of the Partnership name by an authorized person.</span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="ifa04aa8a69de418e832ab1f08fb0d35a_52"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:0.4pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-top:0.4pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-top:0.4pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-top:0.4pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="margin-top:0.4pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-top:0.4pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-top:0.4pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-top:0.4pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to be held April 22, 2025</span></div><div style="margin-top:0.6pt"><span><br/></span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">   The Notice, Proxy Statement, and our Annual Report on Form 10-K for the year ended December&#160;31, 2024 are available at: </span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">http://www.cstproxy.com/cumberlandpharma/2025</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9660; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOLD AND DETACH HERE AND READ THE REVERSE SIDE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9660;</span></div><div><span><br/></span></div><div style="margin-top:0.65pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTICE OF ANNUAL MEETING OF SHAREHOLDERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">To Be Held April 22, 2025</span></div><div style="margin-top:0.25pt"><span><br/></span></div><div style="padding-right:11.25pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned hereby appoints A.J. Kazimi and Kenneth J. Krogulski, or either of them, as proxies, with full power of substitution, and hereby authorizes each of them to represent and vote, as designated on the reverse side, all of the shares of Common Stock of Cumberland Pharmaceuticals Inc., held of record by the undersigned on February 28, 2025 at the Annual Meeting of Shareholders to be held at the Cumberland Pharmaceuticals Inc., 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203 on Tuesday, April 22, 2025, at 9:30 a.m. Central Time, or any adjournment(s) or postponement(s) thereof, with all powers which the undersigned would possess if personally present, upon and in respect of the following matters and in accordance with the instructions specified on the reverse side.</span></div><div><span><br/></span></div><div style="padding-right:11.25pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED SHAREHOLDER. IF NO DIRECTIONS ARE GIVEN, THIS PROXY WILL BE VOTED FOR ALL OF THE DIRECTOR NOMINEES NAMED IN PROPOSAL 1 ON THE REVERSE SIDE AS WELL AS PROPOSAL 2. THE PROXIES NAMED ABOVE ARE HEREBY AUTHORIZED TO VOTE IN THEIR DISCRETION UPON SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING AND ANY ADJOURNMENT(S) OR POSTPONEMENT(S) THEREOF.</span></div><div style="margin-top:0.45pt"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:0.65pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Continued, and to be marked, dated and signed, on the other side)</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>cpix-20250310.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b5516545-3d7c-4e11-85cf-2d47d7746d5a,g:3cc3fa37-86c9-402e-a504-d48283fc97bb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20250310" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20250310">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20250310_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20250310_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_TimingOfStockOptionAndOtherEquityAwardGrants" abstract="false" name="TimingOfStockOptionAndOtherEquityAwardGrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_AdjustedDilutedEBIDTAPerShare" abstract="false" name="AdjustedDilutedEBIDTAPerShare" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CEO" abstract="false" name="CEO" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_NetIncomeExplain" abstract="false" name="NetIncomeExplain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_AdjustedEBITDAExplain" abstract="false" name="AdjustedEBITDAExplain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_PEOYearToYearPaymentAnalysis" abstract="false" name="PEOYearToYearPaymentAnalysis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_NonCEOYearToYearCompensationAnalysis" abstract="false" name="NonCEOYearToYearCompensationAnalysis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100" abstract="false" name="ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>cpix-20250310_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b5516545-3d7c-4e11-85cf-2d47d7746d5a,g:3cc3fa37-86c9-402e-a504-d48283fc97bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cpix_AdjustedDilutedEBIDTAPerShare_label_en-US" xlink:label="lab_cpix_AdjustedDilutedEBIDTAPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted Diluted EBIDTA Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AdjustedDilutedEBIDTAPerShare" xlink:href="cpix-20250310.xsd#cpix_AdjustedDilutedEBIDTAPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AdjustedDilutedEBIDTAPerShare" xlink:to="lab_cpix_AdjustedDilutedEBIDTAPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NonCEOYearToYearCompensationAnalysis_label_en-US" xlink:label="lab_cpix_NonCEOYearToYearCompensationAnalysis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-CEO Year to Year compensation analysis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonCEOYearToYearCompensationAnalysis" xlink:href="cpix-20250310.xsd#cpix_NonCEOYearToYearCompensationAnalysis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NonCEOYearToYearCompensationAnalysis" xlink:to="lab_cpix_NonCEOYearToYearCompensationAnalysis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CEO_label_en-US" xlink:label="lab_cpix_CEO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CEO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CEO" xlink:href="cpix-20250310.xsd#cpix_CEO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CEO" xlink:to="lab_cpix_CEO" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PEOYearToYearPaymentAnalysis_label_en-US" xlink:label="lab_cpix_PEOYearToYearPaymentAnalysis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Year to Year payment analysis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PEOYearToYearPaymentAnalysis" xlink:href="cpix-20250310.xsd#cpix_PEOYearToYearPaymentAnalysis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PEOYearToYearPaymentAnalysis" xlink:to="lab_cpix_PEOYearToYearPaymentAnalysis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TimingOfStockOptionAndOtherEquityAwardGrants_label_en-US" xlink:label="lab_cpix_TimingOfStockOptionAndOtherEquityAwardGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Stock Option and other Equity Award Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TimingOfStockOptionAndOtherEquityAwardGrants" xlink:href="cpix-20250310.xsd#cpix_TimingOfStockOptionAndOtherEquityAwardGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TimingOfStockOptionAndOtherEquityAwardGrants" xlink:to="lab_cpix_TimingOfStockOptionAndOtherEquityAwardGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100_label_en-US" xlink:label="lab_cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">comparison of total shareholder return Assumes Initial investment of $100</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100" xlink:href="cpix-20250310.xsd#cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100" xlink:to="lab_cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AdjustedEBITDAExplain_label_en-US" xlink:label="lab_cpix_AdjustedEBITDAExplain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted EBITDA explain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AdjustedEBITDAExplain" xlink:href="cpix-20250310.xsd#cpix_AdjustedEBITDAExplain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AdjustedEBITDAExplain" xlink:to="lab_cpix_AdjustedEBITDAExplain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NetIncomeExplain_label_en-US" xlink:label="lab_cpix_NetIncomeExplain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income explain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetIncomeExplain" xlink:href="cpix-20250310.xsd#cpix_NetIncomeExplain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NetIncomeExplain" xlink:to="lab_cpix_NetIncomeExplain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>cpix-20250310_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b5516545-3d7c-4e11-85cf-2d47d7746d5a,g:3cc3fa37-86c9-402e-a504-d48283fc97bb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TimingOfStockOptionAndOtherEquityAwardGrants" xlink:href="cpix-20250310.xsd#cpix_TimingOfStockOptionAndOtherEquityAwardGrants"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_cpix_TimingOfStockOptionAndOtherEquityAwardGrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AdjustedDilutedEBIDTAPerShare" xlink:href="cpix-20250310.xsd#cpix_AdjustedDilutedEBIDTAPerShare"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_cpix_AdjustedDilutedEBIDTAPerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CEO" xlink:href="cpix-20250310.xsd#cpix_CEO"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_cpix_CEO" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetIncomeExplain" xlink:href="cpix-20250310.xsd#cpix_NetIncomeExplain"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_cpix_NetIncomeExplain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AdjustedEBITDAExplain" xlink:href="cpix-20250310.xsd#cpix_AdjustedEBITDAExplain"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_cpix_AdjustedEBITDAExplain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PEOYearToYearPaymentAnalysis" xlink:href="cpix-20250310.xsd#cpix_PEOYearToYearPaymentAnalysis"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_cpix_PEOYearToYearPaymentAnalysis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonCEOYearToYearCompensationAnalysis" xlink:href="cpix-20250310.xsd#cpix_NonCEOYearToYearCompensationAnalysis"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_cpix_NonCEOYearToYearCompensationAnalysis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100" xlink:href="cpix-20250310.xsd#cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>cpix-20250310_g1.jpg
<TEXT>
begin 644 cpix-20250310_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #3 Z # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD+W5_J%T\\\S8ZM(Y+,?J:^CRWA2=:HI8F24>J6K?EY?(\[&8[V5-N!]M_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (N_$74?$)D!9]*A'V+2U_V1:Q-F1?:=Y>]<]\.3^[C4# "@!1T Q7I.L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $9E1=S' '>O'_VQ
M_P!K[P'^R1\-F\6Z^POM7O\ =;^'/#\4NV74;D#.,X.R-00SR$85?5BJGT#X
MJ_$KP9\(?AUK7Q,\?ZU%8:1H5A)>:A<R'[L:#. .K,> JCEB0!R17X@_'?\
M:<\9_M<?&^_^,/B^22&&4_9]"TDR933+%6.R$8XW'[\C?Q.QYVA0/9RC*Y9A
M4<Y:0COY^1S5ZWL].IZ-J7Q1\??&_P"(5U\4OBCKIU'6;[Y-ZJ4AM8 Q*V\"
M9/EQ+Z=6.68LQS7K?P[^Y%]17@OP\!;R\#/3I7MG@CQ-H>GWD.D2WRRWSX,6
MFVL;SW4O^Y!$#(__  %37TN,IPIQ2222V78RIW>Y]&_#G[D?T%>DZS_R /\
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MCSZ^:9?A:GLZM1*78_86BOQW'_!W?\*/^C*O$'_A80?_ "/1_P 1=_PHZ?\
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M^W5I_P 4VM? ?Q:6#3?$3A8[2_BPEKJ3=, '_52G^X20W\)_A'TDC;U#8Q0
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MA2O]P_2DAYCZ=S_.E?[A^E?E4%96/OWL?QV?M9_\G4_$S_LH.L_^ETU?H_\
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M3YI=HV0ZCX!>-2?0O'>N1^"FOW HKXR/%F?Q=_;?A'_(^H?#N3O_ )=?B_\
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MU3#8I>_#X?/R^6_H><_%CQY^T;_P5\_;Z?4],TV2^\3^/]<2QT#2O-8PZ79
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MGX1\%_M4_$?2-*TZ!8;#2]+\;W]O;VT0Z)'''*%11V  %5/VL_\ DZCXF?\
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MKB&>0QC2_M%-O7EM?Y[/T/SG(XYQ*,W@6DKJ][>=M_F<'_Q%VV/_ $9-<_\
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MOSS6VI]B_A/Y$_\ @HM_R?[\:O\ LJFO?^E\U?T4?\$ /^40_P '/^O#5?\
MT\7U?SK_ /!1;_D_WXU?]E4U[_TOFK^BC_@@!_RB'^#G_7AJO_IXOJ_2^+?^
M1%A_6/\ Z2?#</?\CFO_ -O?^E(^QJ***_-3[H**** "@G%%8_COQEH/P_\
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M793_ $?Z/Y'G\+Y@H.6#D]-7']5^OWGZ&44B,'7<K9![BEK\YZ'VCV/Y@O\
M@X9_Y2S?$O\ ZY:5_P"FZWK]F?\ @W/C1_\ @D7\,-Z XN=>ZC_J-WU?C+_P
M<,_\I9OB7_UQTK_TW6]?LY_P;F_\HBOAC_U\Z[_Z>[ZOT/B&_P#JIA/^W?\
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MTKP'QY^Q_P"-OAB\FM>!+F;Q)I2_,]L8P+^!?]U %G '9 K^BL>:^LJ",C%
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MEF%]@J#EK>^JW^3/ZS/^&C/V>^G_  O;P;_X5%I_\<I)/VC?V?51F'QU\&Y
M)Q_PD]I_\<K^33_AA+]MG_HT?XD?^$7??_&J/^&$OVV>W[(_Q(_\(N^_^-5Y
M*X,P+?\ O:^Y?_)'H_ZS8[_H&?WO_(_57_@Z9_;,^!/Q+^$G@']F_P"&7Q2T
M3Q#KEIXKEUK6(-"U**Z6QACMI(8Q*T;$([F9L*3G"$D 8S\F_P#!M5:74_\
MP56\,7,$9*VWAG6))3_=4VI0'\V4?C7@7P[_ ."6G_!13XIZI%I/A#]C3X@L
M\KA?/O\ PW/9P)GNTMPJ(H^K"OVP_P""$G_!&#Q3_P $_EU;X]?M"WUC-\1/
M$6E"P@TJP<30Z)9,Z2O&9 ,/.[(FXK\JA, MDFO1QM7*\BX?J8*%93E)-*S5
MVWY:VM^AQX:GC<XSF.)E3Y(JU_EZVZGZ2VX'E CICCZ4Y_N'Z4D48BC6,'.!
MUHF;9"[XZ*37Y<KW/OF?QV_M9_\ )U/Q,_[*#K/_ *735_2C_P $BOCG\%/#
MW_!-;X+:+KWQA\+6-Y;> ;*.YM+SQ!;12Q,%.59&<%3[$5_/]^U!^Q+^V-K7
M[2WQ#UC1_P!E?XA75K=^.=7GMKB#P?>.DL;WLS*ZL(R&4@@@CJ#7"_\ #"?[
M;/?]D?XD?^$7??\ QJOV#,\OP>=9?1I2KJ'+9]'TMW1^:Y?BL7E6+J35%ROI
MU77T/ZS/^&C/V>ST^._@W_PJ+3_XY1_PT7^SY_T7;P;_ .%1:?\ QROY,S^P
MG^VR3G_AD?XD?^$7??\ QJC_ (82_;9_Z-'^)'_A%WW_ ,:KY[_4W _]!:^Y
M?_)'L?ZSX[_H&?WO_(_K,/[1?[/@Z_';P;_X5%I_\<J6R^/WP)U.]ATW3?C5
MX2N+BXD6."W@\26KO([' 55$F222  .M?R7?\,)?ML_]&C_$C_PB[[_XU7IG
M[%_[%O[8'AO]KSX7>(/$'[+?Q LK&Q^(.CW%Y=W7A"\CCAB2]B9G=FC 50 2
M2>!6=7@_!4Z4I+%IV3>R_P#DC2EQ)C:E6,7AFKM+K_D?U8@Y/\J\9_X*/?\
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MQ)UJXL;VT\(WDL4\3WLK(Z.L9#*0001U%>2_\,*_MM;=O_#(_P 2/_"+OO\
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MYT6[V>_ET9]AAZRQ-"-2UN9?CV/Y@O\ @X9_Y2S?$O\ ZXZ5_P"FZWK]G/\
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M1E Z!P#B0>S BO0_!O\ P5:^./@-%L_B#X;TKQ3;H &E_P"/.Y(]2Z*T9/\
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MCN)L3.=HHV+G(4?E2T4;B=Q-HZD"D,:\X49/?%.HH!:"*BIT4#Z"EHHHLEL
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M=5O4BFU24.B&.!3S(VZ6,8'=U]:] C8L@8CK7Y/_ /!>[_E(K^Q%_P!C_/\
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M>R7=O9'Z$_ O]H[X'?M)^%Y_&WP)^+&@^+=(M[LVLNH:%J"3QQSJ 6C8J>&
M93@\X8'O7<=>E?C9^S_H3_\ !"+_ (*H6/[.=UXAO#\#?CII]LF@ZIJ<V4LM
M4B"Q!G<X4,LKE'Z?N[J(G[M?LE&<H/I6F98*&#JQ=.7-3FKQ?==;^:9&#Q,L
M1!J:M.+M)>?^36J%HHHKSSL,SQ?XJT3P1X=OO%OB75H+#3=,LY+K4+VY;;';
MP1J6>1CT"JH))/3%>!?\/=?^":& 3^W!\.N?^IEAKM_V[?\ DS'XL_\ 9-=;
M_P#2*6OSQ_X-Y_V%_P!CO]H#_@G98_$'XU_LU>#/%&N-XNU.W;5=;T*&XG:)
M'38A9P3@9.*];"8/!3R^IBL2Y6C)1M&W57ZGG8BOB%BXT*5KM-W=^ENWJ?H-
M\*/V_OV)_C;K$?A_X6_M9_#S7-0G;;!IECXMM&NI#_LQ>8';\%KV 21G@.#^
M-?G%_P %6/\ @C__ ,$V=(_8Y\??&S1OA/H?PUU_PEX<N=3T3Q'X:/V$"[B0
MM#"\:GRY1+(%BQMWY<;2#BNQ_P"#>;X\?&+X_P#_  3E\/Z_\:-4N]3O-'UV
M^TG2]7OW+37EE R^6S,3F0H7:+<>2(ADD@TJ^!PSP#Q>'D^5-1:DENU=6:>O
MX!2Q=:.*^KUDKM737K;5/4^[:**4=?PKRD>B]$>9?'S]KS]F_P#9>.G-^T)\
M;?#O@Y=6\W^S#K^H);BZ,>W>$W'YMNY<X]179?#[XA^"/BIX-TWX@?#OQ9I^
MMZ+J]LMQINJ:9<K+!=1'HZ,I((-?DU_P<\^"=,^)7Q=_9B^'.MSRQ6>O^,;W
M3;N2 @.D4]QI\3%<]" QQ76_\$&OC/XY_9=^./Q#_P"".W[0VILNM> ]4NM1
M\ 33G O=/<^;(D>>JE9%ND [32?W:]^63QEDT<73E>>K:_NIV;7II<\A9E)9
MC+#SC:.B3\VKV?KK;T/U2) &2< =2:X?XZ?M'_ []FKPK#XX^._Q6T+PGI%Q
M=K:V^H:YJ"6\<LY5F$:LYY;:K' [ GM7;3<Q-_NFOPP_X*J>+O$O_!6#]LCQ
M[\*/ 6M3_P#"J?V9? >L:MKFHV3?NKK5XX&)4,/E8M-$L*GLL$[#J:X\JP"S
M#$<LWRP6K?;M\V]CIQ^+>#H7BKR>B7?J_DE=G[2?!?XX?"G]H7P1!\2_@K\0
M=*\3Z!<RR10:OHUTL\$DD;%74.O!(((/H:ZVO@+_ (-H?^44WA;_ +&;6?\
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MPDZR5VD?JO:S-.I<].V1BDU"[CL;1[R:542-2TCMT4 9)HLO]6?]XU0\<?\
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M^Q5B*^DCF$<)A,%46J2FI+NF]5\T>%]4EB:^*B]+\K3\TM']Y\1?M\_\%=/
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M:OC?XQ0R_P#!+?XI>-[;QSXU?4+&\TVV-LB1QR3A3\T;[PPE!!&.GO7U>/\
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M]RBO#Q=#ZKBIT;WL]UJFNC5CU\/6^L48U+6;Z/IW0DG^K;_=-?DS_P %H?\
ME,A^QM_V'X__ $Z05^LLO$3'_9-?E=_P6]^#/[4NM?M]?L\_M)_ #]F3Q7\1
MM.^'<CWVKVOANR9SNCO8I5A+A6$;,JG!(_E7I</.$<R?,TKQDM=-XM+<XLXC
M*6"=ELX_^E(_5.BOSY'_  5U_;Y _P"4(_QC_P# T?\ R/7K?[%O[=_[3O[2
MWQ9N/ ?QB_X)U_$#X3Z9!IDETGB'Q/<[[>652H%N!Y2_,0Q(Y_A-<M7*\91I
MN<N6R_OQ?X)W-Z>/PU6?+%N_^&2_-'U7110>G%>>=AXY^V-^PK^SA^WC\-%^
M&'[1W@&'5[."0RZ;?12&&\T^8C!E@F7YHR1P1RI[@CBOAZ3_ ((5_MB?LI64
ME[_P3D_X*@>,/#5K Y>R\&^,(C<:>S<D*S(3'C/'_'L3SFO=?^"DGQ'_ ."M
M/P3\<^&/BE^Q-\-O#?COP%IF7\6>#47&LWIPP;#.<&, @KY/[P,!N5UR*\X@
M_P""[GCN311IM]_P2D_:/7Q.NU!I<7@XO9F;T-T2&"Y[^5TKZ# +-:6&7U><
M90EJXMQ:7K&6WR^\\?%/+YUY.K%J2T4K25_1K<Y[]@/_ (*K?M=^'_VXU_X)
MG?\ !2WX>:39>.KF)CX?\7:"HCAU$B)I4#HO[MUD1'*RQ[?F78R @D?IL@QG
MZU^7W[&'[$?[9/[77_!2*U_X*J?MX_#FV^'=OX>L19^ ?AZMR);Q$6*5(FG(
M^ZJ>=+(=V&9W^ZJC!_4(#'%<V<K#+$0]DDGRKG4?A4NMO+;;0WRV6(=.7M+M
M7]UO=QZ7_$****\@]$**** "BBB@ HHHH **** "BBB@ HHHH **** /R*_X
M.U_^2*?!O_L<+_\ ])4K\B/AG_K$^@K]=_\ @[7_ .2*?!O_ +'"_P#_ $E2
MOR(^&?\ K8_H*_7>%_\ DGZ?K+\V?#YA_P CR7R_(]_^'_W4^HKZ ^%_6/ZU
M\_\ P_\ N1_45[_\+^L?UIXOX3W,/\)])_";_61_45]2?!O[\7^[7RU\)N)$
M)]J^G?AAJVDZ%IQUK6]2M[2SMHP]Q=74ZQQQKZEF( 'N:^&S;73J>I2U5CH?
MBF"9)/QKYP^+.I6>F*\UU-M+R^7%&JEGE=CA41!EG8G "J"2> ,U[_J47Q!^
M.%\;/X->#WN;&0D-XKUA'MM,5>/GBR!)>#T\H>6W_/5:],^"/[''P\^%>J0^
M-O$%Q+XE\5!&/]N:E @%J6^\MK"HV6R=1D9D(.&D>N'#XFGA87GOVZ_\ IIR
MT1\\?LJ?\$Z=0\<:U9_%K]I7PXUOI4<JS:5X*NA\]P0<K-? ' 7H1;9.?^6F
M>8Q]RVMK;V4"VUK$$C485%Z >@]!3HXUB01J3@>M.K@Q.*K8NHI3>VR[%TZ:
MIK0****YRPHHHH :\2.<LO/KFA(8HR2B8S3J*5D 4444P"C'.:** (C9VY8L
M8\DG)Y-2*H4;5& *6BE9 (RAE*L,@CFDCACA&(UQGKS3J*87TL%%%% #&@B9
M_,*<^N:>!@8%%% !41L[8MO,0S4M%*R8")&D8VHN .@I>M%%,!CV\,AW.F3]
M31';Q1'*+U'/-/HH>H7&O%'(GENN1Z4U+6",Y1,8.1R:DHI<L>P!00&&"***
M8$9M+=B&,>2.ASS2F"(QB(I\H&,4^BE97 C%K &#[.0<@DGBE>"*3.],YZ@F
MGT4)); ,CMXHL^6F,C'7M3^E%%"26P=;@0",&HS:6Y(;R^A'<]NE244P  #I
M1112LK6 8UM S^8T8R#D'WIR(L:[4&!2T462 *,444P(S:6Y?>8\G.<DF@6M
MN%VB,8'09J2BDTF#U&+;0J<A/U-/HHIV *21%D0HXR#UYI:* (_LMOWCS]31
M]DM_^>0J2BE9 -CACB_U:XIU%%, H(# @C@]:** (A9VX&%0CC'#&E^QVY()
MCZ=.34E%*R8K*]Q%147:HP!2T44QA1110!&UK Y)9,Y]SZYIZJJ+M48 I:*+
M(=VPHHHH$%,$$0E\X)\WKFGT4K*X;!1113 *;)$DJ[9%R/K3J*!-)[D9M+<C
M;LX] QH^RP#^#_QXU)12LAAC%%%%,!'19%*.N0>HIBVL"$%$P1TY-244 %-D
MACE7:Z\#T.*=12:3W CCM+>%MT:$'_>-2 8&!113 " P*D<$<TPVT#')CS^-
M/HI63 C^RV__ #R%*D$49RB8_&GT465[@%%%%,!LD4<HQ(N:;]DM\Y,>>>Y-
M244":3W(Q;0!@XCY!R.>]2444#"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _(K_@[6_P"2*_!H?]3AJ'_I*M?D1\,Q^\C/L*_7;_@[8)'P4^#>
M#S_PE^H$9_Z]4KRW_@DA_P $&M=^/_@?2_VAOVK-5O=!\*ZC$ESH?A2R_=WV
MJ0')6::0C_1XF'W0H+L#G*<9_4,FS#"Y=PS3J5I65Y>KU>Q\=BL/4Q.>S5-7
M:2^6A\N?#**;4KVVTK3K>2XNIVQ!:V\;22R'T5%!+?@#7V5\!_V*_P!KKQI'
M#/H?[//B&"&0 K<ZY NFQX]<7)1R/<*:_6+X&_LP? ;]F[2?["^"?PIT3P[;
MM#LFDL+-1-/R.9)3\\IXZL2:[[8N<[!Q[5\YC.*9U;JC3LN[>OW(^CHX-P7O
M,^&_@[_P3:^.+&&?Q_\ $?1?#D*@"6VT:U?4+@C/:6411QM]8Y!FOHWP#^QE
M\%_ ]S;ZKJ%A=^)=2M65H-1\47/VMHF'1HXL+#"V>\<:FO5U15.0BCZ"EKYV
MMC\57;YI6]-/R.N,.49%"(>%Q@   #&*?117(6%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ?#W_!63]E#3OVROVC_ -F/X1>([$7.A0>.
MM3U?Q' P^62RM;-97C;V=@D9_P"NE?;=C8VFG6R6=C;+#%&@2..,855 P !V
M '%4]0\(^'M4\2:?XOOM-234M+@GAL+L_>A28QF51_O>4F?]T5I#D5TUL3.K
MAZ=)O2%_Q;?]>AC3H1A5G42UE^F@4445S&P4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>cpix-20250310_g2.jpg
<TEXT>
begin 644 cpix-20250310_g2.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "< .(# 2(  A$! Q$!_\0
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MT <A2P'&?YU]0 Y&:>.P=3+L;4PM1IR@VG;:ZT"G4C5IJ:ZA1117*:!1110
M4444 %%%% !1110 4444 %%%% ".VT9KA/VA?V@_AI^S9\,-0^*WQ4UV.QTO
M3XRS%F&Z9_X8T'=B:ZCQCXIT+P3X:OO%OBC4XK+3M.M6N+RZF;:L<:C+$GZ5
M^5MDWQ)_X+=?MDW+->75G\ O -^JQJN535)E/_CQ8_DM?1<.Y+3S2I/$8J7)
MAJ2O4E^48]Y2Z(X\5B?8VA#6<ME^IX7XC_X*/_MP?ML?MZ^ ?$?@>VU;P;X$
MM?%<2:+9K))%'J-J)0'9B,"0D=1T%?NG:^8(%9SEM@)^N*^ OBQX#\)>)_\
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MRX,')E^<_*Q[@<5]L(".IKLS'#X7"XR5/#U54@MI)6N13E*4+R5F.HHHKA-
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M.))SW QD9KZI\>>._"/[/WP?OO&_C"^2VT?POHIFN)#A?W<4?0>YQ@5\#_\
M!*WP?XJ_;D_:K\8_\%0_BUIDBV#2OI'PVL;@'%M:J2&E4'U'&1ZUVY33C6Q>
M)SW%ZTZ3<E?[523]R/G;=]DC.O*480P\-W^"ZO\ KJ?:/['_ .S1X,_9!_9_
M\/\ P8\)P*D>EV"-J5UQNNKDC,LSGN2V237YX7?QO\#?M'_\%7?$W[5/Q&O=
MOP\^!5I_96@[FW"]U9FVJL2_Q.7Z <\BOM'_ (*I?M;V?['G['GB3XB17,:Z
MOJ%N=.T*)F^]<R@KG_@(.:^'_P#@BE_P3P\;_%?PGH_QQ_:-L)K?PK:ZL^L^
M']!F5E.J7[-D7EP#RP7HH/UKUN':$89+CL]Q]3E<[PBW\4G+6:CYO:^RU.?%
M2OB*>&IQT5F_T_S/U=^'>N:WXE\&:?X@\0:'_9MU>6ZS26#2;F@W<A"?4#&?
M>MNF0QB&(1@<#I5/Q)XBL/"VAWGB'5&9;6PM9+BY95R51%+$X[\"OSE^]+1;
ML]CIJ76D5>IK\PO^"WWQ/F_:.^+_ ,._^"<?P[UC=>:MK4.I>,&CDVQVUFAR
M1(?3;EO;;7L.J?\ !>[]@'_A6FK^--.^(5Q_:6F1S"'09[-EN)Y%) "\8P2*
M_-G]FG]G/]N'_@J5^TYXH_:%T<ZAX5TOQ1=2+J/BJ:-HUBL6X%O"3U^7CY:_
M4.">&<1@<94S/-O]GIT8OEE--7FU966[M>^G6QXN88R-6FJ5#WFWK;M?]3ZV
M_:5_:5^(G[6WB'1_^":/_!."ZD71='AAL/&GC2Q&VWMK>-0C(CCMP<D=>U?<
M?[%7[&7PN_8F^$EO\-?A]9^9=R@2ZUK$JYFOK@\L['KC.<#M4'[*O[)OP _8
M"^"Z^&O!-O:V-K9VOG:]X@OB%DNG RTLKG\>_%? _P"V)_P6D^/?QJ^+4GP!
M_P"";WA]9H]-NO\ B9>+)X@RN$/S8+?*D?\ MDUQNECN*+Y9DL>7#4WS3G+3
MFE?XZC[N^D>G8M>RP?+5KZS>B2Z+LC]9HL;04(-29QUKA_V>=9\;^(?@MX7U
MWXD:A8W6O76CPR:O/I<@:W><K\Y0KD$9KYM_X*6?\%@_A9_P3]OM/\&0>&_^
M$F\4WRB9M)AN/+6WASC>[=B>PKXO Y/F699A]2PL.>I=JR\MW?:WF>C.O3I4
MO:3=D?95%?/?[(?_  4D_9Q_:W\+Z+/X;\:Z;IOB35=/^UR>%KN_7[3"O1L=
MFP?3GVKZ 6ZC*AC\N>BFN/$8>MA*\J-:/+*+LT^C-(RC.*E'9DE! /6JL^LZ
M;:W4=G<WT,<LW^IC>4*S_0'K^%317=O,6$4RMM.&VL#@^E8E!,WE)E5_*O!?
M#O\ P4K_ &3?$O[4]U^QSIWQ$_XKBTE>)K%[9A')(J[FC63&TL!VKWMPLR8S
M7S=H?_!*O]E70OVS;K]N.ST"Z_X2ZYW2>2UP?LL=PR[6G$?]\COZUZ&!_LWE
MJ_6W)/E?)R_S>?D9U/:Z<EM]?0^DHW+#DTZFH@08%.KSS0**** "N+^.?QJ\
M!_L__"_6/BQ\1M7CL]*T>U::XD=L%R!PB^K$\ 5VE?FK_P %SM4USXO_ !:^
M"?[$FGWMQ:Z5XU\41W.O- ^TRPHX78?:O:X>RJ.<YM3PTW:.LI/M&*YI?@F<
MN,K_ %>BY]=EZO8Y+X#_  B^-/\ P6<^./\ PTE^T3]ITGX+Z%J!/A/PLK%5
MU/:W#.O<<<M^ K]/O"OA7P[X'T"T\,>$M%M=.T^SC$5O9V<05$0<  #VJ#X=
M_#[PQ\+_  /I7@+PAI,-GINDV4=M:V\* !510*Y7]J;]HKP+^RW\$=>^-'CN
M[6.UT>T9X8F89GFQ\D2^I)KHS?-L3Q!CJ>&PL.6DGRTJ:V2V5^\GNV^I&'HQ
MPE-U)N\MY-GP]_P7%^.7C'XL^,? _P#P3<^!]T\VN^/-0CD\1"UDPT%INX#$
M= 1N)!]!7W/^R[\!?"G[,WP/\/?!3P;;+'9Z'IL<+.J_ZV7'SN?<MDU\*_\
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MG_#FSO.$LM-C.&G4'IN ^]W!KF?V#+"7]N__ (*8_$3]M_7;9[CPSX'8^'O
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M 1SXZYKX5_X*S_$KQ%\8_%7@W_@G3\)M4ECUOQ]?1S^)I+5OFMM*1LR9(Z9
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M4#':BOS$]H**** *?]B:>^LKKLD"FZC@:&.3N(R02/S%7*** "BBB@ HHHH
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M@9KTA$"# IU%:5JU7$5'4J2<I/J]63&,81M%6"BBBLR@HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>cpix-20250310_g3.jpg
<TEXT>
begin 644 cpix-20250310_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIHEB:0PK(I=0"R \@'H
M<?@:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?$CX.ZIX6MY/"5KXA\2 >&%!73YHK:^+V\$L PDL,;K&ZQ."@:)#CY16_P#
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ME^SQX:/A_P 71^$O[7\:>!YHU,=MJ=G9W;QW:,@ ECGX!<!<F%F90S-GS?\
MX(&Z%:_%WX7_ !O\;_$[_B=ZEXNUF*RU^_U(>;+>1/;S/*KLW4,9W)'0_@*
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M^TW_ ,%QO'/C[X@RM=-X:LM<MO#=O<?,NG6UM<)9PI&#PA\N1RV,9>1VZL:
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M*U7Q7XBCT>37+5BLUC;F":60Q./N2MY00,.5!<J0P!%_]F[]FO\ X)Z?M%_
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MZ#KVARW3:J%DN"(H'CN(O)E"ARH99!(Q5?D^]0!WO[1OQV^-'_!+K_@I%:>
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MBMT>1;^UPY6-0"PP.3SQ7RC^RI##/_P;]_%&.>)747FJ, PSR)+4@_@0#^%
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M\T_M;?L;?!?]C#_@E%\7OA;\'+34#IM\%U6ZDUB\%Q,]PUS:*#N"J JK%&%
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M1\"OC;=W>G_"7XLZ#X@N;"-)+VTTS4DDFAC< I(T8.X(P(VOC:V>":K?$_\
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M<_$@_M+^ Y= L[M;6YU>U\66DUNEPR[EAWQR$>85^8(/F(YQBO/OBG##<?\
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M(?BNY^,7PABN=+\665G;I>Z)XBLIFLY(97.^2-Y4)CVRL25+,-O"MGC]$Z*
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M>M?/'[ O[%7[77[+G[(/QE^!?CGX/P7.L^,].N!X<DL/$=FT,DTUH;4I*S2
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M\-/^"?\ XL^$D/A6+PAK%M_PDGQ#N=?LKK3I[&U2>*(V<,,IN9)'213MEBB
M*8+ -N'TO^TC^P+\-_CA^Q+'^QMH<_\ 95GHNDVD/A/494\QK*YM$"PROC&_
M<-RR$<E97(Y(->^44 ?G9\0OV,_VR_VB/V./AI_P3_\ %GPDA\*Q>$-8MO\
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M 4444 %%%% !1110 4444 %%%% !4=W<Q65K+>3[MD4;.^R,NV ,G"J"2?8
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M']X>M??_ ,#O#VH^$?@KX/\ "FKQLEWIGA;3[2Z1NJR1VT:,#^*FOD/X)?\
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5C^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!- &Q1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ,>R_Y'>]_Z\HOYFMBL>R_Y'>]_Z\HOYFMB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K-\8_\BQ>_]<#6E6;XQ_Y%B]_ZX&@"YIW_ "#X/^N*_P A4U0Z=_R#
MX/\ KBO\A4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7&EP$M)"O5M@.?-C/=#DCW'3\UJY=F_ =26(RN,J^!;O.CO.GWE2;W75Q?\
MG)>2Z5?+7S4?>I]8]5YK_(^D**\L^ 7[3OASXNP)H.M"+3?$")\]H6Q'<X'+
M1$_F4/(]P":]3K[W*<WR[/,#'%X*HIPEVZ/LUNFNJ9Z5"O2Q%-3INZ"BBBO2
M-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#'LO^1WO?\ KRB_F:V*Q[+_ )'>]_Z\HOYFMB@ HHHH **** "BBB@
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M.H/?RE+3_"SS?K.+QNF'7+#^9_HCSGPW^SU\9?C]JT?C3X[>(;K3[$G=!8D
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M1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I45F_\
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M/NCG?AG\0OA_\6?#R^(/"+P2 8%S:R1*);9_[KKV]CT..":Z/^SM/_Y\8?\
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M&KZ08+=$S>'.Q ,_*:W*Q_$O_(7T?_K]/_H)H V**** "BBB@ HHHH ****
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M -!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_9BM0//_ .$BN?\ KMJRC/\ WQ&M:UG_ ,$W_P!DJV(,_@&\N/\ KMKET/\
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M_P %3]9XL?A=]DW<#_B201X[?\MG/UY_E7S#^T-=_%N^^,.L7?QUMO)\5/\
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M %;_ ,%3_P#D2']E+X5>&_C;\?= ^&/B^XNXM.U/[5]H>QE5)1Y=K-*NTLK
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M56+HY?&,_:UGSS[O9>B"BBBON#T0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#'\2_\A?1_P#K]/\ Z":V*Q_$O_(7T?\ Z_3_ .@FMB@
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\8_\
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MC9Z?:7%U)*+*VMQ\L21^7&I'.&1@-HXKZ7\*>%M3_98_X*C6_@3P'X]U6_\
M"_QMT/6O$.O^%]1O#-'I6JPRB9KR ?\ +))=[)M[G()(5 @!]@4444 %%%%
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M\BQ>_P#7 UI5F^,?^18O?^N!H N:=_R#X/\ KBO\A4U0Z=_R#X/^N*_R%34
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MBEUD:E; 6&GJP=H+6UBD?RDWX+,,#@85-S;MC_AT/_P3C_Z->TK_ ,&M]_\
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M;\&\/YU4]K6H\M7=5(>Y-/OS+=_XKGR#H?[?'[2_P#U2+PI^U-\(I[I,[5U
M6XM)Y .K*R@P3_\  -O^]7T+\(/VR?V?/C5Y5IX7\=0VFHRX TC6,6UQN/\
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M]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[
M_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WT
MM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM &Q16/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
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M=+;'U>24*=2C[::O).R;UT5M@HHHK]J/H HHHH **** "BBB@ HHHH ****
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MD/LC-6_\9_@1X.^-&D?9]8A^S:C"A%EJL*#S(O\ 9;^^F?X3[X(/->5?%_\
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MVJ+W6_*:]VWF^4^K:*Q? _Q&\!_$O2!KO@#Q?I^KVAQNEL+I9-A/9@#E#[,
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M1M=>MSU<LX(X8RJ?M*>'4I_SS]^5^]Y7L_2PV""&VA2WMH5CC10J1HH"J!T
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MQMTM6L=/U2PC\\9NH5DV!P\4O[LR< D@ G QFOFK_AX;^V%_T5__ ,M_3_\
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M "BBB@ HHHH **** "L?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K]/\ Z":
M-BBBB@ HHHH **** "BBB@ HHHH **** "J?B'2Y];T"^T6VU*6SDO+.6".\
M@)#P,Z%1(N".5)R.1R*N53\1V^L7GAZ_M/#MZEMJ$MG*EC<R#*Q3%"$<C!R
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MQ7^0J:O$K+_@H3^R!%9Q12?%W#+$H8?V!J'! _Z]Z]3^'GQ#\'?%;P=9^/O
M.L?;])O_ #/LEW]GDB\S9(T;?+(JL,.C#D#ID<8-<^,R7.,NI*IB\-4IQ;M>
M4)15][7:2O9/3R.C!9WDV9572PF)IU))7:A.,G;17LFW:[6OFC:HHKG_ !W\
M5OAK\,+/[?\ $+QUI>CQE=R"^O41Y!_L(3N<^R@FN*C1K8BHJ=*+E)[)*[?R
M1W5J]'#TW4JR48K=MI)?-G045\Q?$O\ X*F_ _POYEI\/-!U3Q-<+G9,$^QV
MQ_X'(#)_Y#_&N _X7Y_P44_:2_=?"KX>OX:TJ?[E[;V0@4H>_P!INC\Q'K$
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M'\2_\A?1_P#K]/\ Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=:LVXKTBK)+R=T<!\-/V7/@#\(_+E\#_  PTR"YCP5O[F+[1<@^HEE+,OT!
M]J[^BBOC\5C,7CJKJXFI*<N\FV_O9]GA,%@\!25+#4XPBND4DON5@HHHKF.D
M**** "BBB@ HHHH **** "BBB@ HHJIJVOZ%H$/VG7=:M+*/_GI=W*QK^;$5
M$YPIQ<IM)+J]!-I*[+=%<!X@_:A^!/AW<MS\0;6X<=$T]'N-WT:,%?UKB/$'
M[>WP\LMR>'/".JW[#HUP8[=&^ARY_P#':^:QW&O">77]OC:=UT4N9_=&[_ Y
M*F88*E\51?G^1[M17S7_ ,-9?M ^-_E^''P= C?[LJV4]T5'KO&U1]2,4?\
M".?MV^/_ /D(:X^C0/\ =/VJ&UVC_M@#(/QYKQO^(B8#$Z9=A*^([.%)J/S<
MK67R,/[4I3_A0E+T6GXGTA<W5K90M<WES'%&H^:25PJCZDUR>O\ Q^^"_AG<
M-6^).E;E^]';7'GN/JL6X_I7CUM^P]XX\23K>?$?XOF:3.6\J.6Z8_1Y67'U
MQ76>'_V&_@WI6U]7N-5U-OXEN+L1H?H(U4C_ +ZH_MGC_'?[KEL**Z.M5O\
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M\"O#FUK3X=V<[CJ]^SW&3])"P_2N]HKVL#P7PIEUO88.FFNKBI/[Y7?XF]/
M8*E\--?=?\SY>_::_92UJVUN?QW\*]"^T6-Q\]YI-E$ ]N^.6C0?>0]=J\@D
MX&.G@IT76%OAI;:3<BY+;1;F!O,SZ;<9S7Z-UC^)?^0OH_\ U^G_ -!-?"Y_
MX/95FV8RQ6%KNASN\H\JE&[WY=8\M^VJ[66AYV)R*C6JN<)<M^EK_=L?//[+
MG[+GB-/$=K\1_B/I3V-O8N)M.TZY7$LLHY61U/**IY ."2!QCK]/445]]PQP
MQEO"F7?5,)=W=Y2>\GW?Y)+9>=V_3PF#I8*ER0^;[A1117T9U!1110 4444
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
M\(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0 >)?^0OH_P#U^G_T$UL5RFN>%=.M
M=1TV&.>Y(GN2KEKAB0-O;TK3_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_
M  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
MV**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_
M (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK
M'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!
M](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
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M%*,9QM)71Q?AC]GGX+Z!XYN&T[X?V9\BWCDA6Z9YU1B>H$K,,_RKTP * J@
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MB/>VQ!R@O+))?U1D_/%9<O[*G[2/A<9\'?%F.:)?NQ+J=Q"3_P !(*_F:/\
M6;C#"?[WD\FN]*K"?_DNC#ZWCH?'0?R:?X'TS17RS-H_[;/A$[KK2;C4XEZ;
M)(9\_P#?M@_YU#_PT5\6?"9Q\0?A!=H%^\Q-W:9_&3>*/^(CY10_W[#U\/\
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MQ16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16,_@K1HU+O>7BJ!DDWC
M"N:\0>+_ ((^%]RZY\3;6%U^]"-8WR#_ ( I+?I7/B<9A,'#GQ%2,%WDTE^)
M$ZD*:O)I>IWU%>$^(/VHOV>M'W+INIZ]JC#I]BC=03]92E<?J'[6S:O<&P\
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M_88G_P!7.NDR?^C)SL/Y5[=I'PB\"^'TV:#I(LAC&+0B/_T$"KW_  @^D?\
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M^!;5]+@>',@RVWU7"TX-=5"-_OM?\3KIX7#4?@@E\C8HK'_X0?2/^?F]_P#
MMJ/^$'TC_GYO?_ MJ]HZ#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8
MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
MA!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BL?Q
M+_R%]'_Z_3_Z":/^$'TC_GYO?_ MJI7^A6>C:SI;6LL[>9>8;SIBW13TSTH
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MI^:ASQ7_ &]%_H']I2A_$HS7RNCZ#\5^+?#G@?0I_$GBK5HK*RMQF2:4]^P
M'+,>P&2:\%\;_MV^&+N&YT?PWX$O+J"12@NKJ\6$GGJ$"OQ]2*\H^//QM^(?
MQ4O;32/&^C#2CIBG=IL<4D8\UN?,99"3G;@#/0$XZFO/:_+N+/%W-9X]T<E?
MLZ<?M2BG*3ZZ2344GI:U^M^B\?&YY6=3EP^B76VOXGVK\&?VHOAU\49H/#2-
M-I>J^6%CL[TC$Y Y$;CAC['!] <5Z?7YO6MS<V5S'>6<[Q30N'BEC8JR,#D$
M$="#SFOH/1OVG?VGO&VDVT'@CX:)<8A5)-2ATN:42.!AFW9$:Y(/&.*]_A#Q
M:^M8>5'-J<I58VY73@VYKK>*T37?1.^RMKTX'.^>+C73<NEEO\CZ>J&^U"PT
MRW-WJ5]#;Q+]Z6>4(H_$\5\X_P#"#_MS^/\ _D->+&T>)^F=0BML#Z6P+?GS
M4MC^PKXBUNX%_P#$'XM//+_&(+=YF/\ VTD<'_QVOLO];^(<;_R+\GJM=ZLH
MTOG9W9W_ %[%5/X5"7_;UHGK7B#]HOX(^&MPU+XD::[+U2RD-R<^F(@U<1X@
M_;L^%&G;H]"T;5]2<?=80I#&?Q9MW_CM7?#_ .Q'\$](VMJD6IZHP^\+N^V*
M3](@AQ^-=OH'P4^$GA?:VB?#K28G7[LKV:R2#_@;@M^M')XEX_>6'PT?)2J3
M7W^Z*V;U>L8+YM_Y'BDG[9_Q8\7N8?AI\&_,).%)CGO#^4:IBD\S]O#Q_P#=
MC;1K=_:WM=OYYEKZ3CCCB011(%51A548 %+1_J7F^,_Y&.;UY^5/EHK[HIZ#
M^H5ZG\6O)^EH_D?-:_L;?&+QBPE^)?QD$F3EE\Z>\(]OWA0"NE\/_L(?"S3]
MLFO:]J^HN/O*)4AC/X*I;_QZO;Z*Z,-X<<(4)^TGA_:3[U)2FWZINWX%0RK
MQ=W&[\VV<1X?_9O^!WAK:=/^'&GR,O1[Y&N3GU_>EJ[#3],TW2;<6FE:?!;1
M#I%;Q*BC\ ,5/17U>#RS+<OCRX6C"FO[L5'\DCMIT:5+X(I>BL%%%%=QH%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_B7_D+Z/_ -?I
M_P#036Q6/XE_Y"^C_P#7Z?\ T$T ;%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X+_ ,$ZO^2'ZO\
M]CWK'_H^O>J\%_X)U?\ )#]7_P"Q[UC_ -'T >]4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z":V* "BBB@ HHHH
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M*JZYK>D>&=$O/$FOZA%:6&GVLES>W<[;4AAC4L[L>P"@DGT% %JBOS2^(/\
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M% &/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_036Q0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 8]E_P CO>_]>47\S6Q6/9?\CO>_]>47\S6Q0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB5K_ ,(_$FC_  ;\5IH?BRXT:X7PYJLMO'*EO>["86994="N\ '*G ).,XH
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M6-E'X:O'CLXE80G!6, B@ L?%WAJ.RAC?680RQ*"">AQ4O\ PF/AC_H-0?\
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G
M:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
MOJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'
MPQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^JS]
M5UK2M6UC2ETZ^28I>9<(>F5-;G]G:?\ \^,/_?H5D^(+:W@U?2#!;HF;PYV(
M!GY30!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<MXF^"_PZ\7_ !2\,?&?Q!H;3>(O!T%]#X>OA=RH+9+R-8[@&-6"/N5%&6!Q
MCC%=3110 4444 %%%% !1110 5X+_P $ZO\ DA^K_P#8]ZQ_Z/KWJO!?^"=7
M_)#]7_['O6/_ $?0![U1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^)?^0OH_P#U^G_T
M$UL5C^)?^0OH_P#U^G_T$UL4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/9?\ ([WO
M_7E%_,UL5CV7_([WO_7E%_,UL4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9OC'_D6+W_K@
M:TJS?&/_ "+%[_UP- %S3O\ D'P?]<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K'\2_\ (7T?_K]/_H)K8K'\2_\ (7T?_K]/_H)H V**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KP7_@G5_P D/U?_ +'O6/\ T?7O5>"_\$ZO^2'ZO_V/>L?^CZ /
M>J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K
M]/\ Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#'LO^1WO?^O*+^9K8K'LO^1WO
M?^O*+^9K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *S?&/_(L7O_7 UI5F^,?^18O?^N!H
M N:=_P @^#_KBO\ (5-4.G?\@^#_ *XK_(5-0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C
M^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!- &Q1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>"_\$ZO^
M2'ZO_P!CWK'_ */KWJO!?^"=7_)#]7_['O6/_1] 'O5%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% &/XE_Y"^C_P#7Z?\ T$UL5C^)?^0OH_\ U^G_ -!-;% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!CV7_([WO_7E%_,UL5CV7_([WO\ UY1?S-;% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6;XQ_Y%B]_ZX&M*LWQC_R+%[_UP- %S3O^0?!_UQ7^0J:H
M=._Y!\'_ %Q7^0J:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Q_$O_(7T?_K]/_H)K8K'\2_\A?1_^OT_
M^@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\V_:T^+/[/?P=^!NK^(/VHYHU\%WZC3-6BFTF>]CG$X*")XX4=@&Y&X@ ''(
M)%>DUS'QF^#WP^^/_P ,-9^#WQ3T)=2T'7;3R+^U9BIQD,KJPY5T=5=6'(90
M>U 'XY?&C]DCX=> /BGXP^,O[!7QYU?PQH7AGX2Z?X_T*[_M.023QW%RT;6L
M<ZE)(B J[4DWN7!C?DY7IO\ @I=\3OB5^TK_ ,$POV=_VB_B-"7U*YU34;+6
M;I80@GN!YD,<Q4 !3*MF\F  /F. !Q7JGA'_ (((:':_M,:IX,\1^/\ QI+\
M)8M!MKJSO(]0M8Y;^Z^TLS:?(%R=B#$F\1*"7.TJW-?=/Q;_ &./@%\9?V<!
M^RKXD\&K;>$+>Q@MM*M=.?RY--\D 0RP.0=LB8^\V[=E@P8,P(!\4?\ !?CQ
MQX<\1_L6?"=-)U"*8Z[XDM]3TP1N"9K9=.ERZXZK_I$7(_O#UK[_ /@=X>U'
MPC\%?!_A35XV2[TSPMI]I=(W59([:-&!_%37R'\$O^"%_P &?AQ\3]#\??$O
MXV^*O'FG^%9UE\,^&]95$M+78P=$<;FWHK -L01JQ W C*G[EH *R?'5GXQO
M_"-_9_#_ %BTT_6I("-.O;ZW,L,,F1AG0?>&,\5K44 >%_\ " _\%!/^B_\
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M%??\%#_^C@O G_A+O7O5% '@O_"OO^"A_P#T<%X$_P#"7>C_ (5]_P %#_\
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M@YZ@&O7Z /!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\ "7>O>J*
M/!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWKWJB@#P7_ (5]_P %
M#_\ HX+P)_X2[T?\*^_X*'_]'!>!/_"7>O>J* /!?^%??\%#_P#HX+P)_P"$
MN]'_  K[_@H?_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T?\*^_P""
MA_\ T<%X$_\ "7>O>J* /!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\
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M_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\ "7>O>J*
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M_"OO^"A__1P7@3_PEWH_X5]_P4/_ .C@O G_ (2[U[U10!X+_P *^_X*'_\
M1P7@3_PEWH_X5]_P4/\ ^C@O G_A+O7O5% '@O\ PK[_ (*'_P#1P7@3_P )
M=Z/^%??\%#_^C@O G_A+O7O5% '@O_"OO^"A_P#T<%X$_P#"7>C_ (5]_P %
M#_\ HX+P)_X2[U[U10!X+_PK[_@H?_T<%X$_\)=Z/^%??\%#_P#HX+P)_P"$
MN]>]44 >"_\ "OO^"A__ $<%X$_\)=Z/^%??\%#_ /HX+P)_X2[U[U10!X+_
M ,*^_P""A_\ T<%X$_\ "7>C_A7W_!0__HX+P)_X2[U[U10!X+_PK[_@H?\
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M)+K5IX0"MK"8&4.W/3/% 'K]%%% !1110 4444 %%%% !1110 4444 %%%%
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MBCQ39^-;\QZYX7UJY+"Z1)[>.17B4[&643L(VV[T:-B&)&:^OO\ @H=^V_\
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M_P ,?V;?AY\4G\&_ KPIX4M-/U_4=$U?R;R:2W@92\D.4,BE8X8T!+*K.TC
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M[C5)$"MJ"V\S1I.V."Q4!6/\3(Q[U]'T %%%% !1110 4444 %%%% !1110
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M90% /T]HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4?$B^427,S.P7[%8\98GCD_G0!]T4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% #988IUV31*ZA@P#+D9!!!^H(!^HK\TOV^?^4ZWP!_[ 6C?^G+4
MJ_2^OG_XT_\ !/GP#\:_VQO!7[9>L^.]8L]8\$V=I;V6D6L<1MK@07%Q.I<L
MI<$FX8'!Z** .Y_:L_:B^&'['_P8U+XU?%6_9+.SQ%8V,!'GZC=L#Y=M$#U=
ML$YZ*JLQP%)KX-_9/_9N^.W_  52^/&G_MY_MFP?8/A_I-UO\!>"1GR;J-),
MH K?\NX=09)&&Z=EQ@(!CZO_ &^?^"=G@_\ ;^A\-6'COXJ:_H-EX9:YD@LM
M'CA9+B681@R2>8IR56/"^@=O6OG'_B'"_9W_ .C@O&G_ (#6G_QN@#MOVV1_
MPO?_ (*I_L[_ +.4?[RQ\(Q77C36D'*@HQ:#>/\ ?L@H'_3?G@U] ?%O]H']
MESQO\0M1_8*\;_%)K3Q=XRT&YL7T.VMKB.=K:XM)&<QW!B,*.8=Y7+9R, $\
M5D?"+]AC1?A;^UGK/[5MU\1+K5[R^\%67AG2M)N-/5$TVU@CMD++(')=G-ON
M/RK@R.!P:R/VX_\ @F9\&/VW-7TKQYK'B+5O"GC+0XEBTWQ5H#*)3$KETCE5
MOOA&9F4JR,I8X;'% 'Q]X6\-P?\ !+O_ (*S^#_V<?V:_$=SJ?@_XE6FG+XD
MT+4Q%<3VIGFGA ,P0./*\M;A>AVN0P(()^[O^"@<,47[#7QA>.)5,GP\U=I"
MJX+'[&XR?4X 'T KS7]CC_@DS\'OV5?BA+\>O$WQ!U[X@^.V1TMO$'B1ABTW
M)L:2-,LWF%"4+N[$*<+MR<_0GQO^%FE_''X.^*/@WK>IW%E9^*="NM+NKNU"
MF6&.>)HV=0P(W -D9XH ^5_^"#<T-O\ \$\["XN)52./Q/JC.[G 4"1223V%
M4?\ @C'!+\49OC;^V/?Q-YGQ(^)MPNG-(O(L;8L\07/10;ID_P"V//05[5\
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MQND7B/Q&P_T4.NQWB3+'S&4E3([N=I*C:"V0#ZHHHHH **** "BBB@ HHHH
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M*@JLT+$, V&92&!4AB"#0!^?_P#P5:_9V\%?L)^(]!_X*&?LV?$6_L_'NO\
MQ#GGNHM3F@O8+O[5'<7,DL*-'\J*5$>!D;)E&0<%OTH^$?BVY^)'PM\+?$K5
M=%6QO=<\-V=_-:$<VS7$$<KQ GG 8@?\!%?&GPS_ ."#GP:T/QOI'B#XT_'G
MQ=\0=&\.L/[$\+ZN1':1(I!$+_,Y:+@91/+#8 .1D'[MCCCAC6&&-41% 55&
M  .@ H _-+_@C[_RDA_:;_[#NH?^GB>O3<?\+_\ ^"Z.?];IOP4^&GUC&H7:
M_P#H1COOP-OZBO8OV7/^"?/@']ECX]?$'X^^%_'>L:G?_$.\GN-0L;^.(0VI
MENGN2(RBAB SD<D\"M?]FO\ 8XTS]GOXS_%3XXW'CR?7]7^*.O)?W)GT]81I
MT$;3&.UC(=BZJ)MNXXR(UXXH \>_X*=?\%)M7_9SO+']F+]FG2FU[XO>*A'!
M86UM#Y_]D+.=L3E.1)<.3^[B/ &'?Y=JO)_P3O\ V!]4_8;^''BG]HGXR7K^
M)_BQXCTNXO=?G-R93;H ;AK-)CDR222*&EEY#.%"Y"[GYOX^?\$*/A!^T/\
M&?Q-\;O&G[0/C%=2\3:O-?3PQ06I2 ,?DA0LA.R- J+DYVH*Z+]CO_@C-\'O
MV-_CMIWQY\'_ !<\2ZO?:;:W,$=CJ4%NL3B:)HB240'(#9'- 'P#\)OVTM?\
M-^,_BY^T'^T#^S=XM\4?$#XAZ+>Z;8:TL#PVGA^RFMVC*1(\;$!5V)G((CB"
M@_.Y/T-_P;T_M)^1X:U7]E#_ (5SJ3>=J=_XB_X2D/\ Z(O[JRA^RXV_ZSY=
MWWNAZ5^E/C_PA:?$'P)K?@*_NY((-;TBYT^>>$ O&DT31EESQD!B1FO,?V&_
MV,/!W["OP?O/@[X'\7ZGK5G>:_-JKW>JI&LBR20PQ% (P!M A4^N2: /9:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCA550 !Z"KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !117F?[4_P 7;[X3_#KS-!F$>JZI,;:REQDPC&7E ]0, >[
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MC-OWH1D[VFENWTV/T[_X>&_L>_\ 17__ "W]0_\ D>NU^$'[0_P>^/7]H_\
M"I_%_P#:O]E>3]O_ .)?<0>5YN_9_KHTW9\M^F<8YQD5^1]?:7_!(+_FH?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME;%KB= <A'F<M(R@\A2V ><5#\=/V//V8OVE[VTU3XZ?!71/$5Y81^7:WUW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>cpix-20250310_g4.jpg
<TEXT>
begin 644 cpix-20250310_g4.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !: 8P# 2(  A$! Q$!_\0
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MQI5+7WDVM6_R79"J0DXJ53>\?S/T _X*C_\ *,_]HK_LF/B3_P!-5S7XQ_\
M!'7QA^W?H/[(,EO^S+X4^&>L_#K_ (2&]>:X\020K>_V@5C^T+\]S'\@^3;\
MM?L__P %.+*;4O\ @FU^T%:V\,MQ<W/PV\10Q0Q(99)';2[D*JJ.22:_%?\
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M_E.BE[;Z;9$_NHE?G#\2OV=?'_[.%WY'COP9KGAA$?;]LFM_/TY_I=1[H/\
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MI;=XUV[8)=/;YC*6K)4FX.?]6ZOY#<M;'U;117Y+ZK^V/:Z=\>_C<WQ*^/\
M^TMX,U/1/BW=^#?!&E^!_"CZIIE]_H-G<V>G1-_9%W:37KN]QMMY9?,9<;DV
M_-6^%P<Z_-R]/)O?T)G4Y3]:**\;_80UKXH^(OV1O -[\:;&TTWXGW&F+_;\
M-O''%^\W,$:2.,M'',T7EM(D9V)*9%7Y0*\/_P""M/Q/^,'@OQG\"-'^"VNR
M:=XLU[Q+J=TNF-!#+:^*_P"SM$OM371[AI67RH[LVGD><&4Q>;O_ (:SI8=S
MK>Q3776^FE]2N>T>9H^U**^./C;_ ,% XOCS^S+\)(O@7K7D^./VG773?"5W
M(EM<7'A2V$+2ZMJEQ;F8(TFEP+*'AW,/MOV>!O\ 65UG_!'[XP^(?C__ ,$T
M?@_XR\6:O?>(/$7B'0EN;[4;T)]HNW\V1=S[%"YP!TJI82<:3JRTL[6Z]?\
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M)A:5"C"<92E.UO)[72_4)2DGHKGZ#T45\P?LE?%_Q/XZ_;V_:P\,ZQK5U?\
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80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cpix-20250310_g5.jpg
<TEXT>
begin 644 cpix-20250310_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R '<# 2(  A$! Q$!_\0
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M]8TI)C%I-P99+QB\\3S&*8%]ZDR(8C(YY4;F1E(!=O0/!VN7'B+0_P"T;GR
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40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45775588275824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45775456190720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance Disclosure, Table</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Summary Comp Table Total for CEO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comp Actually Paid to CEO (1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Summary Comp Table Total for non-CEO Named Executive Officers (2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Comp Actually Paid to non-CEO Named Executive Officers</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumberland Total Shareholder Return</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peer Group Total Shareholder Return (3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income (Loss) (4) (in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company Selected Measure - Adjusted Diluted EBIDTA Per Share (5) $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,480)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote</a></td>
<td class="text">In the years of 2024 and 2023, the other NEOs were Messrs. Herman, Anthony, Bitterman and Hamm. In 2022, the other NEOs were Messrs. Pavliv, Herman, Anthony, Bitterman and Hamm. In 2021, the other NEOs were Messrs. Cearnal, Pavliv, Herman and Hamm. In 2020 the other NEOs were Messrs. Cearnal, Pavliv, Herman and Bonner.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">$ 1,112,734<span></span>
</td>
<td class="nump">$ 979,680<span></span>
</td>
<td class="nump">$ 583,435<span></span>
</td>
<td class="nump">$ 1,533,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="nump">$ 979,269<span></span>
</td>
<td class="nump">$ 952,530<span></span>
</td>
<td class="nump">$ 897,497<span></span>
</td>
<td class="nump">872,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote</a></td>
<td class="text">To calculate the compensation "actually paid" to the CEO for 2024 in the Summary Compensation Table ("SCT"), an amount equal to $133,465 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.<span></span>
</td>
<td class="text">To calculate the compensation "actually paid" to the CEO for 2023 in the SCT, deferred compensation of $20,000 was deducted  and an amount equal to $7,150 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.<span></span>
</td>
<td class="text">To calculate the compensation "actually paid" to the CEO for 2022, the stock awards value of $51,800 in the SCT was deducted, deferred compensation of $20,000 was deducted and an amount equal to $385,862 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="nump">$ 315,608<span></span>
</td>
<td class="nump">$ 326,890<span></span>
</td>
<td class="nump">$ 305,570<span></span>
</td>
<td class="nump">411,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="nump">$ 310,121<span></span>
</td>
<td class="nump">$ 307,023<span></span>
</td>
<td class="nump">$ 281,038<span></span>
</td>
<td class="nump">354,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToNonPeoNeoCompFnTextBlock', window );">Adjustment to Non-PEO NEO Compensation Footnote</a></td>
<td class="text">To calculate the compensation "actually paid" to the other NEOs for 2024, the average adjustment amounts included an amount equal to $5,487 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.<span></span>
</td>
<td class="text">To calculate the compensation "actually paid" to the other NEOs for 2023, the average adjustment amounts included deferred compensation of $20,000 was deducted and an amount equal to $133 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.<span></span>
</td>
<td class="text">To calculate the compensation "actually paid" to other the NEOs for 2022, the average adjustment amounts included the stock awards value of $12,950 in the SCT was deducted, deferred compensation of $20,000 was deducted and an amount equal to $8,418 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="nump">$ 46.02<span></span>
</td>
<td class="nump">$ 34.79<span></span>
</td>
<td class="nump">$ 43.69<span></span>
</td>
<td class="nump">90.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeerGroupTotalShareholderRtnAmt', window );">Peer Group Total Shareholder Return Amount</a></td>
<td class="nump">61.52<span></span>
</td>
<td class="nump">43.06<span></span>
</td>
<td class="nump">49.26<span></span>
</td>
<td class="nump">72.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(6,480,000)<span></span>
</td>
<td class="num">(6,279,000)<span></span>
</td>
<td class="num">(5,517,000)<span></span>
</td>
<td class="num">(3,508,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AdjustedDilutedEBIDTAPerShare', window );">Adjusted Diluted EBIDTA Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CEO', window );">CEO</a></td>
<td class="text">Mr. Kazimi serves as CEO since 2000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_NetIncomeExplain', window );">Net Income explain</a></td>
<td class="text">Net income (loss) for 2024 includes $0.2 million for a payout earned on company owned insurance policies. Net income (loss) for 2023 includes a $2.8 million refund of FDA fees for the periods of 2023 and 2022, a gain of $0.5 million to settle a manufacturing dispute and a gain of $0.3 million for a payout earned on a company owned insurance policy. Net income (loss) for 2022 includes a gain from an insurance settlement in the amount of $0.6 million. Net income (loss) for 2021 includes income from discontinued operations in the amounts of $1.994 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AdjustedEBITDAExplain', window );">Adjusted EBITDA explain</a></td>
<td class="text">Adjusted Diluted EBITDA Per Share is calculated using adjusted EBITDA divided by diluted weighted average common shares outstanding. Adjusted EBITDA excludes the impact of (i) income tax expense (benefit), depreciation and amortization, share based compensation, the cost of non-cash cost of goods sold, write-down of expired inventory and interest income and expense.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PEOYearToYearPaymentAnalysis', window );">PEO Year to Year payment analysis</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2023 to 2024, compensation actually paid to the CEO increased by $26,739  or 2.8%. Over the same period, the Company&#8217;s Total Shareholder Return ("TSR") increased by 32.3%, while adjusted EBITDA per diluted share decreased by 98.0%. Net income (loss) for 2024, includes $0.2 million for a payout earned on company owned insurance policies. Comparing the operating loss from 2023 to 2024, operating results improved by 32.7%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary.</span></div><span></span>
</td>
<td class="text">From 2022 to 2023, compensation actually paid to the CEO increased by $55,033  or 6.1%. Over the same period, the Company&#8217;s TSR decreased by 20.4%, while adjusted EBITDA per diluted share increased by 100%. Net income (loss) for 2023, includes a $2.8 million refund of FDA fees for the periods of 2023 and 2022, a gain of $0.5 million to settle a manufacturing dispute and a gain of $0.3 million for a payout earned on a company owned insurance policy. Comparing the operating loss from 2022 to 2023, operating results decreased by 67.5%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary.<span></span>
</td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2021 to 2022, compensation actually paid to the CEO increased by $24,868  or 2.8%. Over the same period, the company&#8217;s TSR decreased by 52%, while adjusted EBITDA per diluted share decreased by 47%. Net income (loss) for 2021 includes several one time gains/income including an increase for discontinued operations of $2 million and a gain from the forgiveness of the PPP loan in the amount of $2.2 million. Operating income (loss) excludes the impact of other gains and losses. Comparing the operating loss from 2021 to 2022, operating results improved by 26%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary and deferred compensation. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2020 to 2021, compensation actually paid to the CEO increased by $85,632 or 10.9%. Over the same period, the company&#8217;s TSR increased by 58%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary and bonus compensation.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_NonCEOYearToYearCompensationAnalysis', window );">Non-CEO Year to Year compensation analysis</a></td>
<td class="text">From 2023 to 2024, compensation actually paid to the other NEOs increased by $3,098 or 1.0%. Over the same period, the company&#8217;s TSR increased by 32.3%, while adjusted EBITDA per diluted share decreased by 98.0%. Net income (loss) for 2024, includes $0.2 million for a payout earned on company owned insurance policies.  Comparing the operating loss from 2023 to 2024, operating results improved by 32.7%. Some key factors that drove the changes in compensation actually paid to the NEO were an increase in salary.<span></span>
</td>
<td class="text">From 2022 to 2023, compensation actually paid to the other NEOs decreased by $25,985 or 9.0%. Over the same period, the company&#8217;s TSR decreased by 20.4%, while adjusted EBITDA per diluted share increased by 100%. Net income (loss) for 2023, includes a $2.8 million refund of FDA fees for the periods of 2023 and 2022, a gain of $0.5 million to settle a manufacturing dispute and a gain of $0.3 million for a payout earned on a company owned insurance policy. Comparing the operating loss from 2022 to 2023, operating results decreased by 67.5%. Some key factors that drove the changes in compensation actually paid to the NEO were an increase in salary.<span></span>
</td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2021 to 2022, compensation paid to the other NEOs declined by $73,341 or 21%. Over the same period, the company&#8217;s TSR decreased by 52%, while adjusted EBITDA per diluted share decreased by 47%. Net income (loss) for 2021 includes several one-time gains/income including an increase for discontinued operations of $2 million and a gain from the forgiveness of the PPP loan in the amount of $2.2 million. Operating income (loss) excludes the impact of other gains and losses. Comparing the operating loss from 2021 to 2022, operating results improved by 26%. Some key factors that drove the decrease in pay during this period were leadership transitions within the NEO group, including a partial year of service by the Executive VP of Sales and Marketing. </span></div>From 2020 to 2021, compensation actually paid to the other NEOs increased by $3,542 or 1.1%. Over the same period, the company&#8217;s TSR increased by 58%. Some key factors that drove the changes in compensation actually paid to the other NEO Group were declines in salary and bonus.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100', window );">comparison of total shareholder return Assumes Initial investment of $100</a></td>
<td class="text"><div style="margin-top:8pt;text-align:center;text-indent:18pt"><img alt="8550" src="cpix-20250310_g3.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=1', window );">Measure:: 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Name</a></td>
<td class="text">Net Revenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=2', window );">Measure:: 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Name</a></td>
<td class="text">Cash Flow from Operations<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=3', window );">Measure:: 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Name</a></td>
<td class="text">EPS before EBITDA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=4', window );">Measure:: 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Name</a></td>
<td class="text">Adjusted Earnings<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AdjustedDilutedEBIDTAPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AdjustedDilutedEBIDTAPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AdjustedEBITDAExplain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AdjustedEBITDAExplain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CEO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CEO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NetIncomeExplain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NetIncomeExplain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NonCEOYearToYearCompensationAnalysis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NonCEOYearToYearCompensationAnalysis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PEOYearToYearPaymentAnalysis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PEOYearToYearPaymentAnalysis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToNonPeoNeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToNonPeoNeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeerGroupTotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeerGroupTotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45775457761296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recovery of Erroneously Awarded Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ErrCompRecoveryTable', window );"><strong>Erroneously Awarded Compensation Recovery</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_TimingOfStockOptionAndOtherEquityAwardGrants', window );">Timing of Stock Option and other Equity Award Grants</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Timing of Stock Option and other Equity Award Grants</span></div>Although the Company does not have a formal policy regarding the timing of awards of stock options, stock appreciation rights (&#8220;SARs&#8221;) and/or similar option-like instruments grants to the Company&#8217;s named executive officers, the Company does not make these awards or any other form of equity compensation in anticipation of the release of material, non-public information. Similarly, the Company does not time the release of material, non-public information based on stock option, SARs or other equity award grant dates for the purpose of affecting the value of any award to the Company's named executive officers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TimingOfStockOptionAndOtherEquityAwardGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TimingOfStockOptionAndOtherEquityAwardGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ErrCompRecoveryTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 6<br> -Subsection F<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Section 19<br> -Paragraph a<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form N-CSR<br> -Section 18<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ErrCompRecoveryTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>8</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>1</UnitCount>
  <MyReports>
    <Report instance="cpix-20250310.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20250310.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20250310.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995440 - Disclosure - Recovery of Erroneously Awarded Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/ErrCompDisclosure</Role>
      <ShortName>Recovery of Erroneously Awarded Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="DEF 14A" isProxy="true" isUsgaap="true" original="cpix-20250310.htm">cpix-20250310.htm</File>
    <File>cpix-20250310.xsd</File>
    <File>cpix-20250310_lab.xml</File>
    <File>cpix-20250310_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cpix-20250310_g1.jpg</File>
    <File>cpix-20250310_g2.jpg</File>
    <File>cpix-20250310_g3.jpg</File>
    <File>cpix-20250310_g4.jpg</File>
    <File>cpix-20250310_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cpix-20250310.htm": {
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20250310",
   "dts": {
    "inline": {
     "local": [
      "cpix-20250310.htm"
     ]
    },
    "schema": {
     "local": [
      "cpix-20250310.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20250310_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20250310_pre.xml"
     ]
    }
   },
   "keyStandard": 16,
   "keyCustom": 8,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 8,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 274,
   "unitCount": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 36,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250310.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250310.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250310.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250310.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
     "longName": "995440 - Disclosure - Recovery of Erroneously Awarded Compensation",
     "shortName": "Recovery of Erroneously Awarded Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cpix:TimingOfStockOptionAndOtherEquityAwardGrants",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250310.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cpix:TimingOfStockOptionAndOtherEquityAwardGrants",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250310.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "cpix_AdjustedDilutedEBIDTAPerShare": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cumberlandpharma.com/20250310",
     "localname": "AdjustedDilutedEBIDTAPerShare",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted Diluted EBIDTA Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "cpix_AdjustedEBITDAExplain": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20250310",
     "localname": "AdjustedEBITDAExplain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted EBITDA explain"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r96",
      "r112",
      "r147"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r89"
     ]
    },
    "cpix_CEO": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20250310",
     "localname": "CEO",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CEO"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "cpix_ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20250310",
     "localname": "ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "comparison of total shareholder return Assumes Initial investment of $100"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r100"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "cpix_NetIncomeExplain": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20250310",
     "localname": "NetIncomeExplain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income explain"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r183"
     ]
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "cpix_NonCEOYearToYearCompensationAnalysis": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20250310",
     "localname": "NonCEOYearToYearCompensationAnalysis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-CEO Year to Year compensation analysis"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r95",
      "r111",
      "r146"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "cpix_PEOYearToYearPaymentAnalysis": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20250310",
     "localname": "PEOYearToYearPaymentAnalysis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Year to Year payment analysis"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r91",
      "r107",
      "r142"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r81",
      "r92",
      "r108",
      "r143"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r99",
      "r115",
      "r150"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r110",
      "r145"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "cpix_TimingOfStockOptionAndOtherEquityAwardGrants": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cumberlandpharma.com/20250310",
     "localname": "TimingOfStockOptionAndOtherEquityAwardGrants",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of Stock Option and other Equity Award Grants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001628280-25-011735-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-011735-xbrl.zip
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MXHO\,-50@0<BCFO.N3\<)L[?Q7CR :[4,!9P?8[J1_4#N%PB*1T?[L)$TE:
M+8'0BQ)AN299'Q05( 47U$3B%@/01XI>GH&?P+4E(^ZG.;#V6P?8J ;DSBW<
M$7"WL9C220%WFR+ZF01&"1LF';0^!?->Y=-:%-AOE<7*'$M4L7DRP K<%IC!
M9]F/,T3;:^UIYUV,UAKU,R1W(@PB4<4-(^R<XI+-3QR"+$DU=DF.$<^",Q'>
M7[#3(5Z&!"U,N#(IL#&I/F#@Y;%Q,O0&Z!=PKH'>X8HE^6J66T*-1BFO8_YT
M5\D07>R@_Y"TO 'LK9^,2', @F;3VL FXJ)Q(RC8:K<NP-,QD'X6['5,R'YT
M<4001->$%RA"? 2&\F0 9%#Y%LO#8:@O++@7ZJ HP-T+?'DEV=%$D*7"'?&K
M$G18PTCPV16PTN)8Y$,23@H["-<89P\<%]0-'SDD& PVE99GIPD5]*01.C?@
M7?"-<GZX0(Y$AFIM/#@PV\S-'317?AP1!0/!^+ ?W.X!][OL)#L-D<9%/\I2
MIQ@-@;=+K:@!01D'CG!RQZKQQ'2NX%O1AU]@FX&!0LLV4,_.&W2;MQ"9%!^E
M/YH?WN(FD$_-VCFX4K#M(\'[@AN+JH2K'(!5)#-S;)>CV3U5OAT: /L*Z8TX
ME^3-PQ8?UB1J]EZIG^"MC4!X-1N;_R0)1L/@YN/;R\U#\/,EW$8KQ:CG-*<9
M29)6L')@JW1+)P%VDHB 0Z52[4.1OHB&1/*=+R@^ KLA!UD =P),:'PDCK+A
MR'(8)H4MQ,^5I\ZW/7NH2(;8K<J,;+R5R&1B.8%_HAGFU36'MB:I0T+X,8I;
MO*Q>+*Z)_UOPKD.X8*&:EY$>]KO@6H"<3J+PY;'C3W!/$9522[0*!7RY>.CS
MQGL76_0R[KSEW*&]L1C*]J-Z0)_.W6@V\RG=C25@Y-;=\@]>WW,_G1NVM9)N
MV+G']]1RN'>,Y<R=DTM'>63/NU\ZYX?HB;W\VG4ZOW=Z1YU/O2/"-?CL,"3@
M<>>R>][#)@>?3\]7RD.[V*)I:07<0NU]MGRW6$>WF/OV%M_ D[@&JA=ZB79&
M29FL+:BU$MN=J[BJ-D!%[16-5E;= S0TWS].]/]V>3+GU*TNJ2Y8X;@M=3#P
MWI7S\M[9I_T<QP96"^M-6CN=JQ+GBJ11'DO' !_@(5[+/G!N65NE([DI0=NA
M4RH=#)[6\Y[+YS@:TS&,HK%$J5%SX&??;<MCE788]E&9RKWP2B:@A\,U#CAI
M19G-S[F?#NZ@<I^LYK9UK\A/=R "3/:)5V7/;DCM6UP8W:(IKO1 "BQ_1<3L
M[^Q3^!,9+8G0^0U;%E[#(GOQE"N?GWR+/@\60>P:B:Y#Z6F?AG(48KI<A+.+
MW._+N;)!%A9?HN5<#7U'2=8?^RE'HT#)47U=M?.N5DSHH@POD(L8<!I$Y'2=
MG^Z\T$$]<5^.G7ISN[UL7XYFN[Z]L_,@?3E:]7;C8?IR[#7KN^VMA^C+H>J4
M'/K?5KU5:J%R8\W2$]NC9"AJVLPI[]E*MAYW^54]16[2^&RU'&^ZK>S=H3KQ
MQ1#$,7"D5T\,U4O'B'\@,32%6;\US/>5*@"59G'(SG$K\U=ETF(,%1TVU#]-
MI_N:^$[]9R":7NB<D13\22FGPP;Q;!)#;A"#+M#'R&I:10\E=VAS>\6:%^V_
MR%-1L3&EE%FW]\H7EE*&O_$BBON%4J=85%WXRJN\:D<W4Y/[(@RH%1GHIPM'
MM!^B"AH;H#Q_#./QMW1K(>O[UA[,BUIX3Z\2<Z' 3J/![O3J5&+E:@?3:^67
M,C_=>:6B1(LMYLU.<UOE)[>VMS<;C9V]9SR Q<JZ2RV[5GZ^M[<46RG"66Q1
M<PM ELGKGYO:LW0)R!,D"2UVH;YT3[KGV%\FAR1U.I].OUURJ+E(!LC.?S_%
M?]X]&>KQ_<.+"?VJ,"REL9OD4K!JYQ68WZDD1EC\UU70 IC@JC,GKV5-Q3)T
MI ,T;_/11CY^;0.]INHW5I:^3KJLH5'N1O NBE;FU<Z@C_FNG_)K8<JHU?M<
M_DN!Y=#IRY$(!MI#/)LQI@IN*65Y-ME4%7#?O>8G4C@+BVSG?0I]N-H;,XHQ
M'=!*_Z94V3P]O)P,_O+)?C9'NR)SNIRQ"[_Q884P&[(:"Q7:G,?-2=K"BR8I
M]VK'WRR0W/T&?[=QT3W8(*I-4DP9A4W7J<CP8DSQ!&J>^%+EYF.$HC!=B0G;
MUGP9&*#PJV+\'9XI+&]F48H<.2!!T"(<JG__2,@.YNP>+%:_ GD5BQ$D'-9I
MN&!B>A5IWBE9'9AC*OQP)ND8*'(475-V!R>D/U,R.26XWV%=A*6@5Y1PY*^\
MI+(#%RNU5!W*S#V8A5\ _C$14]; N1(A!=E -0LX(25A5.IUK $D.#??+G!@
M\2,G(J8D<@&\>=P/Z-]TY^E?^MQA&E1'=>W#I?9\6)[?SPP,Q5WVB8\AF:DB
M> 4<GA0;6!8=-OS3D^C(9Y>>_#&1GL_H'\5K1)4JDU1K!=:6U+@ZI7!R<Y*>
M0/!/J.Y0QEB:)=(,)7PL$R %F(Y)U-=E,7>ZNX15X@?LLB0F@4[+?$A+9$SU
M7&=K15BL8^ Y"P-U+6"0?V6H4 AZN%Y4\:Y'D7,=90%>5#F0L:JQA,5GLECK
MP^\OOS,9T<,L4^CU!=93AB99?F=6J4)A,>/C#ZSL\%G5/LM (^;<@SGP8/_]
M\N]F)YVWN%JYN SHVM17,ZVF*5D:68KC&CJ!CT']@;_GVBJ$VJ-@E^@Q3Z9(
M^#1 52[J]<C'"KA%BMXKBW.;ST1DMQ2TO[3:]9>PMZVWNOC\#E7FF/.#2L+R
MI>5X@3Z\"N)LZ\)^I#D%?.8D&=R_4N4X[-42=>-DQRYGV]X#F7!5V&L/KC,<
M-0I45LEA1#'DQ1-'C8UN3LJIC F!+@2VZ66F_M:"*W"0*CWG$$0[FDU\4NUF
M+5?F0;F!_27EBG0'1B7#C.1BR>O+W]Q. *:WKN1DANA%,#QJ7\#C0.V?B%15
M:PJ#?*#%%FV_3;-SY2#9#9**RHP6A66:2>XA FW'^*[P0\+&-59,H50T567@
M8#6XL63'5S@SO_Q:]2EG/+5G^=!E^3]-^'5_(;K:6N5BL!54F2.GESA="T+B
M=PM"XG6JS:<AW,SD 6!$*#\9?ZZ<YVH,S'$SCG:-7&6C=(1:MV;'<8[;4:LR
MA97L+<C:N"2*'\JO_)R66T<Q2)5J?X[?&_R4K_E)G0(_/N!D\PM,-G\%%&FM
M;C:5O@3Q F?.Y (2AJF8(S*H.BAK@SS8FB:4Q.18BD$YF ,2X_S!0PU1'BN[
MA8P8%>+Q<H/%NCLWSI?FBEHVJ9Q R+#=_I7O9>0Y(XD;<Q1!#^XD4J1ZQO1V
MZ6DS\B:\;^7SP"%C*1U4A@\" 7>WU^L]33W/')3BYW2(%S>57<&5)XJ>DSZH
M^ %ZV= EQ# :-> J(F1E5M$,;V\8@7R44OGZKK2Z.P2IFJ+7*Z30 +X"*0#!
M>9,TYX9\JA]RR!96]$#KC>)L[)#/D4B5$&>8H&T-JT3.& Y5W^A7$/;.%;HH
M!AH51,_"#YV!N(H,E(7@W9 _7,I5+/XXFJ .I%;'OWP%;MU.'\SBD.T+X_7L
MHTLV"QEB_QI8 .O#J>AG@8GRVEL3&O9B--Z<PRCV41"T;W"/)^E\OO*V#E;]
M36P'3G.,JC1/0W,_BA$#"87J<\TF[$&$&:;&U&:NQAC.QL%L8R ?=&'!1TAJ
M,;FZ>>%J,;.>FP]S/N==)5BB?97[Y8&*.0.EIZA6.9'JA/)F)H9.8IY7,F]B
M7J;**RTWO0O6.QSG1,3&CO+92O&DZR=DSRH_=6&38-PL2-FKI[Y%O)[KR.(2
MZ(PGK22<L_ 7JGT<P*& T,J0>CK._Q ;>@6:!2I+GZ:!N$X,[)CAXWQ575FS
M*LN!POI3'6=3[-&2],AE_XIB%3%05G$5 %U%-@?\FHQVO<^&VQ.+)\,[UY^5
M6D H><UV;;^]4]O;WKJIY!!9BXH*PD_2V"?(?W[@+0B4)).> CQ(DQ3^H9W9
MY!ZSL*#(+V!,A.KE5:E.*%ICLO,9Q:KDQ,!'E'1#[E2Q05IR[=3V=_9J6ZT]
M-8-7(&ZH;O9,A;"FN$@4$HJM!%/-7OMQ])WX(NP74EUB>U^ -^H?F%)1VSD3
MJ>("E72$8@%!ZOPRP'\<8;#7:,8U)@!!D0OVW/=Z<)I?HVMY)6/4+/1;44P0
M1R^.B>XYC/=5>8S*JGD8A9L+3 #>W]&-%3BHA0R=A&Y?N@)3IJS]"H3[/9DS
M*1_%08#D*[29JI["J5 5GC95/Q4_3PQ!IJ33>3A%M2PEY8V<G>3A-D_"HL:<
M#7&M(."$,Y2AQ.CMC'Y7?9MJ8'C3Y]-*[41@H@9M#V:7PAPZ7SJ]DXM+^'1V
M@QVV/1!ERB@]VFLW^^N5:JES!^N9!++I.71>[&+R"@3:MSR^K@4:&P;ES)M2
M8@J[5EC*P6T28R8C_D$)T--*9R'JTU7I&#N*/7+PFR3(F3XQ\]#QZGE[&7,\
MY8=1_"22KA4.'PWY^IB7<=QUHC5:E?K#/&-._)7TZ20;PP%/:];4S*OU57H:
M(W4.XH4%,O4<1)6KP'/U?+W?QNS5K*_"V9"KRR-_HHEMSODX;S"--.?\;U4R
M*1/=<Q[*<Y\)W2YAX3%K:_VIPL+X,AVVPR\JXW;;Y0/LO7T%^EJ.B%M((=&,
M<"8(5E9S9B)B-R.5WSTN=@\LT9_LF9\M$+C] @*!*X&$NY@T.., ^<MG;3V6
M(A6]VM JT9D"-56OK@0W3(#$,N>&7H&=I!1*90]9^-'LN>A/C?6$3'-.O.5N
M=2/S5-%2 JCG<W=1])"@@<E9^\^JYCF]S\[)J8.FVOFW ZP.NV!AVCGOPJ>'
MO8/.99=P.;%<C"L=#SKGAS7Z^_3SY]Y!KW-$7_2Z%\X?O:,CK"#K.E:;&3)Q
M07?15BW\^.STHG/$W_><P^[%P7GO$[RFAZ_I73BEBLKW#N:A;< 0&_3:\\YE
M[S/.#(O93C]S)=O9V6GOY!)_CA_!',]!!^E]^7*A=9"3+^>=8Z.#="Z<TV_G
MN,3N61?^"QX[[W[I75QVSV$B9]\^'?4.G,[!P>FW$RJ-^]P[/R;;%E_V)S;R
MA:?PB\/N01=KH1VM?GR@,CI4/^$=EZ?PUY].H8,\;4#W_.A/Y]/YZ;<O7R^=
M3UT8N5M5D4>EFG\ZL%^79Z<G75X>?';X#YC]"?V)0W=//]=X][K.Q>E1USGL
MP9YV[0WB/54%GJ] (>H4.G6@7WXDDIQ'")N-H)K#3 *;5ZKK32QD$OM<'^&G
MQ&IBUT_FM1<!#O+&5U0]Y/C:=>PC*$J>/T"O<4V$(J+(N.XR?"%1.R.S[XVO
M1S+J%R-XZ#*[V_HB"\?+X*%2'E5?4KT%?!M@UC@[;F&!\#K]/E#6]8_F,D"#
MUZ^Q\9T.<,[B8I/2:JUR0Y4)CR$_SXNQ+,^SX=\6*_U;K#K_YB) 0JPA':GJ
M%.9?@I]-,]MY$(",]BH 9*PNM$%)[*T\KD3WJ'N@!<AA[QS^.+T=&6#E7+&7
ME;ZCER_^NH,!.LBNY$P5]IS";I6@&R:^JN23V!G%BN-3#A!IU^1R0Q^:B_XS
MB?$0%6-&#+@A>6GH!YODC,'H0H(A0U7<8SU)"CQGEG#*"#\0H?YK4COR4/8U
MU?[2>)RU]&/BQQ3*ZZA&X949Q>3T@X>T5GZC Y 'E:H5I)7Y1'Y$TL_1U63\
MCR"X3/0?!&(^HI@_):XCH]0(DRV%BHJJ?^?DJ_(6FM7B:V#0W;KS\B(?FMZ<
M$^65??DW#>N "M4_Y9H?+O<A@G6S.(;IHC:G;HQ%/L9CK>J.=("Z].3 IWAF
M[ANM3/4PMWQ)O]QSU[1O?#SA>Z8T9"XEA5VBBZ5D(]PNJQ"+/+\5%V0^,M S
MWHZYFU%-7#,%9D_D#ICCX0=:YR,P!+_;+E3"J<_YV#SMR3^6Z-H(S*%QL+NY
MO[_OH L?I%.CV> 6>H4+(BG?E'H.Z0P2/53'N_*3*%:M?^O.5TGVG7JO?0&*
M8B[QT0.#[ZL[ULVEJ+MY-U["8PGK]X1S>@UB\!,R];,X&H#YP%F(- \,0N.L
ML8H(K"GNAZ0N\2$(#H*X0/($\TC&0[#KSK)@'(68DLY>AP/$Q\#U'. E-X/B
M,[\+3"/K^T'J? NQ#V""23QZ_0>D^CEO?O]V?, I>'GE$[S]FNPIG)5:3MZE
MZ7>4,&>8D>;IA(!SF4@"8 "9A0,6%Z4Z/L&Z\#L3"E6F&2P*N928D(W&I?6'
MOAB&44)_$]@'V%E2)P3[B2J:2GS$XB!91YF?*F43SAI?G06X2YC!I--"O3@;
MFM)]\\+B,2(-]*4D^!L//6LP)C,3V#-\U*=B:OU)JOH+@FU:,C293IK[>TR7
M9ES"-8'5$)\Q:\MIE$JW]?"]/$,-OOHJ19".P.I$BQSW'+B52)&&#Q'2 (/D
M%]/0BS',<@#$1^=\R3,\D>EU%']7TT)G!/Z#X\K [> J;3FZWP5^"\MW@RQ1
M7P.Y;Z%"X^<#86YB:*JM!\ ?!M+#A _R-$RP3([NT3 BO6Z:4%-L'613N\LF
MOJ(=58\,*MH$V1N5K<,9 \41;0,-IWQ-*4U(.)_J%W5F!/B81>*(K11EZ>A:
M8L0O=(ZB#&Z2"(5JX.H<UP_5D_E7%)ZU1@&5D#)(?#4+V.&:3=:S+$DM37_1
M._A6*W,(=.,"ST4WP=!W'6W'DR>GSY**LA$*M&07(5)2&Q 7<)HH"W- #-P@
M2M:[QO2(*Q'[,C7@!6,$74!U/,9&HZBF3X# J <&431>8U6!"S28A6.9.F.U
M"L1R58D,?6*&JMMI8B_-7&G]5%^XWX<T0_:P W%2D],K$63<1ZC0'1HF)[_K
M1%G&0P!1K!+VD!HG_@2YJ?)\PW4>^XF"'O((J(2"C:#\8N:1=X5.<MHN;+W*
M2^4MHO.G),,@V-2[3U /XPDHULC>@AO<-B]'[,\4D#^OV#_68E_-!L0^&)*8
MUX91%B ;73@P1^@R"]JCZX]-=C$Q#^X/R%?8]UA[*9%5$(' N2C.@7@E<!>0
MYQ&))*[ I!O'!;.I'Y,QAH2!26!J:->-">'$XZ$\24CD]D53B;&=0/3%6, =
MQ_S 8P%?7R<@Z$-0:@XC9(-G(DY1G/Y3AD#C!R.9A!*DW:=8>/"=GP3XUS&F
M; /_.78_Q7 3:Y3=X",G FYZ'44P&O+RU/F$.7_P>^#YJ%8<"=PSQ9-P:O_(
M/ ^460'JP9 C\7!O;7.B+X>8$9<ZYP<=2A/#;'_863SD/X&EUY0#E?&W!%>3
M*YP2?,0X0C')+T:4-DM+RU/MM=L7MD<&Q3$IOR,*B%65M A&(QE'I@TW[,MW
ME6:K0"^PK1#\K-W"-RO:H80-X#-#=..JA&9D="H#!U%5LE#G,',R83S56<<T
M0U)]0/PUM-:CDDW@Z<+L[$W[=@$<+N% H=X](B 3'8 7Y]NE5= QM\+%&>&\
M<41<Z:>3#D^%3T,_5F<2H"J 0 I,R1CYDUIA(M>*C^K*FU":-=*(VM-PQ0I-
MHF\)^@02FC$\'5K':"MK%Q%0[3%=M'PM.&#B_[!&N!:)50)B0I.?HK[S3S@^
MI'+GB*,91W*( .^=:Q(D3 ^G$YCL94SU&!'(]C#B)9.2,; .C:X\G1:89JVB
MI8QSX$Z\%.@%L2_Q^'DTK.F4;-6AL,@]4"A_>&Q>Y5?,5H=??P;:*5Z=@G)O
M\ZOYF6-G?A@*%W;L,]SND"K.D1^$TKBAK 3T '.3/)V,"+OMB7^I)'>I0.]J
M,% RZD?7@7.!5FH*=_WHB#7MW-2A1=FJ9'&%'; ^8"ITR3ZC>*9_SFI56"Y%
MTV:1.=9WD96FSQB''A=TI=P+:O0#/$3RPB7)( ORLEI@*[ LOH(U3+6G2'HH
M,U14&<>,$[1<I1Q8/'PLOL-,_3$FRVE5HB@\^LNX+-8E]@O&;W9?0&;-*JMC
M%FK/BBAB/)F:L[-;TP!:-N^?HX?=T+29(N0#Y"G R*P +!N7^\!CJ"X!U:>\
M;#="4=UNL#31!F#?CTH&D-;S2!6P8&Q19*-AC<,DVKA6&IM!1?Q\V%$N $'<
M_3O((VUW]%&72LBQ@'(:P0]1U.:UG_]"\]!.1;60<LGBX91'2JR.-:P(F21&
M-I9]%?G\S2!@JJ?T+#,^LF-TJ!Q%@U5]5RD;Z@4W,:ZBY/R:UW"[")/;A34,
M\5V7TAV%0))#'V,SPOD+%2(URUS+KO8O:74T(7L:7F""YK4"DJ#R$<P<&3P!
MQ!!,-ZD=$"Q_ &.YQ/XI=Q\3?9D0#=)R'30UE66!,R7'2I%(D@D.K10A)C:$
M&M2(PYD?>+83RNF %=J//,PU4-#+8<GQ,TNDKG:Z=Q)+<\QW_12DF*"C5#>&
M9C8&Q8Y($BU?1J54[6')7G%+Y 9&]35L/8EA-(QAD^)T,YN@RX JA'(/SA)$
M=12%GJFJJR0J>@]J5/DEAME]@MF$FY\) LDD0) ',?95 37/1R!!*OQ=RYNA
MY6"BK2^;!>6JE?:L?)%I.DWZ63RTE!?E%)P8W4HKH,:)!FK7=^<"(QLN%<Z2
MLLJN%BPZ\[&#*FS0&&$1T64(0WTWYB!>IKD*'_Z1YX1\52/!*R] RY*H%WVE
MFLLK/\H2[9+VYA?2FI7F^C;[_-@#AKJ<B\"5>)LM34[-) !QB&80NNX(&UM_
M.:(QR &2HY,K9OL-U3U]9\V,.I@M[USH:U<X6F$Y^ESL4S3P.:2))K<+&_S#
M1W$V)!,D8@>E=MV2AQWCE.FU.@R:-&9)72&[D,!O4\2+X+ZV28$&%_'[G42@
M3H)%KI(WR=?WJ=ZQ?E_-M<A)_P4,\XPR>-Q1%)&P.#;$6JGC$@594^SC#4LL
M#Y\/>P+BMV99<*K8@^F.BVIS+5DY,LIE*2*(J%HTQ:MTS22!C#+7C.$X0;T<
MW2) S4F7.:[F_#E/744GV,T=8ZSXGG6ENC\FG!Z D,LI*004L-CLZ@ \!_MV
M5G'!2ZJ9Z&B20 2H;(*DS(+DN__,T-QT.?1<6-U$&5W0$8UTF^OYVS7QN:UM
M);]GR#]AL'BD<1%,$Y^5!-0Q!E'@1[;<$6%5O Z_QSN@S'1+='.?;7I4:[OP
M^D\R_@X7&O@-F-4RM7@%6>9*:<C#[!?= [L,R<\'%3H6B85(L&E&G3&OJ!4W
M4OGR1K9*K2QV%/D)"SM"K_OLQYCA*#@4\DF$WVO."7#$FA-&U\[9R4'NH*CE
MCCWE1*=;<],><,B W3>'",:=,J\LSK:PUV7IUPD"%" 7>LX8]AFR:U8)OPL*
M'LT1IN1[-$$8&.\(S@T=%A1<RT*D"%RU\^;H\)^?WBL%^BWG]F? ]V T+ H&
MU7+@8QH^;*S_;Z'4DN(ZYOE(2+CT0H\"246!= 97,ID&L)L^AY^ >$.E2-FB
MZ0\_^ Z+MWTJY9 LOUU9:C$34>Y<ZA#5ITK'5GZ="I%56)&Y>;G'/*<BZWIA
MIV-<. Y-U7E848>.7-B$8>8;@ZEL'2E!J+J#H ::Y(X;0Z6^3A,K:NXEI7<E
M)=*2#!K4N(CB6.=U;(!M@Z8^!W\^3M0T:LYVPS#F&V,P.PAJ+K6B0T QTA4>
MJ_:L:.:AMJ+QIC0:I)LZ'+/B!XA;+2U[M2(NH%1[U)T.;>,>F%N,R88'E (^
M=7Z'3[-8)IJ/X<"#R,T2AHK ]@6!ML&0"J76MX&%3?*7L."0X0CO 6&+,!02
M?T=*F-:G-BG<"L;1]QRH]2QG469_]?#:0?Z98\BD?%](3 H$Z:%05HY(4W0^
M89R6UT=J,JC^H]PNT*D  D5&DFY&@TVQ^=TG?XNQT@E3WLM<:GF C1),)Q4O
MQN]=S2 WT3 .]/'Y8\J78$9N1!&INGAV%*%B*@[(F#%) ,QUS+4%7CWV,8!A
M446NB.;V2U);Q.;)C]3-@I3,!52CC4$>JKP$T@N4?X.(5CL:X OS]I(V[H=A
M=*58)E(W67T$,,7E&\9.U2[V@0Z^YZZ4@@A"NC?6$R>TY-\JN>1J! ",B'C4
M\36QJB8N9OPGOR26B,5ONF#I16,L949-Q4@[ZX[4+1)4P@LMHOGV4V[-LI52
MM)V*OSW&%CSP?Y.)7RUI]*L-19C#LBQ2*X9KQ W%-"P;2I^.1=P<-YF73Z#3
M")+<O4-Y%VA%Y1HA5Y18"01Y!H9.9#!7Y!$*FI:J 5V/^[./^[/%G/;6,:<[
M>C_NXO[8?07:-:?2."#=R#%=<_X1/Z_W VTM-96=9FVY_.)6"Q')JBQ>3E?7
M<8SYSF1T45@.>BM]5IBL%<93SCOKJ40$$\OX3 V\"*]#$)I-#+*?7ES+5T<+
M(YV),ERQ,A914UW69F NH9P64EM8">YX.I)S+F4BT6ERQNE,E/('JJMT.5V:
MW2*EW^M$,% &-SG8%(AKAG*AX4,*(SFM[8:91.($$5?($]&K:IE$Q28#3HG,
M6Q6BAJ$\T_ 7Z8,ZBT&:/&),M;@.I4J&,6F^:B-]S&@'%?Y(7$]E7A;VH.2X
M4]]>@!XK9 9>Z<TV/4WJ)R@\ZF9C=A.W 026LKOUX5ECUD9KG$A"0KWR86#T
M.FA@&M,,E4D 3WB(WC1]E1K[H-;KM/T]'32^-1BC6W^)F/)'E6IY:W0$34(D
MGCR1\.;8B,4FE.&13XZ<6YQWJT-0L:):3C@>L[:K5?^"]ZK<-0\=8\I5AX]:
M<=G\8IYQL/!<>'X$-QP.9QB!I3H%*@9SM(.6_GA:\< EQE85SBQ7%B0I6H;'
M\&\X.6W1T3<U3(64WS&WT>GRS<69?8%52IRUCE%8S6Y'8I)*.ST^(].0^L2!
ME3ZU$D,+D3IC(1T$69_B0WE2GGI+_LF!X+QSE>&NG-=\,);7#DG,DT.L "3#
M:$X8'+41"R@;GZ3NFD,=9++'^%,$\K9\*C.9W+MF>>,".82I?P^C:S#*A[P\
MRZ)2H2,5"RYR>2X/TW4D-UE2H;CRAPJJ-<]KP+@I.1:42:^=')QT)TKI7*_!
MC?</@<.?8Y^N4#X.4U\NPD+SJ#F[N[49[G%K;K5=T&3&4C3FM'>X?C2/,DRX
MB$D5Q.08:F ^__/L^ L*\;P5H9WP.QM?T:UU*A$6="6K*?0"^@-6OD-772T0
MIH.E#NC!=\5$N$R'JA-3,56!YJ;ZTG&/4S5%R[>CYZ.;2,/P_T"<561JEK.C
MYOPAJ/,Q)7<?$N <\B]X5:B60>4GVD\FZLYA/B70W#+=P $G5<LWW6',UE0*
MJC3.]2ZP5 J5Q R#2;N>'X!QIU-!5&BY]%FSH91EU.AT2V($<HM564E(>ULK
MR4:%H<K1*?P+ZR84AB;7<IOMAPU$3<R>!Q5?7A$&K DKVS))L,,?A@M\X2?4
M/#R]1N6I%*I+3?%)H7L!U;M@8'R3BC?)FS0 (@AT&I)5(DO)._[8.>B>\G,@
M4H#CD>_(%II:D-C9OOSJ/+T]]$I21L!Z2$'@6BZN#HB'.'T6MP>Y[E!TL(%4
M'<,=+[#^G!Q*F5SEN]RAU^8E9"JJ6?55*:B3VF^93:NP:!W& ((>%K,I9G\U
M6SQ543 TPUQL^641LE4\1)@"6-H&EPT3U2N"0_*'RF7*UXB\()=*& 0.!!XD
MIED1-U(R3LL_2E3N_Z6 #(% 8RG0%8LF5XH75Q8G2'N!.\RW:*A:):A#4N*.
M,,37$#!&4NV_3'?.JH $G 42$_Q,XV!*L50>'"KU &:LD- .3L_/3L\[EUWG
MR^GOW?.3SLE!5T.C,3 $PGAF),,U"\OYN,W$;L@"UO='5S!25"E+58Y?2JVQ
M\\%JMO"@4%%>HZ];6.#4++00CC\49ZJ3;;6U-\3$W[Q,0:8CY;3G;ALJB/_R
M$2(^4;%1I%%8_P5*@,'(34JJ/G4B4#R7I1.:GV.&J9)>$<W81BUF*.I,"47S
M,P.A4#"4\9VE]Y@G3#L>[C:M;"WZAXW'8-Z=]W^YHII-;@NDAG/(;BH\;"/0
M(/":SGC 2D+@X[K7A!H@MR?GH=OJ[WP+XGEV'$6Y4_5*1KR7*VG-W(Q7]+7K
M?#KMG!\68)><B\OSTY,O1W\Z\,'I\7'WY/#"N?S:N63$OZ^=\ZY"]F/TQ5G0
M1?R=C>C4[1Q\U=" ^C7.R>EQ[Z3;O7".$ CQT.E\ @[UZ-4ZZRJ?Q41TL_$@
M,&T[*P335D$ZJX31-A^D;<7GC[BCA)+Z9QD8]:6M:#Z0ZV)(KBL/LU<--?N(
MX.0KK$BA55JVC>?KN:-"-3CE_?@, G=K!X(W6A<_[RD!^?9N70D069\FS-VO
M0I DOL<@<GFZK^XLD>LOI1;D\WL9O(;&XG\PPADC=?\K\V-582;E]P*&KZD"
MU+M4ZBNQ].E\ &U2M8Q**RA+*YZ##%3-"OK2VK.?JN:6H+^2VZ/2PE%!59DO
MC7I(J36!$CW;*T,UD>*6&AJ_O#Q+4H0Y&=UV[HM$=\^RMS"6?VG80NV>B>5F
MH;VA-8&ZT\6".]6.,S&0AXC@=..<_)!BP'F[B1JKW;1U54>'EB*F%[,S<YD+
M9H,U*\\Q@4K@S8&)^VFN[.LL,=IW1T7,KS44L:Y>E=1N%-^9I,:*UAY [D97
MV-/D-5S!<XV&KY+SD$>>]XPI>&/GKYR4J-,:5O]1QB:'--.(J_Y%SN9JBJ*F
M<%W(^HN5E3=K>5(*+,:IB"/099G$&*,"(QH)_G[^@=4WX3HWF6O/"G/_N7=Q
M 'HD(=V3('IL*W"5AWFYSZR__(F^_&D=(\V'<(QL[>RM/2-SA5KGVV'OTD'!
MU;N\[()PZIZ=GE^^?,THS^0IQE *=B5E!BELC#S +1(5\36Y:%46AO"B"=?"
MZ/X9+I<'8E])UG.YMR2[N5WI9;&*B\ZD\%2_!M1X#:U>K:X;V 9.SE/1534+
MG= I/+#-A$N9H %ND,)F!:6<5#6%;/(EB/J(H$#&@D*!<^(L>!5-D:O\#SY%
MW4 KI1B/QK>W(V&,2G8]BL:.JI@Q]LV<OE :WX.Z7@M$BC.I<_,WF37H=*0,
MF;$4!*6"V'>P_4ZST=ELZW$NN-@::<;D#G<8S[6YW]ZB>)_ 7J/R/F!<*WYL
M962?/"V' (DTC5<5QI:R"7)?3BS1]%'8IA07+45.E3>H>M@JG] KV/_#W"X/
ML"$V<R)531WXY'B \V";'2/*6";'T>7<(1;X&D*#"+A[8/)HV!H]EUPF&%)U
M)I#[YC]G>H+"#=5N--V."VA=_0B?J.2/[Q<]@0G6>X?#S4 .E)R_Y4PVG_%0
MR)+<><;4\.)V-;<PD7WC(XL@R2%JE3Z@I"Q=G7F>4Z*,BL2S\A5;SD&X/OEG
M.'D\MH@2#^&$W6@B=1)8F#O(F8WJ0P9.G@6ID9)+G;&5B29T4DNR/O@G/'C$
M*R]?7TR'B:B&-YC.^'49:-QR66O5=(Y85=!O 8.T14&> D6I.%P.C3INE1R?
MX4.)5"V2+;"R>W$9H[D5')S:Y9S/B?&10QFLJ?,)J3,_^[FGG<C0YV(> R"T
M/ $L>/:Y'0BZ99;('%ZO/"N7<'^D!1;)=4>$O4C?Y</K[[2WG@Q !H?3:6HF
M-*> GU$#T]?H0L1]$<ID\_0'PD4K2Z+5:+10GW-QXF[>=5PK6QQ-H9Q ?=V5
MGI<4%+TUN3\EN<MQ%#)X@V=1L2[E*&E8\L?([_OL!F&H2(4$=$5)HVZ>X=B7
M(W$%MX0U;'^,[)6,7L+U0,@HG?:OTT )XL6& -$R8)"%-+"R;BDV21!3>BR;
MU\^SSS[@%VO">G;%WNJ%O0S'?--\J[)I_\J\(9L PF 4:;'^1G< _XOPZ5%5
M<+%K#I<73-\N8-Y/(G@]5;Y@CVG\L7'3V3@P,^Q1%59J3M[)1SPUS@7V*[XY
M.^B<?GKK=)'N^;+T['M'WIOV=FNGYFP4L&=4&7;16,5Z5G@JIMMAC[-AN'7A
M5M]%9::1L'TB^9F4+F2G;O1EU0F773#D-<TK,7)GUU"&"J"4CTNU=&<$&_R+
MZE4*Q4BTA_P&_/-"C>6<1'6G"3NG\WENW[^Z#K&^?+]+#\DR\)G-ADIWU3Y>
MZQHJ^3Z0L3H_T8\P3[M0,<8(K_83=[RZ2R@[U>YJ[#TP9N=D$6:UX*'GB>DF
M6':IUSP70I$9&,<WYI+[GB]B"W9WOL_I%;CK3J(4CY;NHY&Y$1QLI,O^M%"O
MK"-&+$T.6>C-*IV?BBS4,#G'#6!?![[.S?%-TA,^Z&5Y$ZSR( @$'6"N26R:
MD='A)@[CG9FL'QYX46^KHU&6 ZGJVH%\LU@7N5?XZRN8E2T^P')U_0F&/RR
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MO%)5QLV68U_7'0BKZL38(J 0"JT.Y'7]I>5:Z1*XSL2HLM:Y@J28.-1[#^Z
M33")B=#.*^#IZ10[AX!,]1]^6$KF"OFL\-_*+AG[WB3R0Z/3LK!3L_!9DZ^0
MY2@HS;;,5Z",V97OVTURL,I*J\WF\VNZXP9J=I^Y&V8@C&*KEYH?3_Y>#++G
MKO&:G0VKJA$F$3K1]06EV^-&$^U)\V,R_%!37!I[8W498=[_UB)7,<2BQ53Y
MT>9EG<98 "."C!B$W?'.9@!*DG#$5GH:Y-]J.8ADB#_1\/\V.C,Z::]HJXN_
M9VP4[8?63Z(*-X@"/S)LKH#T# S!Y4I?JM.TAE;8'9J"N-)+[PL8V#%B0V>N
M*5GQQV12:D!PPL\*@L(,39=%VYJTY:VUW=J\K=AD/[R* DRUB^#5Z'7 $M;"
MBP0R!)PU['I",#$%*N4<SBM,+>E/K7O!/+DDNM"N][E1V@+L#D2E9 &4*_8%
MGJ1\_#A)7",(&@&3![H(E]6+5Z$RIVMY;&V&M,(+N;$6AXFV=@,21;DHIS];
M%$G>.8MQ4 &SR;I)).%MP>]$'RX)56/G19B%)RN+/>V)P.X$_&,0S!3#L7(-
MK%KT6>\1Q;=]$FB#4H80UK6ZQA>_QCUYK%"V9>=_6"<,/%K52,&!<M]<FO4^
MS]OG!4$K'B(5?GT(<[.7R%XH,'R" ]'I2[D%D:.&U, 0$P&*(ZP[EL& ;!WU
MQ"IK)#<)\@[*:#?V)]ISPP%4+.R9<N*&-LT*FZ4-:ZH"HD0CA5904_*1*X&$
M!C.P!K>TP1O#V/C;^:G6)1,/8T5>WM^\OJB8>"9M$&-AS@5)M(<R MM,V,]#
M2CDRF4I$)V_!C&^'OO1OMED4=H@21H@<0HJ?<:9P.GRN$>0^_#G$DKLC=)S&
M>"GA][Y@((/<VB#G!Z<(6XWH@SQ5G[%'DHI,?+L6ME#9S(%,>@?'"PHV%D8"
M"MX,G!"JM,BD$NU(R?<*RZU>@?.@8T.=D(I_8\A-!Y+* 6,[3TPF%FEH0EN,
M..Q(.-F<E;$\G1VDF%Z"-1IDR@@='F)X*J!6Y6%0WC,PL\&\[@>2Z^F*H'OT
M684-,V/R%!=G>S&MRBV+#^96SHQYE%M/-=5]#WXU$%=@MO<9.E!= NMVL.";
M@VZ#SEIR ]#6*/O(FBWE=*/(Q">*]TQQ"[M )2$DVSP J-P\0+5 Q/%]BDZ>
MB>4K )9/K%Z__-M+#B".%,"AXT5&30EH/)[.Q&)C:6=34E!MEAD7_6;S_4:4
MFA%S;3LA'%-VI@+$LA$,;@='<@7($Z!O5D*(!15$"[#B8F6S5:K*3&*(MY<2
M^6Y,6.-MF),>(/ KT"/=$5X'O#B<+8#7P6PA/2YCM!0$!YU+T6]R.8=6+L)-
M;.^79%[(I1!HUV\G1C.SWG5868>5FR\FK+R2K*1'$%-;M4((3\FU>1=816:J
MD E(0G%@S,3GPKS5+-H:61RC[)J5<$HN";@/9)K >#!",<9%J76Z3X.>ISW\
MS+ U$YE*Q7<9JCZ3C,?.B?%Y8)W$MKYX*B[BW7:9"\6;M6*4C(PX9HO%^).)
M4^G0'[6YG!\#(X:#BZ((H4B-BCH_V_C%2>DCXYSILG.F9YPS#^.U7Y4[]X>2
MWC<E2:ETTUMN(ALLL8E]S<>%-1%N5AOFP20BB5'NE"66K+# #7"(18 *$V*8
M0<&QBP9O3"^8FX OQG1WM6^$MY*#'+1KK)84+U+=N>%5<(E)@?9IOPU&BT[%
M4*JSC=ABE@<$Q18J\QUXS=&MB6_6)"W+83%%367R*<Y4F0:@XH/J729O[HIR
M9*^H;I S*'&\ 1X) 2!6ZG:#"$S$LHU#(=A"]+&(!YSGQZ@<DMNW)!<;DRQ.
M,D3Z593?W-_?=R[2R/WNG+*?[(P A>T<:/H-?JS3GVM@"*9^X'2 = /@ZHU=
MHZ6!#D [6WX/_H@G>HD3K68]])*7QU@77]O+YZU(^W"V6#MDV-+BZR=/$,+Y
M>@BE^T;1%SU?I"^\*(3PKW/-BMCQ[&,($7-)LW'*8,!4 *+E/,&)KX0!L-;<
MDL@5C2O. ,=E&#(W=3L^6.A^K!VQ>,/)[4&W-79]SA)#-*B(KX[A/'@/R%="
M^A2"L=;RG>)7Y!O!C J90O$W-0/[*Y0SC1P7WW/A95Y3NI#-&N.:O@YRRS=-
M9' NL<&&]A-D,6[NQI^)8AM&N(;%?,H(5"Y_^#;R]4B<-_H?)/0)8:FG7=#G
M(.\0,_="QE>@>SD*3R'O(D$Y/HC0(G[D3<S?KG$1GO!<PRC\%RA[G"-9.EI,
M\RI^9)4>S2&(]>D]Y>DIR0BJ/EXD$E@Q/@*'1_^KG(V2]$80:IS>C4HPX2PH
MRY\12BB;6V"#+Z7RJ@P\RF.$Z[L^V:<\651I8-=3<RO?J,-),O(MX\DJ[07T
M$% >DH%* @?&.I ^I6\&/EAK0MW+-5;ATYZ@[0]09_>&8>2'E.W+9EPA7\\H
MNN] .)*WGUN^^^@5Q$*N@7TI9U")4,,>R_3M*U$2YQ72>NAZ3%*JA;=UR1M=
M(]@/2*N:I)XGD@ R. O8GZ#V7;-B"3AR.IVP*S+,QGWLX3,P'@[;=6(]QOH]
M6P%P8_.KZLJ8H,3M&\GO@ <3;7/0Z#4V:8"E<T2?3YQ1[>),NY1B.<R4&U0Y
M1-&DB4HFB:[\MG %0HDB ,-%Q?K1NM.=:XM98A_TA4UMM.6 $IP?#X3D(V /
M>H3TMJ:<"#L64R!H(%4,."/?DM1K(0M5K$;K])Q*HZ:%CN2;[$/M3<(.2?A(
MFG+8*Q#7=>>;;L-"?25B [!0T9$,U=2TQN&S ;F2E)?(MMMP [,T#Y0KC8A0
MOX"R(HS%<WUM'R/^4AN4!&&$ C?#_&/EV";6;M(!8!Z>*KND3!/:;;2$9&%K
MZ%6Y=ZJ/SB^)3DYKOU"IAHDDR"$*CG_.55!-+@;.H3DY/!FF5WOGR\NW2+G0
MZX.<C (61J@4<%A3Y>@#C3Z*-95B-Q!;^7\%#.I;J!MXE(BD(D>(7'7:D:!U
MK,$\#5JU,-G2[N<BI<'_LUM2M1:!4Z44O]!'1!>\UJ: A]Z([D^X@AUZXR'<
M?>)D;78G;-78X< SW-EJUG8:C4HRQRN=Q7!U$FFM #-;$'Z4IF^[!XM\^>6?
M]B+;UVRU:^W6MK4]AM/-*'/J<L_=,IVW0TVP-%/2SBK=-8=C ?KU!/_0K&VU
M=FJMQM:\0[+/5LQ?%/72B^6M\[R_8_>6DN\'&N:G"_&W7F:(_YF\_>=YJ\4+
M<05W(W%.)UA@EX5^^F IK\_'OKJ# :<C.?\0889"@NYZ8X<:7-F%O\+9:C3?
M?'_++2==] 00JT#!9E2QL>K*I95:U,?'V1A4:O;S45AL6/3WL7+.C2S1E9O0
MF.QZFA(F<=Y%-LH3!*3*N_M!+P"M8A.XH8QC2K;+DPAX3-;^N-2_Y((\B+S[
M $*NRD'B'J(&_A4^ U7+V#H8Z=;[5T/%BWYTT$63IM".5Q]5%)M-M=*TR#IQ
M\N;+H+$[M-]\>C>_=00'<(5Q"Z$]#VQH7<\.EV>Z@.T;<33U%SAX%G!UYRL:
M69C=X?F)A?(M&(M7*?K<5Q5SD#>UA'3]V,W&"2&28S]&":=*62J:[('F]VQ-
M6/> A,U(W9%-AL4<%;)A.,K+$9L4H^AVAW*R12J?K4H1?W'QT*]Y*<D?JI3D
MDRHE6>&UW%A)4@WS:Y=JW(R>CX:39>;JE-\;BFY,C:=6[U0ZB<[M=]&0\K@Q
M*A4R$^ 287PR*Q98O^^A3<G!0Q_[GIC\_0"!S\Q'+X_&SO+>U"^?4R_8A-OD
MPVOZ>WG'QB* E*>.:1+_\@_PT)0E;-/M8M,(U25*./ X*S*4UP;+2^8;(<Q&
MJ'*+(# MS<Q)DTRM?DA3"HGB/"6+O35]R]5& *KAE#,P3=]1;3PF\%L9YE).
MI83/>H'J3@<&H4HA'LE/9G+D5?-2>+OE#"JX,*GDPYY(K?@]3TLM81QY[,<F
M!$74 ( H-O%_M?<MP4S0?!9Z ZMFKPY+X7&H1"UK:S/MK<%T/K/-M0*86JZ
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MA/>M'O-&,SS). _G,HTZ&R:(V&#L 4G<SS+;',,F'FW,X@IG8<0FHE_(K(_
M'8"R :J($"0%7;X,8'SZ!D>,,%@<GJ]8&KJ!4X]!A/T5@^[.I]6*=&Z)XT $
MUX47F%J+X5$Y(/5$&(F9)T0E$O@3:CJ0MCCFR;A9'1]?(]4F*2PI3YG&EQ:
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M:D,[8H:FX5YA[?\-LSM^M$.^!2WR*ZYM1_1#7!6_Y^^8NG&HU6M_H_WV&:X
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MQ#.+1^<'_/A__0"U\OFW+KV1>T#UM38Y9AVT9F>"JN$?-K W._0]BF9(@M-
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MA+\)C0B^N22JZ-W+Z 0]QE>BY$@1HW1YME!BD$@OH/:+I8&5X^+1,5&2,ZT
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M](6"B>HG=D\%N](9:O*H9;U56X;9W)48JU".RHL,M*3*X#D3Q2O!9NUFH4\
M_*[HMB*\:]8[L_FN;*2Y@O;FH2TF0"E0;Q_4\"<V5%>@WCZH?ZD;G<Z+ GIC
MP-WQ1*.J %ZWL7KU\^^HN7S52]QYQK#'M=6C)[2>7TCJB]Z][&KO'=UQN/,_
M"]4%5:[[2ABLXIU/ >(>\L?U="P%M;5U)04R#K)&58U' 4S(%Z-=WUMX[9\X
M;NF=1FV[KHM2P=S><SE9J)_9BBJ\/8/CP.[LECT6"LXOX*M00$Z&5F_+1Z%
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MI6?O :JVEJ*J\+8/IJQ2N@\%5<IONA>H6D>3>[+?5*'J,%'UK,QAH;Z+/&#
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MJ+7W;E,-H]VV]FU3IF%:S:5+O4"/NNZ^=0(K%I/,R99:1K;TB!T^MQG8@<*
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MSC2-AJE@N9E)RYT&4&;CX#3$9W,]SX^>R_D.2WY7A!B.=E5G5V=_D7RF?0+
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MNX$!H^S+3F+C6L; #^DU.$%D8(?CY(-['V]N"%)(UQX#)V*G0QQ_!M_ %IR
M+M(#4+T?S.BE#@X^8F%"XOB9V.P\01X>/;;645H!M7?^-?-1?2A35:TB0=[Y
M*;D)M&1&YIW8<MX+#L\[02Z)OT'#(",'Z+/LV)SD>3X^Y\W)[=D=3LU#+8^S
M*/87+(O+_5*W++W1:@J!/(QQ] 3.9!83_FCD'RP/_XI=(@_\%Y^/+#=.O"F
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MQYWD]:[5H#5 Z'E4F/0&GSC)_N[D[3'D@MV5LY QE63Y4RK?HCYF$1;2C.T
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MNX<9;]U5R5KY#;I !.(H,7Y=+X2#ZAK;&?%<*M\[#K95<%@L@ ?Z+4(T]OP
MO64X664I!Z)$RR'3XJF&+"- \5K(RAWF4H0\OYJD?>2&K<P5R\3;BAF+F1H
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M/#R?3![<1O%818N1@/?F5"_<=#(.GWBA:'8+DIC.N(D%:Y8M)T#A1(DI*N2
MXPD3%L<0HF8&7D262<[IPTD4D2(/37&8?HD!Z.&<U06CJSDGE$TFN.68ZE6N
M/4/!"4)F#O*20<,TS]PW/L$*G$(O*.CB@E(,,RR?7(8MXY7!6W5F7C1PGZN9
M%4'4?LVS+\?,S5):TC"3GVSP"Y3B %7D2G2$1Q'Y9QP&GCR$4\$+AV+D73GP
MD7#[927W1(9,J"1"=ZP_% 8L\@B*(1<D/D3AA/P]F!(5._R&A#:&@I4D8Z)<
M#JO7O+M29%;E3YTW9EB]HX= K!14V75;-XEM%[;1&Z;_K6M]T _@N-'I@(K
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M%IS#['51#V[=%B<2_XP&/GKQ=*K[RN5=UME%"<P-5C[RV'?HRKA'[XZ?(@E
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M4L[MP;,!#EN,>5(1KY^97.I(H%I14/4ZMH50C?KA4+" 7@780"1X80T=VW
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M((.N/X3UH-)K0UZ9!: 2#QFI&^FU7E5-N</SSY3!@A#8-#[!:\D<L7R(IGY
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MDBRBGI?16YJ$!R2ZH3,X)SJT$(,S1?KD)[CJB^(!%\-K$."3)[Z@$+9D?FR
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MY(FSF?+9C.7-Z8]>Q27+O[:]LRM+V^9JDJ_&+WRL>!'@6*\;RIJ9^]8PQ7N
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M4-PLSWLSRR#5B=4@J9)]D_DCDD=R#Y>/T/D]+=J?P_\@SZMF^M \_[[]E^M
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MS#3O@L&'M)6]KOZ,<>M&AU N-Z*"K4#J-4D=UU3C\^#?#B820;Z" ^1A/66
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MAYT"RL<)"NN\7M:1+)F1H)BN'6W28OK-B$?LKW JW$;+@*GO6#_EE4?C0,8
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M]:"4@,CWE_SYSGB8:RG__>EZP[>JMW[)*>%II.&?*F[W540FOC)FS9#FRIQ
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M&QEZI'IN14^2/OW"O?CV4D]7 P:&EZXB09NV-B1'.YQ_9I*L\$2^JDCIV.Z
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MA4'W.O?SSY&%2B7SDI):C/U]M2--U>X;RN3G<E,GF"?ND4R@+Q#50JE$L(
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MYU%W!#TO*OF1R#3;XLA4%'OLS8%/#M;;_+-;JE-OX?%!XM^'O+1'+[EHS7V
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MU3O5AMW9RD.%)3MH=+_.;),OM./=?U*6Y[<-!/8"5*=-].;>GCW9--U<KC:
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MRGB>6ZU3=^S9S WF9^[WR45#]1MV!M23*4<^S0<+BVVI(D'NR!0'UEA6['W
M?1:<.X.0H*4[,38%0/'ZW^Q6O69H ,DU_O'5AC?G:^^?EDM?'O63(-\$O7R
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MLCN"H;4J$F+JQ2F*!,=0%3J('>@>HO6U->^GUG_1^Z3KY<?;82!>'*3<I[N
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MTT$_#%S_<@UR_8\T8FKC9=6GJ91N"XN##HB6?NG'/ZJJJ_E0GGFN->O#".F
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M9V!,'^SO"#"?Q&( I"[Q]AOMP%DY1<%.C;>C6K7+\0^H'!YZIS9E?F)%X*>
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M]F,'P[E*XQ]P/]*[;)FO^"IIDZ%(96-MUI+]4UY>OWOX .E_T_9/G=,Z#J=
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M)4P04><3TM",)D,HP^B1CT37ZZ@]K!'-P6@(#H"A'Q9%*FRXR"N4  SA+I'
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M>)5TG[EU?=F,=$ AR>>&BZ9UK(&-'%F.PJ"_KQ?TCU]LNVE=@X']2A6.)*K
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MZN"7H29C%XNY\9!QV:/$!8<A'\_$&,9&T(T]9VJ"C-A&Z=LK(KJ7VV$?LO.
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MT5(/'&;A(QO:CQBBQTM[OK XAPX'H\M:-IHUJQT@XP$:JA<&4G^F9HZX+!H
M'^XQXK;%)^)2:.='&;V2LQJVB9<ZT.Q6@R4DN6EL6+'W^BOHJ5J)O/%?2FM3
M'^Y&P,HK^?!DCZJ;/W@_,T&'I3DH$B(L;PM.;,UZ]TL3==E7O82EHA?QC(Z
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M7:<EHI]O=?%N?!^%$4MFN*M7="K["39)8B%(ED64@W?[8:0>!!_RO#N98^;
MZ 'J=[V)3/1IY0@8072>!S;U99O%M+8WWKVESGZ'C):*TK0[H$7HC.Z\"[@D
M!<08]XSW#XXP=5&"](V )+WK#NR,O0OH.RM>B%%1BNN@4GZJ<O^3E&KQ54_<
M0L<1S(\Z*XCP4Y0:8#:*IFS.,4&]NWJ?/OSAY&* W*)UVZ=5!O'; ,J$B\?
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M^OF'\E:?AC<Y]N\(]7_Y2I$_=?(,5R^^/G<UD:67/!+DLA\,;CR5\RVLVL3
MT)#<]/8<MZ<9MV:RF+Z:<,'S_IR"I),[(&O'32@%]%2D#/4 BR[*,.20;.#9
MS+GCA4EY3VO*+ 5<ZE3N?0_XTOCJJE9MU-5Y=9O1-#,;;@,HS22>JO^7KU^L
MY<96 0-G;TI0!=$=1]J$43VRW&1,%UVHQS4W)710*NIT^0R"0EHYK'JM]T.
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MQ7M8HB-[8QK5\O1M!?)$T+"'OY,4B0'-OA#!/Q%!(A8];!HG@%\ /\*SX^?
M];$9ZM"Z+RW0GS*O\-;UU<U!T7HOHB=/UT7%F#[0LMNT8C&1G(86&3[R^&L&
MDFG-ZF_+DP>OU4FN'@=SBW[6TZA*IQ2XVN\_:5&#GU%6E:1I>=CO1W3%YX4
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M,00SWJ%A*X?BHA:/0QMESWOG>I-Q#UM^^STRUY.22!Z2ZJ6QS@VJAJ)F<<Q
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MS2>=Q<Q.:Y';YL#T$H$/$VJ!LKF$_A.3@#P?9!U[U3*8;&#[X2Q!NM&J8&7
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M39F)Q#XN+PT1$*!]G7@O641'?[^0(JO"YX[*04-ML+=^9F]@^M4?M$99&W&
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M?%J'9VM!9[&RJFXU*,**JZ(U#0+O.J@%R _K!-7 \U C(!&JAK5Z6*_7KL,
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M"\7?F=NK_P!02P$"% ,4    "  1B&I:>%<8P$;C  "?D@@ $0
M    @ $     8W!I>"TR,#(U,#,Q,"YH=&U02P$"% ,4    "  1B&I:MY1]
M=Y@#   M#@  $0              @ %UXP  8W!I>"TR,#(U,#,Q,"YX<V10
M2P$"% ,4    "  1B&I:(6. "82)  !9DP  %               @ $\YP
M8W!I>"TR,#(U,#,Q,%]G,2YJ<&=02P$"% ,4    "  1B&I:*/VL ] G  !M
M*0  %               @ 'R< $ 8W!I>"TR,#(U,#,Q,%]G,BYJ<&=02P$"
M% ,4    "  1B&I:.LQDV'LB 0!6BP$ %               @ 'TF $ 8W!I
M>"TR,#(U,#,Q,%]G,RYJ<&=02P$"% ,4    "  1B&I:]F9\RQ O  #V,
M%               @ &ANP( 8W!I>"TR,#(U,#,Q,%]G-"YJ<&=02P$"% ,4
M    "  1B&I:MF2D89L(  !E"0  %               @ 'CZ@( 8W!I>"TR
M,#(U,#,Q,%]G-2YJ<&=02P$"% ,4    "  1B&I:B9S6<"P$   7&P  %0
M            @ &P\P( 8W!I>"TR,#(U,#,Q,%]L86(N>&UL4$L! A0#%
M  @ $8AJ6I<[R?Q> P  ;1,  !4              ( !#_@" &-P:7@M,C R
C-3 S,3!?<')E+GAM;%!+!08     "0 ) $X"  "@^P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>cpix-20250310_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20250310"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20250310.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>2</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>3</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>4</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-2">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-3">0001087294</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-4">DEF 14A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c-1" id="f-1">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <cpix:TimingOfStockOptionAndOtherEquityAwardGrants contextRef="c-1" id="f-5">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Timing of Stock Option and other Equity Award Grants&lt;/span&gt;&lt;/div&gt;Although the Company does not have a formal policy regarding the timing of awards of stock options, stock appreciation rights (&#x201c;SARs&#x201d;) and/or similar option-like instruments grants to the Company&#x2019;s named executive officers, the Company does not make these awards or any other form of equity compensation in anticipation of the release of material, non-public information. Similarly, the Company does not time the release of material, non-public information based on stock option, SARs or other equity award grant dates for the purpose of affecting the value of any award to the Company's named executive officers.</cpix:TimingOfStockOptionAndOtherEquityAwardGrants>
    <ecd:PvpTableTextBlock contextRef="c-1" id="f-6">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.756%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.202%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.132%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.979%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.979%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Summary Comp Table Total for CEO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Comp Actually Paid to CEO (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Summary Comp Table Total for non-CEO Named Executive Officers (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Comp Actually Paid to non-CEO Named Executive Officers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumberland Total Shareholder Return&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Peer Group Total Shareholder Return (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income (Loss) (4) (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Company Selected Measure - Adjusted Diluted EBIDTA Per Share (5) $&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,279)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt contextRef="c-1" decimals="INF" id="f-7" unitRef="usd">1112734</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-1" decimals="INF" id="f-8" unitRef="usd">979269</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c-1" decimals="INF" id="f-9" unitRef="usd">315608</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c-1" decimals="INF" id="f-10" unitRef="usd">310121</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c-1" decimals="INF" id="f-11" unitRef="usd">46.02</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt contextRef="c-1" decimals="INF" id="f-12" unitRef="usd">61.52</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-13" unitRef="usd">-6480000</us-gaap:NetIncomeLoss>
    <cpix:AdjustedDilutedEBIDTAPerShare contextRef="c-1" decimals="INF" id="f-14" unitRef="usd">0.01</cpix:AdjustedDilutedEBIDTAPerShare>
    <ecd:PeoTotalCompAmt contextRef="c-2" decimals="INF" id="f-15" unitRef="usd">979680</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-2" decimals="INF" id="f-16" unitRef="usd">952530</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c-2" decimals="INF" id="f-17" unitRef="usd">326890</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c-2" decimals="INF" id="f-18" unitRef="usd">307023</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c-2" decimals="INF" id="f-19" unitRef="usd">34.79</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt contextRef="c-2" decimals="INF" id="f-20" unitRef="usd">43.06</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c-2" decimals="-3" id="f-21" unitRef="usd">-6279000</us-gaap:NetIncomeLoss>
    <cpix:AdjustedDilutedEBIDTAPerShare contextRef="c-2" decimals="INF" id="f-22" unitRef="usd">0.48</cpix:AdjustedDilutedEBIDTAPerShare>
    <ecd:PeoTotalCompAmt contextRef="c-3" decimals="INF" id="f-23" unitRef="usd">583435</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-3" decimals="INF" id="f-24" unitRef="usd">897497</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c-3" decimals="INF" id="f-25" unitRef="usd">305570</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c-3" decimals="INF" id="f-26" unitRef="usd">281038</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c-3" decimals="INF" id="f-27" unitRef="usd">43.69</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt contextRef="c-3" decimals="INF" id="f-28" unitRef="usd">49.26</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c-3" decimals="-3" id="f-29" unitRef="usd">-5517000</us-gaap:NetIncomeLoss>
    <cpix:AdjustedDilutedEBIDTAPerShare contextRef="c-3" decimals="INF" id="f-30" unitRef="usd">0.24</cpix:AdjustedDilutedEBIDTAPerShare>
    <ecd:PeoTotalCompAmt contextRef="c-4" decimals="INF" id="f-31" unitRef="usd">1533713</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c-4" decimals="INF" id="f-32" unitRef="usd">872629</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c-4" decimals="INF" id="f-33" unitRef="usd">411776</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c-4" decimals="INF" id="f-34" unitRef="usd">354379</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c-4" decimals="INF" id="f-35" unitRef="usd">90.68</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt contextRef="c-4" decimals="INF" id="f-36" unitRef="usd">72.08</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">-3508000</us-gaap:NetIncomeLoss>
    <cpix:AdjustedDilutedEBIDTAPerShare contextRef="c-4" decimals="INF" id="f-38" unitRef="usd">0.45</cpix:AdjustedDilutedEBIDTAPerShare>
    <cpix:CEO contextRef="c-1" id="f-39">Mr. Kazimi serves as CEO since 2000.</cpix:CEO>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="c-1" id="f-40">In the years of 2024 and 2023, the other NEOs were Messrs. Herman, Anthony, Bitterman and Hamm. In 2022, the other NEOs were Messrs. Pavliv, Herman, Anthony, Bitterman and Hamm. In 2021, the other NEOs were Messrs. Cearnal, Pavliv, Herman and Hamm. In 2020 the other NEOs were Messrs. Cearnal, Pavliv, Herman and Bonner.</ecd:NamedExecutiveOfficersFnTextBlock>
    <cpix:NetIncomeExplain contextRef="c-1" id="f-41">Net income (loss) for 2024 includes $0.2 million for a payout earned on company owned insurance policies. Net income (loss) for 2023 includes a $2.8 million refund of FDA fees for the periods of 2023 and 2022, a gain of $0.5 million to settle a manufacturing dispute and a gain of $0.3 million for a payout earned on a company owned insurance policy. Net income (loss) for 2022 includes a gain from an insurance settlement in the amount of $0.6 million. Net income (loss) for 2021 includes income from discontinued operations in the amounts of $1.994 million.</cpix:NetIncomeExplain>
    <cpix:AdjustedEBITDAExplain contextRef="c-1" id="f-42">Adjusted Diluted EBITDA Per Share is calculated using adjusted EBITDA divided by diluted weighted average common shares outstanding. Adjusted EBITDA excludes the impact of (i) income tax expense (benefit), depreciation and amortization, share based compensation, the cost of non-cash cost of goods sold, write-down of expired inventory and interest income and expense.</cpix:AdjustedEBITDAExplain>
    <ecd:AdjToPeoCompFnTextBlock contextRef="c-1" id="f-43">To calculate the compensation "actually paid" to the CEO for 2024 in the Summary Compensation Table ("SCT"), an amount equal to $133,465 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ecd:AdjToPeoCompFnTextBlock>
    <ecd:AdjToPeoCompFnTextBlock contextRef="c-2" id="f-44">To calculate the compensation "actually paid" to the CEO for 2023 in the SCT, deferred compensation of $20,000 was deducted  and an amount equal to $7,150 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ecd:AdjToPeoCompFnTextBlock>
    <ecd:AdjToPeoCompFnTextBlock contextRef="c-3" id="f-45">To calculate the compensation "actually paid" to the CEO for 2022, the stock awards value of $51,800 in the SCT was deducted, deferred compensation of $20,000 was deducted and an amount equal to $385,862 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ecd:AdjToPeoCompFnTextBlock>
    <ecd:AdjToNonPeoNeoCompFnTextBlock contextRef="c-1" id="f-46">To calculate the compensation "actually paid" to the other NEOs for 2024, the average adjustment amounts included an amount equal to $5,487 was deducted, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:AdjToNonPeoNeoCompFnTextBlock contextRef="c-2" id="f-47">To calculate the compensation "actually paid" to the other NEOs for 2023, the average adjustment amounts included deferred compensation of $20,000 was deducted and an amount equal to $133 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:AdjToNonPeoNeoCompFnTextBlock contextRef="c-3" id="f-48">To calculate the compensation "actually paid" to other the NEOs for 2022, the average adjustment amounts included the stock awards value of $12,950 in the SCT was deducted, deferred compensation of $20,000 was deducted and an amount equal to $8,418 was added, representing the result of the stock calculations required by Item 402(v)(2)(iii)(C) of Regulation S-K.</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <cpix:PEOYearToYearPaymentAnalysis contextRef="c-1" id="f-49">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2023 to 2024, compensation actually paid to the CEO increased by $26,739  or 2.8%. Over the same period, the Company&#x2019;s Total Shareholder Return ("TSR") increased by 32.3%, while adjusted EBITDA per diluted share decreased by 98.0%. Net income (loss) for 2024, includes $0.2 million for a payout earned on company owned insurance policies. Comparing the operating loss from 2023 to 2024, operating results improved by 32.7%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary.&lt;/span&gt;&lt;/div&gt;</cpix:PEOYearToYearPaymentAnalysis>
    <cpix:PEOYearToYearPaymentAnalysis contextRef="c-2" id="f-50">From 2022 to 2023, compensation actually paid to the CEO increased by $55,033  or 6.1%. Over the same period, the Company&#x2019;s TSR decreased by 20.4%, while adjusted EBITDA per diluted share increased by 100%. Net income (loss) for 2023, includes a $2.8 million refund of FDA fees for the periods of 2023 and 2022, a gain of $0.5 million to settle a manufacturing dispute and a gain of $0.3 million for a payout earned on a company owned insurance policy. Comparing the operating loss from 2022 to 2023, operating results decreased by 67.5%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary.</cpix:PEOYearToYearPaymentAnalysis>
    <cpix:PEOYearToYearPaymentAnalysis contextRef="c-3" id="f-51">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2021 to 2022, compensation actually paid to the CEO increased by $24,868  or 2.8%. Over the same period, the company&#x2019;s TSR decreased by 52%, while adjusted EBITDA per diluted share decreased by 47%. Net income (loss) for 2021 includes several one time gains/income including an increase for discontinued operations of $2 million and a gain from the forgiveness of the PPP loan in the amount of $2.2 million. Operating income (loss) excludes the impact of other gains and losses. Comparing the operating loss from 2021 to 2022, operating results improved by 26%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary and deferred compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2020 to 2021, compensation actually paid to the CEO increased by $85,632 or 10.9%. Over the same period, the company&#x2019;s TSR increased by 58%. Some key factors that drove the changes in compensation actually paid to the CEO were an increase in salary and bonus compensation.&lt;/span&gt;&lt;/div&gt;</cpix:PEOYearToYearPaymentAnalysis>
    <cpix:NonCEOYearToYearCompensationAnalysis contextRef="c-1" id="f-52">From 2023 to 2024, compensation actually paid to the other NEOs increased by $3,098 or 1.0%. Over the same period, the company&#x2019;s TSR increased by 32.3%, while adjusted EBITDA per diluted share decreased by 98.0%. Net income (loss) for 2024, includes $0.2 million for a payout earned on company owned insurance policies.  Comparing the operating loss from 2023 to 2024, operating results improved by 32.7%. Some key factors that drove the changes in compensation actually paid to the NEO were an increase in salary.</cpix:NonCEOYearToYearCompensationAnalysis>
    <cpix:NonCEOYearToYearCompensationAnalysis contextRef="c-2" id="f-53">From 2022 to 2023, compensation actually paid to the other NEOs decreased by $25,985 or 9.0%. Over the same period, the company&#x2019;s TSR decreased by 20.4%, while adjusted EBITDA per diluted share increased by 100%. Net income (loss) for 2023, includes a $2.8 million refund of FDA fees for the periods of 2023 and 2022, a gain of $0.5 million to settle a manufacturing dispute and a gain of $0.3 million for a payout earned on a company owned insurance policy. Comparing the operating loss from 2022 to 2023, operating results decreased by 67.5%. Some key factors that drove the changes in compensation actually paid to the NEO were an increase in salary.</cpix:NonCEOYearToYearCompensationAnalysis>
    <cpix:NonCEOYearToYearCompensationAnalysis contextRef="c-3" id="f-54">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2021 to 2022, compensation paid to the other NEOs declined by $73,341 or 21%. Over the same period, the company&#x2019;s TSR decreased by 52%, while adjusted EBITDA per diluted share decreased by 47%. Net income (loss) for 2021 includes several one-time gains/income including an increase for discontinued operations of $2 million and a gain from the forgiveness of the PPP loan in the amount of $2.2 million. Operating income (loss) excludes the impact of other gains and losses. Comparing the operating loss from 2021 to 2022, operating results improved by 26%. Some key factors that drove the decrease in pay during this period were leadership transitions within the NEO group, including a partial year of service by the Executive VP of Sales and Marketing. &lt;/span&gt;&lt;/div&gt;From 2020 to 2021, compensation actually paid to the other NEOs increased by $3,542 or 1.1%. Over the same period, the company&#x2019;s TSR increased by 58%. Some key factors that drove the changes in compensation actually paid to the other NEO Group were declines in salary and bonus.</cpix:NonCEOYearToYearCompensationAnalysis>
    <cpix:ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100 contextRef="c-1" id="f-55">&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;img alt="8550" src="cpix-20250310_g3.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/&gt;&lt;/div&gt;</cpix:ComparisonOfTotalShareholderReturnAssumesInitialInvestmentOf100>
    <ecd:MeasureName contextRef="c-5" id="f-56">Net Revenue</ecd:MeasureName>
    <ecd:MeasureName contextRef="c-6" id="f-57">Cash Flow from Operations</ecd:MeasureName>
    <ecd:MeasureName contextRef="c-7" id="f-58">EPS before EBITDA</ecd:MeasureName>
    <ecd:MeasureName contextRef="c-8" id="f-59">Adjusted Earnings</ecd:MeasureName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
